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Abstract  
Genes   encoding   for   protein   kinases   are   the   most   frequently   mutated  
genes   in   cancer,   as   kinases   play   pivotal   roles   in   the   regulation   of  
cellular   pathways   that   are   crucial   for  malignant   transformation.   DYRK  
(dual-­specificity   tyrosine-­regulated   kinases)   are   an   evolutionary  
conserved  family  of  protein  kinases,  which  participate   in   the  regulation  
of   critical   cellular   processes   important   for   tumor   development.   In   this  
Thesis  work,   the  putative  role  of   the  DYRK  family  members  as  drivers  
in   cancer   has   been   explored   through   an   extensive   analysis   of   The  
Cancer  Genome  Atlas-­TCGA  data.  The  expression  of  DYRK  genes  was  
found  altered  in  tumor  samples,  and  the  member  DYRK1A  emerged  as  
the  most   promising   candidate   to   act   as   a   tumor   driver.   The   impact   of  
DYRK1A   cancer-­associated   somatic   mutations   has   been   evaluated  
through   specific   functional   screens,   which   showed   that   most   of   the  
mutations   analyzed   lead   to   loss   of   activity   and/or   protein   stability.   By  
using   a   CRIPSR/Cas9-­based   approach,   DYRK1Awt/wt   genotype   has  
been   restored   in   HEC59,   a   heterozygous   DYRK1A-­mutated  
endometrial  carcinoma  cell   line.  Reversion  to  the  wt  genotype  reduced  
cell   survival   and   strongly   impaired   HEC59   clonogenic   capacity,   while  
complete  DYRK1A   loss   led   to   opposite   phenotypes.  Mouse   xenograft  
experiments  showed  reduced  tumor  volume  and  delayed  growth  of  the  
modified  cells  compared  to  parental  HEC59,  indicating  that  variations  in  
DYRK1A   dosage   negatively   affect   tumor   growth   in   vivo.   Finally,   an  
integrated   analysis   of   transcriptome-­proteome-­phosphoproteome  
profiles   in   DYRK1A-­edited   clones   provided   hints   on   molecular  
mechanisms   dependent   on   DYRK1A   dosage   in   endometrial   cancer  
such   as   activation   of   the   interferon-­STAT1   pathway   in   reverted  
DYRK1A-­WT  cells.  Other  possible  mechanisms   for  DYRK1A-­mediated  
tumor  suppressive  function  are  also  discussed.  All  together,  the  results  
provide  evidence  that  DYRK1A  is  a  novel  tumor  driver.  






Los   genes   que   codifican   para   proteína   quinasas   son   los   genes   más  
frecuentemente   mutados   en   cáncer,   ya   que   las   quinasas   juegan   un  
papel   fundamental   en   la   regulación   de   procesos   cruciales   para   la  
transformación   tumoral.   Las   quinasas  DYRK   (dual-­specificity   tyrosine-­
regulated  kinases)  son  una  familia  de  proteína  quinasas  evolutivamente  
conservadas,   que   participan   en   la   regulación   de   procesos   celulares  
como  proliferación,  diferenciación  y  supervivencia.  En  esta  Tesis  se  ha  
estudiado  el   potencial   de   los  miembros  de   la   familia  DYRK  de  actuar  
como  drivers  en  cáncer.  Mediante  un  extenso  análisis  de  datos  de  The  
Cancer  Genome  Atlas-­TCGA,  se  ha  encontrado  que   los  genes  DYRK  
están   alterados   en   tumores,   y   el   miembro   DYRK1A   resultó   ser   el  
candidato   más   prometedor.   El   impacto   de   mutaciones   somáticas   en  
DYRK1A   se   ha   evaluado   mediante   ensayos   funcionales,   y   se   ha  
demostrado   que   la   mayoría   de   las   mutaciones   analizadas   causan  
pérdida  de  actividad  y/o  estabilidad.  Utilizando  la  técnica  CRIPSR/Cas9  
de   edición   genética,   se   ha   restaurado   el   genotipo   DYRK1Awt/wt   en  
células   HEC59,   una   línea   celular   tumoral   de   cáncer   de   endometrio  
haploinsuficiente  para  DYRK1A.  La   reversión  al   genotipo  wt/wt   afecta  
el  potencial  clonogénico  de  estas  células,  muy  probablemente  debido  a  
una   reducción   en   supervivencia,   mientras   que   la   pérdida   total   de  
DYRK1A   conlleva   la   aparición   de   fenotipos   opuestos.   Los   tumores  
generados   por   inyección   en   ratones   de   células   HEC59   con   distintas  
dosis   de  DYRK1A  manifiestan   retraso   en   su   desarrollo   y   un   volumen  
tumoral   reducido,   en   comparación   con   los   tumores   derivados   de   la  
línea  parental  haploinsuficiente,  lo  que  indica  que  tanto  la  ganancia  de  
DYRK1A   como   su   pérdida   afectan   negativamente   al   crecimiento  
tumoral   in   vivo.   Finalmente,   se   ha   llevado   a   cabo   un   análisis   de   los  
perfiles   de   transcriptoma-­proteoma-­fosfoproteoma   de   HEC59   y   los  
clones   derivados,   para   identificar   mecanismos   moleculares  
dependientes   de   la   dosis   de   DYRK1A   en   cáncer   de   endometrio.   El  
Abstract  
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análisis   ha   revelado   la   activación   en   la   ruta   del   interferon/STAT1   en  
células   DYRK1A-­WT   revertidas;;   se   discuten   además   otros   posibles  
mecanismos   responsables   de   la   función   supresora   de   tumores  
mediada  por  DYRK1A.  En  conjunto,   los   resultados  descritos   sugieren  
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1.  Dual-­specificity  tyrosine-­regulated  kinases  (DYRKs)  
1.1.  The  DYRK  subfamily  of  kinases  
Protein   kinases   represent   one   of   the   largest   and  most   widely   studied  
superfamiy   of   proteins,   and   comprises   over   500  members   in   humans  
(Manning  et  al.,  2002)   (Figure   I.1A).  Dual-­specificity   tyrosine-­regulated  
kinases   (DYRKs)   belong   to   the   CMGC   group   of   kinases,   which   also  
includes   Cyclin-­dependent   kinases   (CDKs),   Mitogen-­activated   protein  
kinases   (MAPKs),   CDK-­like   kinases   (CDKLs),   Serine-­arginine-­rich  
protein   kinases   (SRPKs),   Cdc2-­like   kinases   (CLKs)   and   RCK   family  
(Figure   I.1B).   In   turn,   DYRK   family   is   formed   by   3   subfamilies:   the  
DYRK   subfamily,   Homodomain-­interacting   kinases   (HIPKs)   and   pre-­
messenger  RNA  processing  protein  4  kinases  (PRP4Ks)  (Aranda  et  al.,  
2011).   From   now   on,   DYRK   will   refer   to   the   DYRK   subfamily.   In  
humans,   there   are   5  DYRK  members,   divided   phylogenetically   in   two  
classes:   class   I   DYRKs   are   DYRK1A   and  DYRK1B,   whereas   class   II  
DYRKs  include  DYRK2,  DYRK3  and  DYRK4  (Figure  I.1B).  
Even   though   all   DYRK   members   share   a   highly   conserved   catalytic  
domain   and   a   DYRK-­specific   motif,   the   DYRK   homology   (DH)-­box,  
class  I  and  class  II  DYRKs  present  class-­specific  domains  (Figure  I.2).  
In   particular,   class   II   DYRKs   are   characterized   by   the   N-­terminal  
autophosphorylation   accessory   region   (NAPA),   which   is   essential   for  
catalytic  activation  (Kinstrie  et  al.,  2010).  
1.2.  DYRK  genes  expression  
DYRK1A  was  the  first  member  of  the  family  to  be  identified,  by  infering  
its  sequence  homology  with  the  mnb  gene  in  D.  melanogaster  (Guimera  
et   al.,   1996).   Mammalian   DYRK   genes   were   then   identified   and  
characterized   by   amplifying   and   cloning   DYRK1A-­homologous  
sequences   using   total   cDNA   from   3T3-­L1   cells   (Becker   et   al.,   1998).  
DYRKs   expression   is   controlled   by   alternative   promoters   generating  
transcripts   with   distinct   5’-­untranslated   regions   (UTR);;   moreover,  
alternative   splicing  events   generate  multiple   protein   isoforms   (Aranda,  





Figure   I.1  Phylogenetic  organization  of   the  DYRK   family  of  kinases.  A)  The  DYRK  
subfamily  of  kinases  in  the  human  kinome  tree.  AGC  (containing  protein  kinases  A,  G  and  
C);;  CAMK  (calcium/calmodulin-­dependent  protein  kinase);;  CK1  (casein  kinase  1);;  CMGC  
(containing  cyclin-­dependent  kinase,  MAPK,  glycogen  synthase  kinase  3  and  CDC2‑like);;  
STE  (homologues  of  yeast  sterile  7,  sterile  11  and  sterile  20);;  TK  (tyrosine  kinase);;  TKL  
(tyrosine  kinase-­like).  Adapted   from   (Manning  et  al.,   2002).  B)  Evolutionary   relationship  
among   the  different  subfamilies  of   the  CMGC  group  of  protein  kinases   (see   text   for   the  
complete   name   of   the   subfamilies).   C)   Evolutionary   tree   of   DYRK   family   of   kinases:  
PRP4K  (in  orange),  HIPK  (in  violet)  and  DYRK  (in  green).  At:  Arabidopsis   thaliana;;  Ce:  
Caenorhabditis   elegans;;   Dd:   Dictyostelium   discoideum;;   Dm:   Drosophila   melanogaster;;  
Hs:  Homo   sapiens;;   Sc:  Saccharomyces   cerevisiae;;   Sp:  Schizosaccharomyces   pombe.  
Adapted  from  (Aranda  et  al.,  2011).  
  
Among   the   DYRK   family   members,   class   I   DYRKs   appear   to   be  
ubiquitously   expressed   in   all   human   tissues,   with   DYRK1A   levels  
homogeneously   represented   and   DYRK1B   most   highly   expressed   in  
testis  and  skeletal  muscle  (Leder  et  al.,  1999)(Figure  I.3),  whereas  the  
expression   of   class   II   members   follows   a   tissue-­restricted   profile  
(Becker,   et   al.,   1998)(Figure   I.3).   DYRK2   expression   is   low   in   most  
human  tissues,  except  for  the  intestinal  tract  (Figure  I.3).  Murine  Dyrk3  
was   initially   found   expressed   in   testis   and   in   the   erythroid   lineage  
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(Zhang  et  al.,  2005),  whereas  in  humans,  expression  appears  restricted  
almost   exclusively   to   the   testis   (Figure   I.3).   Finally,   DYRK4   was   also  
found  highly  expressed  in  testis  in  mouse  (Sacher  et  al.,  2007)  (Figure  





Figure  I.2  Classification  and  protein  structure  of  human  DYRK  subfamily  members.  
Schematic   representation   of   mammalian   DYRK   family   of   kinases   indicating   phylogeny,  
grade   of   homology   and   protein   domains.   Shared   domains   among   all  members   are   the  
catalytic   domain   (KINASE)   domain   and   the  DYRK-­homology   box   (DH).  Class   I   DYRKs  
present   two  nuclear   localization   signals   (NLS1  and  NLS2)  and  a  PEST  motif.  DYRK1A  
includes  also  a   tract  of  13  consecutive  histidine   residues   (His)  and  a   region  enriched   in  
serine/threonine   residues  at   the  C-­terminus.  Class   II  DYRKs  show  a   common  structure  
with  the  characteristic  NAPA  domain  at  the  N-­terminus.  
  
Figure   I.3  DYRKs  gene  expression.  Heatmap  showing  RNA  expression   levels   in  TPM  
(transcript  per  million)  of  DYRK   family  genes  across  human   tissues.  Data  obtained  and  
figure  adapted  from  the  Genotype-­tissue  expression  (GTEx)  portal.  
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1.3.  The  protein  kinase  DYRK1A  
Human   DYRK1A   gene   is   located   in   the   chromosome   21   (HSA21),  
mapping   in   the   Down   syndrome   (DS)   critical   region   (DSCR),   and  
certainly  represents  the  most  extensively  studied  member  of  the  family.  
The  particular   interest  on  this  kinase  is  mainly  due  to  its   importance  in  
tissue  development  and   in  DS  etiology   (Arbones  et  al.,  2019).  For   the  
purpose  of  this  thesis  work,  which  considers  the  whole  family  of  DYRK  
kinases   but   focuses   especially   on   the   member   DYRK1A,   a   more  
detailed   description   of   what   is   currently   known   about   this   kinase,  
including   activation,   mechanisms   of   regulation   and   its   implication   in  
human  disease,  is  provided  in  this  section.  
1.3.1.  Mechanism  of  activation  
The  definition  “dual-­specificity”  is  due  to  the  ability  of  DYRK  kinases  to  
phosphorylate   both   tyrosine   (Y)   and   serine/threonine   (S/T)   residues,  
even  though  Y-­phosphorylation  is  restricted  to  the  autophosphorylation  
activity.   As   most   of   protein   kinases,   full   activation   of   DYRK   kinases  
depends   on   the   phosphorylation   of   a   Y-­residue   within   the   activation  
loop,  which  leads  to  a  crucial  conformational  switch  from  an  inactive  to  
an  active  state  (Himpel  et  al.,  2001;;  Kentrup  et  al.,  1996;;  Nolen  et  al.,  
2004).  For  DYRK  kinases,   this  key  event   results   from  an  autocatalytic  
reaction,  which  occurs  during  protein  synthesis  (in  the  case  of  DYRK1A  
in   Y321),   generating   a   constitutively   active   kinase   (Lochhead   et   al.,  
2005).   In   addition,   Lochhead   and   colleagues   provided   experimental  
evidence   that   DYRK1A   nascent   kinase   forms   a   folding   intermediate,  
which   has   Y-­specificity   and   is   able   to   catalyze   autophosphorylation  
during  protein  maturation.  Thus,  once  mature,  the  Y321-­phosphorylated  
kinase   is   folded,  and   its   residue-­specificity   shifts   to  S/T   (Lochhead,  et  
al.,   2005).   Nevertheless,   this   model   has   been   questioned   by   other  
studies.   In   particular,   it   has   been   shown   that   Y321   dephosphorylation  
does  not  trigger  a  complete  loss  of  activity  in  vitro  (Adayev  et  al.,  2007;;  
Becker   and   Sippl,   2011),   and   other   investigators   even   claimed   that  
mature  DYRK1A  retains  Y-­phosphorylation  activity  (Walte  et  al.,  2013).  
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DYRK1A   has   been   proposed   to   be   a   proline-­directed   kinase,   with   a  
RPX(S/T)P   consensus   sequence   (Himpel   et   al.,   2000);;   however,   this  
specificity  does  not  seem  to  be  so  stringent,  with  other   residues   (S,  A  
and  V)  allowed  in  the  P+1  position  (Soundararajan  et  al.,  2013).  
The  regulation  of  protein  kinases  is  crucial  for  the  normal  cell   function.  
As   the   other  members   of   the   family,   DYRK1A   is   constitutively   active,  
thus   requiring   other   mechanisms   for   regulation;;   these   may   include  
modulation  of  DYRK1A  enzymatic  activity  by  allosteric  mechanisms  and  
interaction   with   regulatory   proteins   and   intracellular   protein   levels.   In  
turn,   the  protein  accumulation   levels  depend  on   the   interplay  between  
different  molecular  mechanisms,  which   concurrently   participate   to   rule  
protein   turnover.   Finally,   a   third   layer   of   regulation   is   defined   by   the  
distribution   of   the   kinase   in   distinct   cellular   compartments,   which  
determines   differential   substrate   accessibility.   All   these   aspects   are  
discussed  in  the  next  sections.  
1.3.2.  Protein  expression  
Protein   amounts   directly   depend  on  gene  expression   levels   and  post-­
transcriptional  regulatory  events.  As  previously  mentioned,  DYRK1A   is  
expressed   through   distinct   transcripts,   due   to   alternative   promoters  
(Figure  I.4A),  with  different  activity  and  regulation  (Maenz  et  al.,  2008).  
Alternative   splicing   events   give   rise   to   two   distinct   protein   isoforms,  
different  in  9  aa  at  the  non-­catalytic  N-­terminus  (Guimera,  et  al.,  1999),  
and   with   no   reported   differences   in   terms   of   expression   levels   and  
function  (Figure  I.4B).  A  29  aa-­shorter  isoform  might  be  produced  as  a  
result  of  pB  promoter  usage  and  exon  2  skipping  (Figure  I.4A)  (Maenz,  
et   al.,   2008).   Several   transcription   factors   have   been   shown   to  
modulate  DYRK1A   expression,   including   E2F1   (Maenz,   et   al.,   2008),  
RE1   silencing   transcription   factor   (REST)   (Lu   et   al.,   2011),   Nuclear  
factor   of   activated   T-­cells   (NFAT)   (Lee   et   al.,   2009),   and   T-­box  
transcription   factor   5   (TBX5),   the   latter   during   miR-­10b-­induced,  
invasive   breast   tumorigenesis   (Kim   et   al.,   2016).   Post-­transcriptional  




miR-­1246   (da  Costa  Martins  et   al.,   2010;;  Zhang  et   al.,   2011).  Finally,  
results   from   our   group   demonstrated   that   DYRK1A   transcript   and  
protein   levels   seem   to   be   cell   cycle-­dependent,   increasing   during   cell  
cycle   progression   and   reaching   the  maximum  during   the  G2/M  phase  
(Di  Vona  and  de  la  Luna,  unpublished  results).  
  
  
Figure   I.4   Promoter   usage   and   alternative   splicing   events   in   DYRK1A.   A)   Distinct  
promoters  control  DYRK1A  expression   (see   text   for  more   information  on  promoters  pA,  
pB  and  pM).  The  existence  of  an  upstream  promoter  (pX)  is  inferred  from  the  presence  of  
active-­transcription-­chromatin   marks   based   on   ENCODE   data.   B)   The   use   of   an  
alternative  splicing  acceptor  site  in  exon  4  regulates  the  inclusion/exclusion  of  a  segment  
of   27   nucleotides,   and   thereby   of   a   9   amino   acid   region.   Adapted   from   (Aranda   et   al.,  
2011).  
  
1.3.3.  Protein  stability  
DYRK1A  is  targeted  to  proteasome  degradation,  as  it  has  been  proven  
to   be   sensitive   to   proteasome   inhibitors   (Alvarez,   2004).   However,   a  
clear   regulatory   mechanism   for   DYRK1A   degradation   has   not   been  
elucidated   yet.   By   looking   at   the   protein   domains,   the   presence   of   a  
PEST  motif   suggests   that  DYRK1A  protein  may  have  a  short  half-­life,  
since   this   type   of   sequence   has   been   generally   associated   to   fast  
degradation   (Rogers   et   al.,   1986).   Few   cellular   factors   have   been  
shown   to   be   regulators   of   DYRK1A   turnover;;   among   these,   the  
chaperone  Heat  shock  protein  90   (HSP90)  and   the  co-­chaperone  Cell  
division  cycle  37   (CDC37)   interact  with  DYRK1A  during   its  maturation  
process  (Sonamoto  et  al.,  2015).  The  scaffold  protein  DDB1  and  CUL4  
associated   factor   7   (DCAF7;;   also   named  WDR68   or  HAN11)   forms   a  
complex  with  DYRK1A   (Glenewinkel   et   al.,   2016;;  Skurat   and  Dietrich,  
2004).   This   interaction   is   also   conserved   in   evolution   and   it   has   been  
confirmed   in   zebrafish   and   in   D.   melanogaster   (Nissen   et   al.,   2006;;  
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DYRK1A  activity  during  development  and  cell  differentiation.  Recently,  
Yousefelahiyeh  and  colleagues  showed  that  DYRK1A  protein  levels  are  
reduced   in   DCAF7-­knock-­out   cells   and   that   such   decrease   does   not  
depend  on  proteasome  activity  (Yousefelahiyeh  et  al.,  2018).  
Interestingly,   DYRK1A   stability   and   catalytic   activity   could   be  
functionally   linked,   since   an   inactive   form   by   mutation   in   the   ATP  
binding   site,   K188R,   has   a   shorter   half-­life   compared   with   the   WT  
protein   (Alvarez,   2004).   This   could   represent   a   cellular  mechanism   to  
promote  degradation  of  non-­functional  kinases.  Supporting   this  model,  
intramolecular   autophosphorylation   on   S97   by   a   folding   intermediate  
seems  to  play  a  central  role  in  preventing  protein  degradation  (Kii  et  al.,  
2016).   In   this   context,   results   from   our   lab   also   demonstrated   that  
Nemo-­like   kinase   phosphorylates   DYRK1A   in   several   residues   and  
proposed   that   these   events   mediate   its   degradation   via   proteasome,  
suggesting   that   other   kinases   could   be   involved   in   the   regulation   of  
DYRK1A  stability  (Arató,  2010).  
1.3.4.  Subcellular  localization  
DYRK1A  localizes  in  different  cellular  compartments,  depending  on  the  
cell   type,   adding   another   layer   of   complexity   in   DYRK1A   regulation.  
Despite   of   a   prevalent   cytosolic   enrichment   observed   in   different   cell  
lines   (Di  Vona  et   al.,   2015)   (and  unpublished   results   from  our  group),  
and   in   central   nervous   system   (CNS)   tissues   (Hammerle   et   al.,   2003;;  
Wegiel  et  al.,  2004),  endogenous  DYRK1A  localization  in  cell  nuclei  of  
primary   cerebellar   cells   and   C2C12   myoblasts   has   been   shown  
(Fernandez-­Martinez   et   al.,   2009;;   Marti   et   al.,   2003).   Moreover,  
DYRK1A   accumulation   in   cell   nuclei   following   ectopic   expression   has  
been  observed  in  other  cell  types  of  the  CNS  (Sitz  et  al.,  2004;;  Yabut  et  
al.,  2010),  and  in  several  human  cell  lines  (Alvarez  et  al.,  2003;;  Rozen  
et   al.,   2018).   Besides,   DYRK1A   associates   to   specific   cellular  
structures,  both  in  the  cytoplasm  and  in  the  nucleus,  including  synaptic  
membranes,   vesicles   and   cytoskeletal   fractions   (Aranda   et   al.,   2008;;  




the  nucleus,  DYRK1A  is  found  in  high  molecular  weight  complexes  and  
it   is   recruited   to   chromatin   at   proximal   promoters   where   it   regulates  
gene  expression  (Di  Vona,  et  al.,  2015).   In  addition,  different  DYRK1A  
phosphorylated  forms  show  distinct  cellular  distribution  (Kaczmarski,  et  
al.,  2014;;  Kida  et  al.,  2011),   indicating   that  DYRK1A  post-­translational  
modifications  are  also  implicated  in  this  type  of  regulation.  
When   ectopically   expressed,   DYRK1A   mostly   accumulates   in   the  
nucleus   thanks   to   two   nuclear   localization   signals   (NLS)   (Figure   I.2),  
both   necessary   for   full   DYRK1A   nuclear   translocation   (Alvarez   et   al.,  
2007).   The   kinase   shuttles   between   the   nucleus   and   the   cytosol  
through   a   dedicated   nuclear   export   signal   (de   la   Luna's   lab,  
unpublished   results).   It   is   therefore   possible   that   the   different  
subcellular   localization   between   the   endogenous   DYRK1A   and   the  
overexpressed   one   could   be   due   to   alterations   in   the   equilibrium  
between   the   export   and   import   mechanisms.   Within   the   nucleus,  
DYRK1A   is   found   concentrated   to   nuclear   speckles   (Alvarez,   et   al.,  
2007).   The  His-­repeat   at   the  non-­catalytic  C-­terminus   (Figure   I.2)   has  
been  proved  to  be  responsible  for  the  accumulation  in  nuclear  speckles,  
suggesting   possible   interactions   with   other   factors   involved   in   RNA  
metabolism,  gene  expression  and  splicing  regulation  (Galganski  et  al.,  
2017;;  Salichs  et  al.,  2009).  
1.3.5.  Modulation  of  kinase  activity  
As  for  other  CMGC  group  kinases,  dephosphorylation  of   the  activation  
loop-­tyrosine  might  represent  a  mechanism  for  DYRK1A  inactivation  in  
cells.   Nevertheless,   no   phosphatases   targeting   DYRK1A   have   been  
identified  so  far.  
DYRK1A-­interacting   proteins   have   been   shown   to  modulate   DYRK1A  
activity.  Results   from  our   group   indicate   that   binding   of   the   regulatory  
factor  14-­3-­3β,  which   is  mediated  by  an  autophosphorylation  event  on  
the   S520   residue   (S529   in   the   longest   isoform)   enhances   DYRK1A  
enzymatic   activity   (Alvarez,   et   al.,   2007).   DYRK1A   interacts   with  
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another   member   of   the   same   family   of   proteins,   14-­3-­3ε,   which   also  
resulted   in   increased  DYRK1A  activity   (Kim  et  al.,  2004).  The  scaffold  
protein  DCAF7  has  been  also  shown  to  modulate  DYRK1A  activity,  by  
helping   in   substrate   recruitment   (Glenewinkel,   et   al.,   2016).   Other  
DYRK1A  activity-­modulating  factors  are  Sprouty-­related  protein  with  an  
EVH1   domain   1/2   (SPRED1/2)   proteins,   which   have   been   found   to  
compete  for  substrate  binding,  thereby  inhibiting  its  kinase  activity  (Li  et  
al.,   2010).  Finally,   the  Large   tumor   suppressor   kinase  2   (LATS2)  was  
found   to   phosphorylate   DYRK1A   and   increase   its   ability   to  
phosphorylate   Lin52,   a   member   of   the   DREAM   (dimerization  
partner/DP  retinoblastoma-­like,  E2F  and  MuvB)  complex  (Tschop  et  al.,  
2011).  
1.3.6.  DYRK1A  in  disease  
DYRK1A   is   a   dosage   sensitive   gene,   meaning   that   little   variations   in  
protein   amounts   give   rise   to   severe   phenotypes;;   both   germline   gene  
extra-­dosage   as   well   as   haploinsufficiency   are   associated   to  
developmental  defects  and  human  pathologies  (Arbones,  et  al.,  2019).  
As  mentioned   in   previous   sections,   DYRK1A   is   located   in   the   DSCR  
and   it   is   found  1.5-­fold  overexpressed   in  DS   individuals   (Dowjat  et  al.,  
2007;;  Guimera,  et  al.,  1996).  Several  DYRK1A-­overexpressing  mouse  
models   have   been   shown   to   reproduce   morphological   and   cognitive  
defects   associated   to   DS:   altered   special   learning,   impaired   motor  
abilities   (Altafaj   et   al.,   2001),   memory   defects   (Ahn   et   al.,   2006),  
abnormal   retinal   size   and   function   (Laguna   et   al.,   2008),   skeletal  
alterations   (Blazek   et   al.,   2015),   and   higher   risk   to   develop   childhood  
leukemia   (Malinge   et   al.,   2012).   Interestingly,   several   works   have  
shown  that  genetic  or  pharmacological  normalization  of  DYRK1A  levels  
in  mice  models  with  partial  trisomy  rescued  some  of  the  abnormal  traits  
associated  with  DS,  including  impaired  learning  skills,  cognitive  deficits,  
hippocampal   development-­associated   memory   defects,   abnormal  
skeletal  and  retina  phenotypes  (Blazek,  et  al.,  2015;;  De  la  Torre  et  al.,  




Human   population   genomic   studies   include   DYRK1A   among   the  
intolerant   to   loss-­of-­function   (LoF)   genes,   highlighting   DYRK1A   as   a  
highly   essential   gene   (Lek   et   al.,   2016).   It   is   not   surprising   then,   that  
Dyrk1a-­/-­   mice   are   embryonic   lethal   (death   at   E10.5-­E13.5)   (Fotaki   et  
al.,   2002)   and   that   DYRK1A   haploinsufficiency   is   associated   to   a  
specific   human   disease.   In   diploid   organisms,   functional   loss   of   one  
allele   can   cause   haploinsufficiency   when   the   reduced   amount   of   the  
gene  product   is   not   able   to   preserve  normal   function,   therefore  giving  
rise  to  specific  phenotypes.  The  first  indications  that  loss  of  one  copy  of  
DYRK1A   caused   developmental   defects   and   could   be   linked   to  
pathological   traits   came   from   studies   on   mnb   haploinsufficient   flies  
(Tejedor   et   al.,   1995)   and   Dyrk1a+/-­   mice   (Fotaki,   et   al.,   2002).   In  
addition   to   a   smaller   brain   and   body   size,  Dyrk1a   heterozygous  mice  
showed  seizures,  cognitive  deficits,  autistic-­like  behaviors  (Arranz  et  al.,  
2019;;   Raveau   et   al.,   2018),   which   are   common   to   those   showed   by  
individuals   with  DYRK1A   haploinsufficiency.   After   the   identification   of  
DYRK1A  truncations  and  de  novo  missense  mutations  in  clinical  cases  
of   intellectual   disability   (ID)   and   autism   spectrum   disorder   (ASD)  
patients  with  specific  pathological   traits  (Courcet  et  al.,  2012;;  Moller  et  
al.,   2008;;   van   Bon   et   al.,   2011),   in   2016   van   Bon   et   al.   stated   that  
DYRK1A   haploinsufficiency   was,   in   fact,   a   novel   syndrome   (DHS)  
causing   a   specific   clinical   phenotype,   characterized   by   ID,   ASD,  
microcephaly,   intrauterine   growth   retardation,   seizures   and   a   specific  
facial  gestalt   (van  Bon  et  al.,  2016).  During   the   last   years  many  more  
cases   of  DYRK1A   de   novo   disrupting  mutations   have   been   identified  
and  DHS  is  currently  considered  a  rare  developmental  syndrome  within  
ASD,  included  in  the  Online  Mendelian  Inheritance  in  Man  database  as  
mental   retardation  autosomal  dominant  7   (MRD7;;  OMIM:614104),  and  
in   the   Orphanet   (ORPHA:464306)(Bronicki   et   al.,   2015;;   Earl   et   al.,  
2017;;  Ji  et  al.,  2015;;  Luco  et  al.,  2016).  Moreover,  our  group   recently  
published   an   extensive   biochemical   characterization   of   all   DYRK1A  
missense  mutations   reported   so   far,   which   shows   that   most   of   these  
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variants   cause   total   impairment  of  DYRK1A  kinase  activity   (Arranz,   et  
al.,  2019).  
One  of  the  most  frequently  studied  DYRK1A  substrates  is  Tau  (Woods  
et   al.,   2001),   an   important   microtubule   associated   protein   (MAP)   in  
neurons.   Hyperphosphorylated   forms   of   Tau   have   been   extensively  
associated   to   Alzheimer's   disease   (AD)   onset   (Harrison   and   Owen,  
2016).   Moreover,   DYRK1A   also   phosphorylates   Amyloid   precursor  
protein   (Ryoo   et   al.,   2008),   suggesting   that   DYRK1A  might   influence  
the  formation  of  Aβ  peptides.  High  mRNA  levels  of  DYRK1A  were  found  
in   the  hippocampus  of  AD  patients  (Kimura  et  al.,  2007)  and  DYRK1A  
inhibition   improved   pathological   phenotypes   in   mice   models   of   AD  
(Branca  et  al.,  2017),  providing  additional  evidence  for  a  possible  role  of  
DYRK1A   dysregulation   in   AD.   Furthermore,   alterations   in   DYRK1A  
expression   levels   have   been   also   associated   to   Parkinson’s   disease  
(Barallobre  et  al.,  2014;;  Cen  et  al.,  2016).  
Altered  DYRK1A  levels  have  been  also  linked  to  heart  defects  (Hille  et  
al.,  2016;;  Kuhn  et  al.,  2009;;  Raaf  et  al.,  2010)  and  bone  homeostasis  
(Lee,   et   al.,   2009).   Finally,   several   reports   suggest   that   targeting  
DYRK1A   leads   to   an   increase   in   pancreatic   β-­cells   proliferation,   thus  
making   DYRK1A   inhibition   through   chemical   compounds   a   potential  
therapeutic  solution  for  treating  diabetes  (Belgardt  and  Lammert,  2016;;  
Kumar  et  al.,  2018;;  Wang  et  al.,  2019).  
Experimental   evidence   achieved   during   last   years   also   suggest   that  
DYRK1A,  as  well  as  others  members  of  the  family,  might  participate  in  
tumor  formation  and  DYRKs'  expression  levels  have  been  found  altered  
in   certain   cancer   types.   These   findings   will   be   discussed   more  








2.  DYRK  kinases  in  cancer  
2.1.  The  cancer  genomics  revolution  
Cancer   is   one   of   the   leading   causes   of   death  worldwide.   In   2018,   18  
million  new  cases  were  diagnosed  and   it   is  predicted   that   this  number  
will   rise   to   24   million   new   cases   in   2040   (International   Agency   of  
Research  on  Cancer,  GLOBOCAN  2018)  (Ferlay  et  al.,  2019).  Cancer  
encompasses   a   set   of   diseases   that   arise   as   a   consequence   of  
uncontrolled  proliferation  and  spreading  of  transformed  malignant  cells.  
In  the  late  70s,  researchers  discovered  the  first  cancer-­causing  genes,  
demonstrating   what   had   been   speculated   for   decades:   cancer   is  
provoked  by  alterations  of  the  DNA  genomic  sequence  (Stehelin  et  al.,  
1976;;  Tabin  et  al.,  1982).  As  a  consequence  of   the  new  availability  of  
human   genetic   information,   cancer   genomics   emerged   as   a   new   field  
and   involved   research   efforts   to   collect   sequencing   data   from   cancer  
samples,  aimed  to  identify  recurrent  genomic  alterations  in  cancer  cells.  
The  first  on-­line  Catalogue  of  Somatic  Mutations  in  Cancer  (COSMIC),  
a   curated   collection   of   mutations   in   cancer   samples   available   for  
research  community,  was  created  in  2004  (Bamford  et  al.,  2004).  In  this  
line,   in   2006   National   Center   Institute   (NCI)   launched   a   pilot   project  
named  The  Cancer  Genome  Atlas  (TCGA),  and  a  full  project  in  2009;;  in  
parallel,   an   international   research   unit   launched   the   International  
Cancer  Genome  Consortium   (ICGC)   (International  Cancer  Genome  et  
al.,   2010).   In   an   outstanding   article   published   in   Nature   Reviews   in  
2009,  Michael  Stratton,  Peter  Campbell  and  Andrew  Futreal  stated  “we  
look  forward  to  the  explosion  of  information  about  cancer  genomes  that  
is   imminent  and   the   insights   into   the  process  of  oncogenesis   that   this  
promises   to  generate”   (Stratton  et  al.,  2009).   Indeed,   thanks   to   further  
advances   in   sequencing   technologies,   which   have   considerably  
improved  their  sensitivity  and  resolution  capacity,  the  field  has  exploded  
in   the   last   decade.   Many   independent   large-­scale   studies   aimed   to  
sequence   and   analyze   hundreds   to   thousands   of   tumor   samples,  
covering  different  tumor  types,  were  conceived  (Meyerson  et  al.,  2010;;  
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Vogelstein  et  al.,  2013;;  Zhang  et  al.,  2018).  Other  platforms  of  cancer  
data   annotation   and   visualization,   such   as   cBio   Cancer   Genomics  
Portal  (cBioPortal)  (Cerami  et  al.,  2012)  and  IntOGen  (Gonzalez-­Perez  
et  al.,  2013)  appeared.  The  last  event   in  this  story  is  the  publication  of  
the   Pan-­Cancer   Atlas   by   the   TCGA   consortium:   an   extended  
comprehensive  analysis  of  more  than  11,000  tumor  samples  spanning  
33  tumor  types,  based  on  multiple  genome-­wide  platforms  (Hoadley  et  
al.,  2018).  
2.2.  Discovery  of  new  cancer  driver  genes  
One   of   the   main   goal   of   cancer   genomics   is   to   identify   new   cancer-­
related  genes  and  to  understand  how  they  participate  to  tumor  initiation  
and  progression.  As  previously  mentioned,   cancer   is   a  disease  of   the  
genome.  Neoplastic   transformation   of   a   normal   cell   into   a   cancer   cell  
and   the   following   steps   of   tumor   progression   are   driven   by  
accumulation   of   genetic   alterations   that   confer   selective   growth   and  
survival   advantages   (Figure   I.5).   These   mutations   are   called   “driver”  
mutations,   and   they   must   be   distinguished   from   the   vast   majority   of  
mutations   (“passengers”)   present   in   tumor   genomes   that   do   not  
contribute   to   the   malignant   phenotype   of   the   cell.   Indeed,   driver  
mutations   are   estimated   to   represent   only   the   1-­2.5%   of   the   total  
number  of  mutations  in  cancer  samples  (Vogelstein,  et  al.,  2013).  Such  
mutations   occur   in   genes   responsible   for   the   oncogenic   properties   of  
cancer  cells,  which  are  therefore  defined  as  cancer  driver  genes.  
As   suggested   by   Vogelstein   and   colleagues,   it   is   likely   that   all   major  
cancer   driver   genes,   the   ones   that   are   recurrently   found   mutated   in  
tumor   cells,   have   already   been   identified   (Vogelstein,   et   al.,   2013).  
However,   there   is   a   broad   land   of   low   frequency-­mutated   genes   that  
contribute   to   the   oncogenic   phenotype,   which   are   harder   to   identify.  
These   low-­penetrance  genes,  which  were   defined  as   the   “hills”   of   the  
cancer  landscape  to  distinguish  them  from  the  high  frequency-­mutated  
genes   (“mountains”)   (Wood  et   al.,   2007),   are   the  ones   that   determine  




Driver   genes   that   are   mutated   less   frequently   in   tumors   represent   a  
potential   source   of   tumor-­specific   targets   to   be   exploited   for  
personalized   therapies.  Thus,  one  major   challenge  of   cancer  genomic  
research  has  been   to   develop  efficient   computational   tools   to   analyze  
cancer   mutation   patterns   that   could   disclose   new   driver   genes   and  
pathways.   Several   methods   have   been   described   so   far  
(Dimitrakopoulos  and  Beerenwinkel,  2017;;  Tokheim  et  al.,  2016),  each  
method   considering   different   parameters   to   define   the   likelihood   of   a  
gene   to   be  a   tumor   driver   and   thus  generating   lists   of   potential   driver  
genes.   For   instance,   Tumor   Suppressor   and   Oncogene   (TUSON)  
explorer   was   developed   to   predict   the   potential   of   a   given   gene   to  
function   as   tumor   suppressor   or   oncogene,   computing   profiles   of  
somatic   mutations   and   copy   number   alterations   (Davoli   et   al.,   2013).  
Other  approaches,  such  as  HotNet2   (Leiserson  et  al.,  2015),  consider  
alterations   in   whole   pathways   and   gene   networks,   rather   than   single-­
gene   lesions.   The   previously   mentioned   IntOGen   platform   includes  
complementary  algorithms  to  identify  driver  genes  by  detecting  different  
types   of   biases   (Gonzalez-­Perez,   et   al.,   2013),   such   as   the  
accumulation  of  high-­impact  mutations  (OncodriveFM,  (Gonzalez-­Perez  
and   Lopez-­Bigas,   2012))   or   the   clustering   in   particular   regions   of   the  
protein  sequence  (OncodriveCLUST,   (Tamborero  et  al.,  2013)).  These  
last  methods  are  considered   in   this  Thesis  work  and  a  more  accurate  
description  is  found  in  the  Materials  and  Methods  section.  Following  the  
release   of   the   Pan-­Cancer   Atlas,   a   collaborative   effort   by   several  
cancer  computational  groups  resulted  in  the  most  extensive  exploration  
of  cancer  data  to  identify  driver  genes  to  date  (Bailey  et  al.,  2018).  The  
study  was  carried  out  integrating  26  different  tools  and  generated  a  list  









Figure   I.5   Accumulation   of  mutations   during   development   and   cancer   formation-­
progression.   Representation   of   passenger   and   driver   mutation   events   occurring   since  
the  very  first  mitotic  cell  divisions  in  embryogenesis  until  tumor  formation  and  progression  
in   the   adult   organism,   encompassing   organism   life   periods   and   cancer   stages.   Intrinsic  
mutation  processes  and  environmental  effects  are  the  leading  causes  of  accumulation  of  
mutations;;   dysregulation   of   the   DNA   damage   machinery   components   can   lead   to   a  
mutator   phenotype   characterized   by   an   accelerated   mutational   process   and   eventual  
chemotherapy   can   also   enhance   the   mutation   burden.   Adapted   from   (Stratton,   et   al.,  
2009).  
  
2.3.  Protein  kinases  are  tumor  drivers  
Protein  kinases  catalyze  reaction  by  which  the  gamma  phosphate  of  an  
ATP  molecule   is   transferred   to   the  hydroxyl  group  of  a  substrate.  This  
simple  chemical  event   represents   the  most   common  post-­translational  
modification   in   living   systems   and   dramatically   affects   the   function   of  
the   substrate,   thus   playing   a   central   role   in   the   modulation   of   most  
cellular  processes.  Notably,  mutations   in   kinase  genes  are  associated  
to   many   types   of   human   disorders,   including   cancer   (Lahiry   et   al.,  
2010).  
The   protein   product   of   the   first   discovered   oncogene,   the   cellular  
homologous  of  the  v-­Src  gene  of  the  Rous  Sarcoma  virus,  was  found  to  
have  kinase  activity   (Collett  and  Erikson,  1978;;  Stehelin,  et  al.,  1976).  
Forty  years   later,  many  other  oncogenes  and  tumor  suppressor  genes  
are  known  to  encode  for  protein  kinases,  and  dysregulation  of  signaling  
pathways  caused  by  mutated  protein  kinases  is  extensively  associated  
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In   2004,   the   first   census   of   genes  mutated   and   casually   implicated   in  
cancer,  the  Cancer  Gene  Census,  was  published  (Futreal  et  al.,  2004),  
and   it   revealed   that   the   most   common   domain   encoded   by   cancer  
genes   is   the   kinase   domain   (Futreal,   et   al.,   2004).   Thus,   following  
cancer  genomic  studies  uncovered  driver  mutations  in  larger  groups  of  
protein   kinases   (Greenman   et   al.,   2007;;   Kan   et   al.,   2010).   More  
recently,   lists   of   cancer   driver   genes   provided   by   the   analysis   and  
interpretation  of  cancer  genomic  data  generated   in   large-­scale  studies  
confirmed  a  strong  enrichment  for  protein  kinases  (Fleuren,  et  al.,  2016)  
(Figure  I.6).  Interestingly,  DYRK1A  appears  as  a  tumor  driver  kinase  in  
the   lists   provided  by  Fleuren  and  colleagues   (Figure   I.6),   since   it  was  
included  among   the   potential   tumor   drivers   from   the   analysis  with   the  
previously  mentioned  TUSON  method  (Davoli,  et  al.,  2013).  
  
Figure   I.6   Driver   kinases   and   their   cancer-­associated   alterations.   Human   kinome  
phylogenetic   tree  showing  89  driver  kinases  extracted  from  cancer  genomic  studies  and  
the   type  of   genetic   alterations   found   in   tumor   samples.  The  DYRK   family   is   highlighted  
with  a  purple  circle.  DYRK1A  is  the  only  member  of  the  family  included  in  the  list  and  it  is  
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While   cancer   genomic   studies   were   collecting   new   data   on   cancer  
somatic   mutations   occurring   on   kinase   genes,   high-­throughput   RNAi  
screens   started   to  provide  exciting  new   insight  on   kinase-­dependency  
by  tumor  cells  (Baldwin  et  al.,  2008;;  Baldwin  et  al.,  2010;;  Bommi-­Reddy  
et   al.,   2008;;   Grueneberg   et   al.,   2008;;   Grueneberg   et   al.,   2008).   All  
these  pieces  of   information  contributed   to   identify  novel   tumor-­specific  
driver   kinases   that   represent   potential   targets   for   new   therapeutic  
interventions.  Indeed,  kinases  are  easily  targeted  with  small  molecules.  
Considering  the  link  between  altered  protein  kinase  activity  and  onset  of  
human  pathologies,  it  is  not  surprising  that  many  kinase  inhibitors  have  
already   been   identified   and   approved   for   therapies.   In   1995,   the   first  
kinase   inhibitor   (Fasudil,   targeting   ROCK   kinase)   was   approved   for  
treatment  of  cerebral  vasospasm  (Shibuya  et  al.,  1992).  Studies  aimed  
at  targeting  the  BCR-­ABL  fusion  gene,  which  causes  the  expression  of  
constitutively  active  ABL  kinase   (Koretzky,  2007),   led   to   the  discovery  
of   a   phenyl-­amino-­pyrimidine   ABL   inhibitor   later   called   Imatinib   by  
Novartis   (Buchdunger   et   al.,   2001;;   Druker   et   al.,   1996).   Imatinib   was  
approved  by  the  Federal  Drug  Administration  (FDA)  for  the  treatment  of  
chronic   myeloid   leukemia   in   2001   and   represents   the   first   kinase  
inhibitor  approved  by  the  FDA  for  cancer  therapy.  In  the  following  years,  
other   inhibitors   targeting   well   known   cancer   kinases   like   Erlotinib  
(targeting   Epidermal   growth   factor   receptor   [EGFR])   and   Sofarenib  
(targeting   Raf,   Vascular   endothelial   growth   factor   receptor   [VEGFR]  
and  Platelet-­derived  growth   factor   receptor   [PDGFR]β)  were  approved  
for   non-­small-­cell   lung   cancer   and   renal   cell   carcinoma,   respectively  
(Bonomi,   2003;;   Escudier   et   al.,   2007).   Identification   of   novel   kinases  
contributing   to   tumor   initiation/progression   prompted   academic   and  
pharmaceutical   researchers   to   put  major   efforts   in   drug   discovery.   To  
date,   there   are   41   kinase   inhibitors,   targeting   single   or  multiple   tumor  
driver  kinases,  approved  by  FDA  for  cancer  treatment,  with  hundreds  of  





However,  specificity  of  kinase   inhibitors   is  a  noteworthy   issue.  Most  of  
the  compounds  currently  used   in   research  and  clinics   target   the  ATP-­
binding   pocket,   which   is   conserved   throughout   the   kinome   and   thus  
compromised   specificity.   Independent   studies   have   examined   the  
specificity   of  widely   used   kinase   inhibitors   demonstrating   that  most   of  
them   have   low   specificity   (Bain   et   al.,   2007;;   Fabian   et   al.,   2005;;  
Fedorov  et  al.,  2007;;  Karaman  et  al.,  2008).  
Although   many   novel   kinases   potentially   involved   in   cancer  
development   have   been   identified   in   genomic   studies   and   functional  
screens,  there  is  a  strong  need  for  further  cellular  and  molecular  studies  
to   better   elucidate   how   they   participate   in   oncogenic   processes.  
Academic  and  pharmaceutical  research  remains  largely  biased  towards  
kinases   that   are   most   extensively   described   so   far   (Fedorov   et   al.,  
2010),   while   efforts   to   understand   cellular   mechanisms   regulated   by  
novel  putative  driver  kinases  should  be  improved.    
2.4.  DYRK1A  in  cancer  
DYRK1A   kinase   is   a   pleiotropic   factor   that   phosphorylates   a   broad  
group   of   substrates   involved   in   many   different   cellular   processes.   As  
remarked   by   Vogelstein   et   al.,   the   pathways   that   are   responsible   for  
selective   growth   advantage   in   cancer   cells   are   limited   and   can   be  
organized   in   three   core   cellular   processes:   cell   fate,   cell   survival   and  
genome   maintenance   (Vogelstein,   et   al.,   2013).   Strikingly,   DYRK1A  
phosphorylates   and   modulates   the   activity   of   several   cellular   factors  
regulating   cellular   processes   that   are   included   in   the   three   categories  
(Figure  I.7).  
In   the   past   decade,   a   number   of   research   works   have   ascribed   to  
DYRK1A  opposite   functions   in  cancer,  drawing  a  complex  scenario.   In  
fact,  DYRK1A  is  suggested  to  act  both  as  a  tumor  suppressor  and  as  a  
tumor  promoter,   in  different  biological  contexts  (Figure  I.8).  The  pieces  
of  research  regarding  potential  functions  of  DYRK1A  in  mediating  tumor  
initiation/progression  are  summarized  in  the  next  sections.  
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Figure   I.7   DYRK1A   substrates   involved   in   cancer-­related   cellular   processes.  
Substrates  of  DYRK1A  that  are  described  to  participate  in  cell  fate  decisions  (green),  cell  
survival  regulation  and/or  proliferation  (light  blue)  or  genomic  stability  maintenance  (red)  
pathways.   Many   of   these   proteins   are   ascribed   to   more   than   one   cancer-­related   core  
process  (see  the  text  for  more  details).  BRCA1  (Barba,  2017),  Caspase-­9  (Laguna,  et  al.,  
2008),  CDK5L  (Oi  et  al.,  2017),  CREB1  (Yang  et  al.,  2001),  Cyclin  D1  (Chen  et  al.,  2013),  
Cyclin  D3  (Thompson  et  al.,  2015),  FOXO1  (Woods  et  al.,  2001),  GLI1  (Mao  et  al.,  2002),  
GSK3β  (Song  et  al.,  2015),  HIP1  (Kang  et  al.,  2005),  ID2  (Lee  et  al.,  2016),  JUN  (Morton  
et  al.,  2003),  Lin52  (Litovchick  et  al.,  2011),  MYC  (Liu  et  al.,  2014),  NFATc1/c2/c4  (Arron  
et   al.,   2006),  NOTCH   (Fernandez-­Martinez,  et   al.,   2009),   p27/KIP   (Soppa  et  al.,   2014),  
p53  (Park  et  al.,  2010),  RNF169  (Roewenstrunk,  2016),  SIRT1  (Guo  et  al.,  2010),  Sprouty  
(Aranda,  et  al.,  2008).  
  
2.4.1.  The  interaction  of  DYRK1A  with  viral  oncoproteins  
The   first  evidence  of  a   role  of  DYRK1A   in  cell   immortalization  derives  
from  studies  on  oncogenic  viruses,  which  suggested  a  role  for  DYRK1A  
in  cell  transformation  in  oncovirus-­associated  cancer  models.  As  the  S.  
cerevisiae   DYRK   Yak1p,   both   DYRK1A   and   DYRK1B   bind   to   the  
adenovirus  oncoprotein  E1A  (Komorek  et  al.,  2010;;  Zhang  et  al.,  2001)  
(Figure   I.8),   which   is   responsible   for   adenovirus-­induced   oncogenic  
transformation   (Frisch   and   Mymryk,   2002).   This   interaction   is  
dependent  on  the  scaffold  protein  DCAF7,  which  serves  as  an  adaptor  
for   DYRK1A-­E1A   binding,   which   in   turn   might   promote   the  
phosphorylation   of   E1A   at   S89   (Glenewinkel,   et   al.,   2016).   This  
interaction  appears  to  contribute  to  the  adenovirus  ability  to  regulate  the  




























viral   oncoprotein   regulated   by   DYRK1A   is   the   human   papilloma   virus  
(HPV)   E7   protein   (Figure   I.8).   By   using   primary  mouse   keratinocytes,  
Chang   and   colleagues   showed   that   Dyrk1a   mRNA   levels   were  
increased  when  cells  were   immortalized  by   infection  with   the  high   risk  
HPV   strain   16   (HPV16)   and   that  Dyrk1a   expression   levels   correlated  
with   those   of   the   virus   regulatory   protein   E7   (Chang   et   al.,   2007).  
Analysis  of  cervical   lesions  from  HPV-­derived  patient  samples  showed  
that   DYRK1A   protein   levels   were   increased,   compared   with   the  
respective  normal  tissue  (Chang,  et  al.,  2007).  A  molecular  mechanism  
by   which   DYRK1A   interacts   and   phosphorylates   the   HPV16   E7,   thus  
increasing  its  stability,  has  been  proposed  (Liang  et  al.,  2008).  
2.4.2.  DYRK1A  is  engaged  in  cell  cycle  regulation  
Cell   cycle   entry/arrest   is   based   on   the   activation   of   key   regulators   in  
response   to   external   stimuli,   which   leads   to   changes   in   gene  
expression.   Uncontrolled   proliferation   of   cancer   cells   is   often   a  
consequence   of   disruption   of   cell   cycle   checkpoints;;   indeed,   cellular  
factors  involved  in  the  fine-­tuned  regulation  of  cell  cycle  are  often  found  
altered  in  cancer  (Kastan  and  Bartek,  2004).  DYRK  kinases  have  been  
described   as   cell   cycle   kinases   (Becker,   2012)   and   DYRK1A  
phosphorylates   key   cell   cycle   modulators   like   Cyclin   D1   and   p27Kip1,  
thus  promoting  cell  cycle  exit   (Chen,  et  al.,  2013;;  Soppa,  et  al.,  2014)  
(Figure   I.8).   Indeed,   the   activity   of   DYRK1A   on   Cyclin   D1   and   D3   is  
linked   to   differentiation   decisions   in   cells   from   different   origin   as  
neurons  and  lymphocytes  (Najas  et  al.,  2015;;  Thompson,  et  al.,  2015).  
Several   groups   have   reported   interactomes   of   DYRK1A   based   on  
proteomic  approaches.  The  cell  cycle  regulators  retinoblastoma  protein  
(pRB)   or   pRB-­like   proteins-­like   p107   and   p130   are   detected   as  
DYRK1A   interacting   proteins   (Varjosalo   et   al.,   2013),   although   no  
functional  roles  for  these  interactions  have  been  defined.  
The   dimerization   partner   (DP),   RB-­like,   E2F   and   multi-­vulval   class   B  
(MuvB)   complex   (DREAM   complex)   is   a   highly   conserved,   master  
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mediator  of  cell  cycle  arrest  in  G0  (quiescence)  and  a  repressor  of  cell  
cycle   progression-­gene   expression   (Sadasivam   and   DeCaprio,   2013).  
DYRK1A   was   shown   to   be   a   DREAM   complex   kinase,   since   it  
phosphorylates   the  DREAM  key  component  Lin52.  Phosphorylation  of  
Lin52   on   S28   promotes   DREAM   complex   assembly   and   thereby  
triggers   cell   cycle  exit   (Litovchick,   et   al.,   2011)   (Figure   I.8).  Moreover,  
the  DYRK1A/DREAM  complex  appears   to  be   required   for  cell  entry   in  
oncogene-­induced  senescence  (Litovchick,  et  al.,  2011).  The  activation  
of   the   DREAM   complex   by   DYRK1A   was   suggested   to   be   the  
mechanism   responsible   for   ovarian   cancer   cell   dormancy   (MacDonald  
et   al.,   2017),   a   particular   quiescent   state   in   which   ovarian   cells   form  
spheroids,   escape   chemotherapy-­induced   apoptosis   and  migrate   from  
the   primary   tumor   site   (Shield   et   al.,   2009).   Moreover,   DYRK1A   has  
been   shown   to   mediate   a   similar   mechanism   in   gastroinstestinal  
stromal   tumor   (GIST)   cells   quiescence   induced   by   treatment   with  
imatinib  (Boichuk  et  al.,  2013).  
2.4.3.   DYRK1A   modulates   Receptor   tyrosine   kinases   (RTKs)-­
dependent  signaling  
A  very   important   family   of   kinases   involved   in   cancer-­pathways   is   the  
receptor  tyrosine  kinases  (RTK)  one.  By  coupling  growth  factor   ligand-­
binding   and   signaling   cascade   activation,   RTKs   represent   key  
regulators   of   many   cellular   processes,   such   as   cell   proliferation   and  
survival,   which   are   crucial   for   development   and   organogenesis  
(Lemmon  and  Schlessinger,  2010);;  RTKs  dysregulation  is  associated  to  
cancer   onset   and   metastasis   (Du   and   Lovly,   2018).   They   are   found  
altered  at  high   frequencies   in   tumors,  either  by  activating  mutations  or  
overexpression,   which   lead   to   the   hyperactivity   of   the   downstream  
signaling   (Du   and   Lovly,   2018).   Strikingly,   28   RTKs   out   of   58   known  
ones  are   found   in   the   list  of   tumor  driver  kinases  provided  by  Fleuren  
and   colleagues   (Fleuren,   et   al.,   2016).   Moreover,   most   of   the   kinase  
inhibitors  and  monoclonal  antibodies  approved  for  cancer  therapy  target  




EGFR  is  one  of   the  most  extensively  characterized  RTKs  (Lemmon  et  
al.,   2014).   EGFR   amplification   and/or   gain-­of-­function   mutations   are  
found  in  many  cancer  types  such  as  lung  cancer  (Sharma  et  al.,  2007)  
and   glioblastoma   (Eskilsson   et   al.,   2018).   Our   lab   and   collaborators  
showed   that   DYRK1A   prevents   EGFR   endocytosis-­mediated  
degradation  by  phosphorylating  the  RTK-­negative  regulator  Sprouty2  in  
neural   stem   cells   (Ferron   et   al.,   2010)   (Figure   I.8).   Following   this  
observation,   Pozo   and   colleagues   showed   that   DYRK1A   depletion  
reduced   EGFR   levels   in   glioblastoma   cell   lines   and   proposed   that  
EGFR   degradation   was   prevented   by   DYRK1A   also   in   brain   tumors.  
Notably,   they   also   showed   that   DYRK1A   levels   are   upregulated   in  
glioma   patient   samples   and   correlate   with   EGFR   levels   (Pozo   et   al.,  
2013).  
Last   year,   our   group  and   collaborators  published  a   study   in  which  we  
proposed  a  similar  correlation  between  the  RTK  c-­MET,  the  receptor  of  
hepatocyte  growth  factor  (HGF),  and  DYRK1A  protein  expression  levels  
in  pancreatic   ductal   adenocarcinoma   (PDAC)   tumor   samples   (Luna  et  
al.,  2018)  (Figure  I.8).  MET  is  another  well-­established  oncogene  found  
altered   in   many   types   of   cancer,   and   the   HGF-­MET   axis   is   often  
associated  with  activation  of  migration  and  invasion  pathways  in  cancer  
cells  (Birchmeier  et  al.,  2003;;  Spina  et  al.,  2015).  Our  data  shows  that  
DYRK1A   promotes   tumor   progression   through   the   stabilization   of   c-­
MET  (Luna,  et  al.,  2018).  As   results   included   in   this  article  have  been  
part   of   my   research   work   during   this   PhD   project,   it   is   included   as  
Annex  I.  
Another  RTK  regulated  by  DYRK1A  is  VEGFR2,  which  acts  as  a  major  
regulator   of   the   biogenesis   and   sprouting   of   blood   vessels  
(angiogenesis),   by   inducing   proliferation,   migration   and   invasion   of  
endothelial  cells  (Herbert  and  Stainier,  2011)  (Figure  I.8).  Results  from  
our  group  in  primary  endothelial  cells  support  a  pro-­angiogenic  role  for  
DYRK1A,   since   DYRK1A   depletion   caused   defects   in   VEGFR2-­
dependent   signaling   and   reduction   of   the   angiogenic   transcriptional  
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response.   Mechanistically,   these   effects   appear   to   be   the   result   of  
reduced  VEGFR2  accumulation  (Rozen,  et  al.,  2018).  
Altogether,  these  works  provide  evidence  of  a  general  role  for  DYRK1A  
in   positively   regulating   the   stability   of   RTK   receptors   in   different  
physiological  contexts.  
  
Figure   I.8  DYRK1A  modulates  cellular   factors   involved   in   tumorigenesis.  Overview  
of  DYRK1A  and  its  interaction  with  cellular  factors  involved  neoplastic  transformation  and  
cancer-­related   pathways.   Pro-­tumorigenic   and   tumor-­suppressive   functions   have   been  
proposed  by  independent  research  works  and  they  are  summarized  in  this  scheme  (see  
text).   Viral   oncoproteins   are   indicated   with   red   ovals,   RTK   with   purple   ovals   and  
intracellular   factors   and   complexes  with   green   ovals.   Adapted   from   (Nizetic   and  Groet,  
2012).  
  
2.4.4.  Regulation  of  NFAT  proteins  by  DYRK1A  
NFAT   proteins   represent   a   conserved   family   of   transcription   factors  
involved  in  vertebrate  development  and  immune  system  function,  which  
are   activated   in   response   to   increased   Ca++   intracellular   levels   in  
response   to   the   activation   of   many   different   signaling   pathways  

































including  cell  growth,  survival  and  angiogenesis,  dysregulation  of  NFAT  
proteins   is   linked   to   tumor   progression   (Mancini   and   Toker,   2009).  
DYRK1A  was   found   to  be  a   regulator  of  NFAT  signaling  pathway   in  a  
RNAi  screen  in  Drosophila  (Gwack  et  al.,  2006);;  since  NFAT  activation  
and  translocation  to  the  nucleus  is  prevented  by  hyperphosphorylation,  
DYRK1A  was  proposed  to  act  as  a  negative  regulator  of  NFAT  proteins,  
and  overexpression  of  DYRK1A  in  DS  models  was  suggested  to  impair  
normal   NFAT   function   (Arron,   et   al.,   2006)   (Figure   I.8).   The   effect   of  
DYRK1A  overexpression   in   negatively   regulating  NFAT  activation   has  
been  shown  in  several  pathological  scenarios  such  as  the  promotion  of  
megakaryoblastic   leukemia   (Malinge,   et   al.,   2012),   bone   homeostasis  
(Lee,  et  al.,   2009),  or   cardiomyocyte  hypertrophy   (Kuhn,  et  al.,   2009).  
Nevertheless,   our   group   proposed   an   opposite   role   for   DYRK1A   in  
regulating   NFAT   signaling   in   endothelial   cells.   Indeed,   DYRK1A   was  
shown   to   promote   VEGF-­dependent   NFAT   activation,   since   loss   of  
DYRK1A   activity,   either   through   knockdown   or   inhibition,   had   a  
dramatic   negative   impact   on   VEGF/Ca++/NFAT   signaling,   with   severe  
consequences   on   physiological   angiogenis   (Rozen,   et   al.,   2018).  
Together,   these   findings   indicate   that   changes   in   DYRK1A   dosage  
might   have   different   outcomes   on   NFAT   signaling,   depending   on   the  
cellular   context.   A   potential   negative   feedback   loop   regulatory  
mechanism   between  NFATc1   and  DYRK1A   has   also   been   proposed,  
adding   further  complexity   to   this  crucial  molecular  partnership   (Lee,  et  
al.,  2009)  (Figure  I.8).  
2.4.5.  DYRK1A  in  cancer:  some  extra  clues  
Besides   the   targets   described   in   the   previous   sections,   DYRK1A  
regulates  cellular  factors  that  are  extensively  described  to  participate  in  
malignant   transformation   processes,   as   it   is   the   case   of   the   tumor  
suppressor  p53.  TP53  represents  the  most  frequently  mutated  gene  in  
cancer,  with  variants  that  promote  tumor  initiation  either  by  suppressing  
p53   expression/activity   or   through   gain   of   function   (Martincorena   and  
Campbell,  2015;;  Sabapathy  and  Lane,  2018).  It  encodes  for  the  tumor-­
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suppressor   protein   p53,   whose   function   has   been   extensively   studied  
both   in   physiological   and   pathological   conditions.   Transcriptional  
regulation,   DNA   damage   repair,   induction   of   apoptosis   and   cell   cycle  
restrain   are   among   the   complex   network   of   p53   cellular   functions  
(Kastenhuber  and  Lowe,  2017).  DYRK1A  phosphorylates  p53  on  S15,  
enhancing   its   activity   and   thus   promoting   cell   cycle   arrest   in   neuronal  
embryonic   cells   (Park,   et   al.,   2010)   (Figure   I.8).   Moreover,   p53  
negatively   regulates   DYRK1A   by   inducing   the   expression   of   the  
microRNA  miR-­1246,   which   in   turns   suppresses   DYRK1A   expression  
(Zhang,   et   al.,   2011),   suggesting   a   negative   feedback   regulatory  
mechanism  (Figure  I.8).  
Inhibitor  of  DNA  binding  2  (ID2)  is  a  transcriptional  inhibitor,  which  has  
been   found   to   enhance   cancer   cells   stemness   and   invasive   capacity  
(Lasorella  et  al.,  2014).  Despite   the   tumor-­promoting   role  supported   in  
glioblastoma   (Pozo,   et   al.,   2013),   both   class   I   kinases   DYRK1A   and  
DYRK1B   phosphorylate   ID2   on   T27,   preventing   its   binding   to   von-­
Hippel   Lindau   and   thus   hampering   its   oncogenic   function   in  
glioblastoma   models   (Lee,   et   al.,   2016)   (Figure   I.8).   Moreover,   low  
levels  of  DYRK1A/DYRK1B  were  associated  to  poor  clinical  outcome  in  
glioma  patients.  
Dosage  imbalance  of  DYRK1A  was  found  to  alter  the  cellular   levels  of  
REST  transcription   factor   (Canzonetta  et  al.,  2008;;  Lepagnol-­Bestel  et  
al.,   2009),   a   key   regulator   of   neuronal   development,   which   has   been  
found   to   exert   a   potent   tumor   suppressive   role   and   prevent   epithelial  
cell   transformation   (Westbrook   et   al.,   2005).   As   well   as   for   p53,   a  
negative   feedback   loop   governing   the   DYRK1A-­REST   interplay   has  
been  suggested  (Lu,  et  al.,  2011)  (Figure  I.8).  
Additional   critical  pathways  modulated  by  DYRK1A  are   the  Hedgehog  
(HH)  and  Notch  signaling  pathways.  They  play  major  roles  in  vertebrate  
development   and   dysregulation   of   these   pathways   promote   tumor  




DYRK1A  interacts  and  phosphorylates  the  intracellular  domain  of  Notch  
and  thus  weakens  its  function  in  neural  cells  both  in  cell  culture  and   in  
vivo   (Fernandez-­Martinez,   et   al.,   2009).   On   the   other   hand,   DYRK1A  
phosphorylates   and   thus   promotes   nuclear   translocation   and  
transcriptional   activity   of   Glioma-­associated   oncogene   homologous   1  
(GLI1),  a  major  downstream  effector  of  HH  signaling  (Ehe  et  al.,  2017;;  
Mao,  et  al.,  2002;;  Schneider  et  al.,  2015).  
Finally,   a   direct   role   for  DYRK1A   in   promoting   tumor   progression   has  
been   suggested   by   additional   research   efforts.   Increased   DYRK1A  
protein   levels   were   observed   in   tissue   microarrys   of   head   and   neck  
squamous  cell  carcinoma  (HNSCC)  samples,  and  DYRK1A  knockdown  
or  chemical  inactivation  in  HNSCC  cell  lines  led  to  impaired  proliferation  
and   invasion   (Radhakrishnan   et   al.,   2016).   By   analyzing   RNA-­seq  
TCGA   data,   Kim   and   colleagues   found   DYRK1A   downregulation   in  
breast   cancer   samples;;   DYRK1A   was   proposed   to   act   as   a   tumor  
suppressor  in  mice  models  of  breast  carcinoma  and  that  its  expression  
was   dependent   on   the   transcription   factor   TBX5,   which   is   in   turn  
suppressed  by  the  oncogenic  microRNA  miR-­10b  (Kim,  et  al.,  2016).  
2.4.6.  Down  syndrome  and  cancer  
Thanks   to   the   increase  of   life  expectancy  of  DS   individuals   in   the   last  
decades  (Zhu  et  al.,  2013),  epidemiologic  studies  aimed  at  defining  the  
incidence   of   common   human   pathologies   and   comparing   with   normal  
population  have  become  more  and  more  accurate.  These  studies  have  
demonstrated   that   people   with   DS   have   a  marked   lower   incidence   of  
most  solid  tumors  (Boker  et  al.,  2001;;  Hasle  et  al.,  2000;;  Hasle,  2001;;  
Patja  et  al.,  2006)  and  reduced  cancer-­associated  mortality   (Hill  et  al.,  
2003;;   Yang   et   al.,   2002),   compared   with   age-­adjusted   non-­DS  
population.   The   only   exceptions   are   germ   cell   tumors,   in   particular  
testicular   germ   cell   tumors   (Hasle,   2001;;   Hill,   et   al.,   2003),   and  
childhood   leukemia   (Lee  et  al.,  2016).   Indeed,  DS  children  have  10   to  
50-­fold   increased  risk  of  developing  acute   lymphoblastic   leukemia  and  
acute   myeloid   leukemia   (AML)   (Hasle,   2001).   Moreover,   acute  
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megakaryoblastic   leukemia   (AMKL),   which   is   preceded   by   transient  
myeloproliferative   disorder,   a   particular   malignancy   characterized   by  
megakaryoblast   clonal   expansion,   has   a   500-­fold   increased   incidence  
in   DS   children   (Al-­Kasim   et   al.,   2002).   Overexpression   of   RUNX1,   a  
tumor   suppressor   gene   located   in  HSA21,  was  proposed  as   the  main  
factor   responsible   for   the   perturbation   of   early   hematopoietic  
differentiation   (De   Vita   et   al.,   2010),   while   mutations   in   GATA1   are  
detected  in  nearly  all  AMKL  affected  DS  infants  (Wechsler  et  al.,  2002).  
Additionally,  Malinge  and  colleagues  suggested  DYRK1A  as  a  potent,  
megakaryoblastic   oncogene   (Malinge,   et   al.,   2012);;   their  model   relies  
on   the   negative   regulation   of   NFAT   proteins   by   DYRK1A,   as   NFAT  
factors  were  previously  indicated  as  regulators  of  myeloid  differentiation  
(Kiani  et  al.,  2007).  In  line  with  this  model,  both  Regulator  of  calcineurin  
1   (RCAN1/DSCR1)   and   DYRK1A-­dependent   negative   regulation   of  
NFAT   proteins   was   proposed   as   potential   cause   of   the   lower   solid  
tumors  incidence  in  DS  (Baek  et  al.,  2009).  
However,   and   in   conflict   with   this   model,   DYRK1A   expression   levels  
were   found   reduced   in   AML   patient   samples   and   moreover,  
overexpression   of   DYRK1A   led   to   impaired   AML   cell   proliferation   by  
inducing  cell  cycle  arrest  (Liu,  et  al.,  2014).  Much  more  research  would  
be   required   to   better   delineate   the   role   of   the   overexpression   of  
DYRK1A   in   protecting   trisomic   tissues   from   cancer   appearance   and  
progression.  
2.4.7.  DYRK1A  inhibitors  and  their  impact  in  cancer  
Given  the  functional   impact  of  DYRK1A  overexpression   in  DS,   intense  
efforts  have  been  dedicated   to   identify  specific   inhibitors  with  potential  
use  as  therapeutic  tools  (Jarhad  et  al.,  2018).  However,  as  many  kinase  
inhibitors,  none  of   the  DYRK1A  inhibitors  described  to  date  are  strictly  
specific  for  DYRK1A,  which  limits  data  interpretation  and  highlights  the  
need  of  novel,  highly-­specific  inhibitors  for  research  and  clinical  trials.  A  




The   natural   ATP-­competitor   that   has   been   most   largely   used   as  
DYRK1A   inhibitor   is   the   β–carboline   alkaloid   harmine   (Bain,   et   al.,  
2007;;   Gockler   et   al.,   2009).   Given   the   good   results   in   attenuating  
DYRK1A   overexpression   effects   in   mouse   models   (Laguna,   et   al.,  
2008),   harmine   was   suggested   as   a   promising   compound   for   clinical  
trials  of  DS  therapy  or  other  DYRK1A-­associated  pathologies  (Wang  et  
al.,   2015):   however,   its   capability   to   inhibit   also   monoamine   oxidase  
enzymes   (Kim   et   al.,   1997)   complicates   its   application   in   clinics.  
Notably,  harmine  has  cytotoxic  effects  in  different  cancer  cell  lines  (Cao  
et  al.,  2011;;   Ishida  et  al.,  1999;;  Luna,  et  al.,  2018;;  Pozo,  et  al.,  2013;;  
Radhakrishnan,  et  al.,  2016;;  Uhl  et  al.,  2018;;  Zhang  et  al.,  2016)  and  
synergistic  effects  with  anti-­tumor  drugs  (Atteya  et  al.,  2017;;  Boichuk,  et  
al.,   2013;;   MacDonald,   et   al.,   2017);;   moreover,   harmine   treatment   in  
glioma   and   pancreatic   ductal   carcinoma   xenografts   inhibits   tumor  
growth  (Luna,  et  al.,  2018;;  Pozo,  et  al.,  2013).  
Another   natural   compound   that   has   DYRK1A   inhibitory   capacity   and  
rescues   DYRK1A   overexpression-­associated   phenotypes   is   the  
polyphenol   derivative   of   the   green   tea   leaves   epigallocatechin   gallate  
(EGCG)   (De   la  Torre,  et  al.,  2014;;  Guedj  et  al.,  2009;;  McElyea  et  al.,  
2016).   EGCG   is   currently   under   clinical   trial   for   treatment   of   DS  
individuals   (de   la   Torre   et   al.,   2016).   The   anti-­cancer   properties   of  
green   tea   and   its   derivatives,   including   EGCG,   have   been   proved   in  
many  studies  with  animal  models   thanks   to   their   potential   targeting  of  
many  different  intracellular  pathways  (Yang  et  al.,  2009).  
Other   DYRK1A   inhibitors   with   reported   anti-­tumor   effects   are  
roscovitine   and   its   derivatives,   which   are   currently   in   clinical   trials  
(Demange   et   al.,   2013).   However,   these   compounds   show   higher  
specificity   for   members   of   the   CDK   family,   which   might   explain   their  
anti-­proliferative   properties.   A   Casein   kinase   2   inhibitor,   CX-­4945  
(Silmitasertib),  with  pro-­apoptotic  and  anti-­angiogenic  effects  (Siddiqui-­
Jain   et   al.,   2010)   and   currently   tested   in   clinical   trials   for   multiple  
myeloma  and  cholangiocarcinoma,  has  been  recently  reported  to  act  as  
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a   potent   inhibitor   of   DYRK1A   and   to   restore   neurological   defects   in  
minibrain-­overexpressing  Drosophila  models  (Kim  et  al.,  2016).  
Lately,   promising   results   have   been   achieved   with   two   derivatives   of  
benzothiazole,  called  INDY  and  FINDY,  which  attenuate  malformations  
caused   by  DYRK1A   high   dosage   in   Xenopus   laevis   (Kii,   et   al.,   2016;;  
Ogawa  et  al.,  2010).  Of  note,  INDY  shows  similar  properties  as  harmine  
in  compromising  ovarian  cancer  spheroids  viability   (MacDonald,  et  al.,  
2017).  
2.5.  Other  DYRKs  in  cancer  
Other  members  of  the  DYRK  family  of  kinases  have  been  associated  to  
cancer-­related   cellular   processes   and   found   altered   in   tumors.   In  
particular,  many   indications  of   this   link  have  been  collected   for  human  
class   I  DYRK1B  and  class   II  DYRK2,  which  are  described   in   the  next  
sections.  
2.5.1.  DYRK1B  in  cancer  
Evidence   that   the  DYRK1A  closest  paralogue,  DYRK1B   -­  also  named  
minibrain-­related   kinase   (Mirk)   -­   plays   a   role   in   promoting   tumor  
progression  in  specific  biological  contexts  has  been  provided  during  the  
last   years.   A   string   of   research   contributions   proposed   a   pro-­
tumorigenic   role   for   DYRK1B   in   different   tumor   types,   supported   by  
increased   DYRK1B   protein   levels   in   tumor   samples,   which   include  
liposarcoma   (Chen   et   al.,   2018),   rhabdomyosarcoma   (Mercer   et   al.,  
2006),  osteosarcoma  (Yang  et  al.,  2010),  lung  (Gao  et  al.,  2009),  breast  
(Chen   et   al.,   2017),   ovarian   (Friedman,   2013;;   Gao   et   al.,   2012)   and  
pancreatic  cancer  (Deng  et  al.,  2006;;  Deng  and  Friedman,  2014).  The  
chromosomal   region   containing   DYRK1B   (19q13.2)   has   been   found  
amplified   in   ovarian   cancer   samples   and   cell   lines   (Hu   et   al.,   2011;;  
Thompson  et   al.,   1996),   as  well   as   in  PDAC  samples   (Kuuselo  et   al.,  
2007;;   Luna,   et   al.,   2018).   Supporting   a   functional   role   for   DYRK1B  
amplification   and   overexpression   PDAC,   treatment   of   PANC1-­derived  




Friedman,   2014).   In   agreement   with   these   findings,   we   showed   that  
DYRK1B  knockdown  impaired  PANC-­1  cells  proliferation,  migration  and  
invasion  (Luna,  et  al.,  2018)(Annex  I).  
DYRK1B  phosphorylates  many  DYRK1A  substrates,  including  cell  cycle  
regulators   such   as   Cyclin   D1,   p27Kip1   and   Lin52   (Deng   et   al.,   2004;;  
Litovchick,   et   al.,   2011;;   Zou   et   al.,   2004).   Therefore,   DYRK1B  
overexpression  has  been  suggested   to  promote   the  maintenance  of  a  
reversible   quiescent   state   in   cancer   cells,   while   DYRK1B   knockdown  
has  been  linked  to  cell  cycle  entry,   increased  DNA  damage,  enhanced  
apoptosis   and   increased   sensitivity   to   reactive   oxygen   species   and  
chemotherapeutic  drugs  (Deng  et  al.,  2009;;  Ewton  et  al.,  2011;;  Hu  and  
Friedman,  2010;;  Hu,  et  al.,  2011;;  Hu  et  al.,  2013;;  Jin  et  al.,  2009).  
2.5.2.  DYRK2  in  cancer  
DYRK2   represents   the   class   II   DYRK   member   with   more   research  
contributions,  mostly  related  to  its  ability  to  modulate  tumor  progression.  
The   first  evidence  derives   from  genomic  analysis  and  differential  gene  
expression   studies,   which   underscored   DYRK2   overexpresssion   as  
associated   to   its   genomic   locus   amplification   in   esophageal   and   lung  
adenocarcinomas  (Miller  et  al.,  2003),  GIST  tumors  (Koon  et  al.,  2004),  
gastric  adenocarcinoma   (Gorringe  et  al.,   2005),   liposarcomas   (Italiano  
et  al.,  2008)  and  gliomas  (Maher  et  al.,  2006;;  Shen  et  al.,  2017).  
DYRK2  phosphorylates  and  modulates  key  factors  involved  in  cell  cycle  
arrest/progression   (Becker,   2012;;   Nihira   and   Yoshida,   2015).   Thus,  
DYRK2  phosphorylates  and,  thereby  enhances,  the  degradation  rate  of  
the  pro-­proliferative   transcription   factors  c-­Jun  and  c-­Myc   (Taira  et  al.,  
2012).  Moreover,  DYRK2  was   found   downregulated   in   different   tumor  
types   and   its   expression   inversely   correlated   with   c-­Jun/c-­Myc  
expression   and   with   aggressiveness   of   breast   tumors   (Taira,   et   al.,  
2012).  
Epithelial-­to-­mesenchymal   transition   (EMT)   is  a   cellular   transformation  
process  that  plays  a  role  in  embryonic  development  and  is  implicated  in  
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cancer   progression   to   invasive   stages   (Brabletz   et   al.,   2018).   DYRK2  
phosphorylates   and   primes   for   ubiquitination-­mediated   degradation  
Snail   (Mimoto   et   al.,   2013),   a   transcriptional   repressor   that   promotes  
EMT   (de   Herreros   et   al.,   2010),   providing   additional   evidence   that  
DYRK2   prevents   the   activation   of   aggressive   phenotypes   in   breast  
cancer   cells.   In   clear   contrast   with   this   model,   Guo   and   colleagues  
proposed   a   pro-­oncogenic   function   for   DYRK2   in   breast   cancer,   as   it  
was  shown  to  promote  breast  cancer  cell  proliferation  and  tumor  growth  
in   xenograft   models   through   direct   phosphorylation   of   the   26S  
proteasome   (Guo   et   al.,   2016);;   in   addition,   high   levels   of   DYRK2  
correlated   with   poor   prognosis   in   breast   cancer   patients   (Guo,   et   al.,  
2016).  The  publication  did  not  discussed  any  on   the  conflicting   results  
with  previous  reports.  Recently,  the  natural  drug  curcumin  was  found  to  
act   as   a   potent   inhibitor   of   DYRK2,   to   impair   cell   proliferation   and  
invasion   and   to   induce   apoptosis   in   myeloma   and   breast   cancer   cell  
lines  (Banerjee  et  al.,  2018).  
DYRK2  has  been  also  described  as  a  regulator  of  other  cancer-­related  
processes,   such   as   DNA-­damage   response   and   apoptosis.   In  
particular,   DYRK2   phosphorylates   p53   and   positively   regulate   p53-­
mediated   apoptosis   in   response   to   DNA   damage   (Taira   et   al.,   2007).  
This   mechanism   is   dependent   on   the   kinase   ATM,   which  
phosphorylates   DYRK2,   allowing   DYRK2   escaping   from   MDM2-­
mediated  degradation  in  the  cell  nuclei  (Taira  et  al.,  2010).  Whether  this  
process   has   an   impact   on   the   role   of   DYRK2   on   cancer   progression  
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Although   substantial   improvements   have   been   achieved   in   research  
and   clinical   practice,   cancer   still   represents   a   severe   threat   to   human  
health.   Thanks   to   recent   advances   in   sequencing   technologies   and  
computational   tools,   many   new   tumor   driver   genes   have   been  
identified.   Protein   kinases,   which   orchestrate   a   complex   network   of  
signaling  pathways  and  thus  regulate  cellular  processes  responsible  for  
the  maintenance  of  tissue  homeostasis,  are  found  dysregulated  at  high  
frequencies   in  cancer  cells.   Indeed,   the  kinase  domain   represents   the  
most   frequently   mutated   domain   in   cancer.   DYRK   protein   kinases  
participate  in  the  regulation  of  cell  fate  and  cell  survival  and  have  been  
found   altered   in   tumor   samples,   but   little   is   known   about   their   role   in  
cancer.  Thus,  the  aims  of  this  Thesis  work  are:  
  
i.   to   interrogate   cancer   genomics   and   transcriptomics   data   to  
generate   a   comprehensive   description   of   the   profile   of  
alterations  of  DYRK  genes  in  tumor  samples  and  to  determine  
their  potential  role  as  tumor  drivers.  
  
Once  the  member/s  of  the  family  that  most  likely  may  function  as  tumor  
driver/s  were  identified:  
  
ii.   to   characterize   the   impact   of   cancer-­associated   mutations   on  
the  function  of  the  kinase.  
iii.   to  further  investigate  how  they  contribute  to  tumor  initiation  and  
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1.  Plasmids  
The   plasmids   listed   in   this   section   were   purchased   from   companies,  
provided   from   other   research   groups,   or   generated   during   the   thesis  
work  by  cloning  or  mutagenesis,  as  indicated.  The  identity  of  the  cloned  
sequences  was  checked  by  DNA  sequencing.  
1.1.  Backbone  vectors  
-­   pcDNA-­3:  mammalian  expression  vector  (Invitrogen).  
-­   pEFGP-­C1:   mammalian   expression   vector   to   express   green  
fluorescent  protein  (GFP)  under  the  control  of  a  cytomegalovirus  
(CMV)  promoter  (Clonetech).  
1.2.  Mammalian  expression  vectors  for  tagged  proteins  
-­   pHA-­DYRK1A   plasmids:   expression   vectors   encoding   human  
DYRK1A   (754   aa   isoform;;   Acc.   No.   NM_130436)   with   an   N-­
terminal  influenza  hemagglutinin  (HA)  tag  (Alvarez  et  al.,  2003).  
-­   All   the   DYRK1A   variants   listed   below   were   generated   by   site-­
directed   mutagenesis,   using   specific   5’-­end   phosphorylated  
primers  (Table  MM.1)  and  pHA-­DYRK1A  as  template.  
  
Table  MM.1  Primers  used  for  mutagenesis  with  the  mutated  codon  highlighted  in  bold.    
DYRK1A  
























Catalytic  inactive  variant,  
used  as  negative  control  
in  functional  assays  
(Alvarez  et  al.,  2003).  













































































Variant  found  in  cancer  
databases.  
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R438H   5’-­GGAGGACCTGGTGGGCGACATG-­
CTGGGGAGTCAGGTCATACG-­3’  




Variant  found  in  cancer  
databases.  
R559C   5’  AGACACACAGTCCCCAGGTGTG-­
TCAGCAATTTCCTGCTCCTC  3’  
Variant  found  in  cancer  
databases.  
*,  aa  numbers  refer  to  the  longest  isoform  of  DYRK1A  (763  aa;;  Acc.  No.  NM_1396.4),  to  
maintain  the  numbering  of  cancer  databases.  
**,  the  DYRK1A-­K188R  variant  is  indicated  in  this  thesis  manuscript  as  KD  (kinase  dead).  
  
1.3  Plasmids  for  the  production  of  lentiviral  particles.  
-­   pCMV-­VSV-­G:   lentiviral   packaging   vector   expressing   the  
vesicular   stomatitis   virus   G   envelope   protein;;   obtained   from  
Addgene  (plasmid  #8454,  (Stewart  et  al.,  2003)).  
-­   pCMV-­dR8.91:   second   generation   packaging   plasmid   encoding  
for   the  human  immunodeficiency  1  virus  gag,  pol  and  rev  genes  
(Zufferey  et  al.,  1997);;  kindly  provided  by  D.  Trono  (Laboratory  of  
Virology   and   Genetics,   Ëcole   Polytechnique   Fédérale   de  
Lausanne,  Switzerland).  
-­   pWPXL:   lentiviral   transfer   vector,   encoding   GFP   protein   under  
the   control   of   Elongation   factor   1-­alpha   (EF-­1α)   promoter;;  
obtained  from  Addgene  (plasmid  #12257).  
-­   pWPI:   bicistronic   lentiviral   transfer   vector,   encoding   the   GFP  
protein   under   the   control   of   EF-­1α   promoter   and   an   internal  
ribosomal   entry   site   (IRES),   to   allow   independent   translation;;  
obtained  from  Addgene  (plasmid  #12254).  
-­   pLv-­DYRK1A-­GFP:   lentiviral   transfer  vector  encoding   for  human  
DYRK1A  (754  aa  isoform)  fused  to  GFP  (Di  Vona  et  al.,  2015).  
-­   pLv-­DYRK1A-­IRES-­GFP:   lentiviral   transfer   vector   encoding   for  
DYRK1A  (754  aa  isoform;;  Acc.  No.  NM_130436)  and  IRES-­GFP  
(Rozen  et  al.,  2018).  
1.4.  Plasmids  for  genome  editing  
-­   PX458:   multicistronic   expression   vector   encoding   for  
Streptococcus   pyogenes   Cas9   and   GFP,   separated   by   a   2A  
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peptide,   under   the   control   of   CMV   promoter;;   obtained   from  
Addgene  (plasmid  #48138;;  (Ran  et  al.,  2013)).  
-­   The   following   plasmids  were   generated   by   cloning   single   guide  
RNA   (sgRNA)   sequences   (Table   MM.2)   in   the   PX458   vector,  
under  the  control  of  the  U6  promoter  at  the  Protein  Technologies  
Facility  (CRG).  
  
Table  MM.2  Plasmids  for  genome  editing  of  the  endometrial  cancer  cell  lines.  
Vector  name   sgRNA  sequence  
pEN-­sgRNA60   5’-­GCCCTCTGCCCCAACTGACA-­3’  
pEN-­sgRNA61   5’-­GTTTGGCAGTCCTTGTCAGT-­3’  
pEN-­sgRNA63   5’-­GTGGCAGTCCTTGTCAGTTG-­3’  
pHEC-­sgRNA76   5’-­GCGCTTTTATCAGTCTCCAG-­3’  
pHEC-­sgRNA86   5’-­GGCATTCCCAGTAGCACCTC-­3’  
  
  
2.  Techniques  for  DNA  manipulation  
2.1.  Purification  of  plasmids  
Plasmid  DNA  was  extracted  from  bacterial  cultures  using  the  QIAGEN  
Plasmid   Mini   or   Maxi   Kit   (Qiagen),   depending   on   the   volume   of   the  
culture   (3   ml   for   Mini,   200   ml   for   Maxi),   following   the   manufacturer’s  
instructions.  
2.2.  DNA  sequencing  
Plasmids  were   sequenced   using   the   Sanger   sequencing  method  with  
100-­300  ng  DNA,  3.2  pmol   primers,   and   the  Big  Dye  Terminator   v3.1  
Ready   Reaction   Cycle   Sequencing   Kit   (Applied   Biosystems),   at   the  
Genomic   Sequencing   Service   (UPF-­PRBB,   Barcelona).   The  
Polymerase  Chain  Reaction  (PCR)  conditions  are  in  Table  MM.3.  
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Table  MM.3  PCR  conditions  for  the  sequencing  reaction.  
   T   time  









2.3.  Analysis  of  genomic  DNA  
Genomic   DNA   (gDNA)   was   extracted   from   HEC59   and   EN   cell   lines  
and   the   clones   generated   during   CRISPR   (clustered   regularly  
interspaced   short   palindromic   repeats)-­mediated   genome   editing,   for  
genotyping.  Cells  were   lysed   in  gDNA   lysis  buffer   (25  mM  NaOH,  0.2  
mM  ethylendiamine  tetracetic  acid  [EDTA])  and  incubated  for  30  min  at  
98ºC.   Neutralization   buffer   (40   nM   Tris-­HCl   pH   8.0)   was   added   and  
samples  were  centrifuged  at  4,000xg   for  10  min  at   room   temperature.  
The  DNA-­containing  supernatant  was  isolated  and  DNA  was  quantified  
with  NanoDrop.  
The  detection  of   the  genomic   fragment   for   genotyping  was  performed  
by  PCR  with  0.5-­1  µg  gDNA,10  pmol  primers,  and  a  PCR  Master  Mix  2x  
reagent  (Promega)  PCR  conditions  are  in  Table  MM.4.  
  
Table  MM.4  PCR  conditions.  
   T   time  








Elongation   72ºC   5  min  
  
The  PCR  products  were  separated  by  electrophoresis  in  a  1%  agarose  
gel   to  confirm   the  expected  size.  The   identity  of   the  PCR  product  was  
further   confirmed   by   digestion   with   restriction   enzymes   and   DNA  
sequencing.  In  this  case,  the  DNA  was  purified  using  the  QIAGEN  PCR  
product  purification  kit  (Qiagen).  
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The  DYRK1A   genotype  was  determined  by   either  Sanger   sequencing  
of  the  PCR  product  as  described  above  (template  DNA  amount  reduced  
to  10-­20  ng)  or  by  digestion  with  restriction  enzymes.  
All  restriction  enzymes  were  purchased  from  New  England  BioLabs  and  
the  digestion  reaction  was  performed  by   incubating  50-­100  ng  of  PCR  
DNA  with  1-­5  units  of  enzyme  for  1  h  at  the  conditions  indicated  by  the  
provider.  
2.4.  Site-­directed  mutagenesis  
Point  mutations  were   introduced   in  plasmids  using   the  QuickChange®  
Site-­directed   Mutagenesis   Kit   (Stratagene),   following   the  
manufacturer’s   instructions.  The  5’-­end  phosphorylated  primers   (Table  
MM.1)   were   purchased   from   Fisher   Scientific.   Mutations   were  
confirmed  by  DNA  sequencing.  
  
3.  Cell  culture  and  in  vivo  models  
3.1.  Cell  lines  
The  following  human  cell  lines  have  been  used  in  this  work:  
-­   HEK-­293T:   epithelial   cell   line   derived   from   human   embryonic  
kidney  transformed  with  the  large  T  antigen  of  SV40  virus.  
-­   HeLa:   epithelial   cell   line   derived   from   human   cervical  
adenocarcinoma.  
-­   HEC59:   epithelial   cell   line   derived   from   human   endometrial  
endometrioid  carcinoma.  
-­   EN:   epithelial   cell   line   derived   from   human   endometrial  
endometrioid  carcinoma.  
HEK-­293T   and   HeLa   cells   were   obtained   from   the   American   Type  
Culture   Collection   (www.atcc.org).   HEC59   cells   were   purchased   from  
the   Japanese  Collection   of   Research   Biorecourses   (JCRB)  Cell   Bank  
(cellbank.nibiohn.go.jp/english).  The  EN  cell  line  was  obtained  from  the  
Leibniz-­Institut   DSMZ-­German   Collection   of   Microorganisms   and   Cell  
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Cultures   (www.dsmz.de).   HEK-­293T   and   HeLa   cells   were   grown   in  
Dulbecco’s  Modified  Eagle’s  Medium   (DMEM,  GIBCO,  Thermo  Fisher  
Scientific)   supplemented   with   10%   (v/v)   fetal   bovine   serum   (FBS;;  
GIBCO,   Thermo   Fisher   Scientific)   and   antibiotics   (100   U/ml   penicillin  
and   100   U/ml   streptomycin,   Invitrogen)   at   37°C   and   in   a   5%   CO2  
atmosphere.  HEC59  and  EN  cells  were  grown   in   the  same  conditions,  
except  for  the  FBS  concentration  that  was  increased  to  20%.  
3.2.  Cell  transfection  
For  the  DYRK1A  enzymatic  activity  screen,  HEK-­293T  were  transfected  
in   100-­mm   plates   with   7.5   or   15   μg   DNA   depending   on   the  
production/stability   levels   of   the   protein   variant,   using   the   calcium  
phosphate  method   (Graham  and  van  der  Eb,  1973).  For   the  DYRK1A  
stability   screen,  HEK-­293T   cells   were   transfected   in  MW6   plates  with  
3.3  μg  DNA  per  well  (3.0  µg  pHA-­DYRK1A  plasmid  and  0.3  µg  pEGFP).  
The  DNA-­calcium  phosphate  precipitate  was  removed  after  16-­20  h  by  
washing   the   cells   with   phosphate-­buffered   saline   (PBS)   and   adding  
fresh  medium.  Cells  were  processed  48  h  post-­transfection,  according  
to  the  purpose  of  the  experiment.  
For   genome   editing,   HEC59   and  EN  were   transfected   in  MW6   plates  
with   2.5   µg   of   plasmid   plus   4.0   µg   of   single-­stranded   donor  
oligonucleotide   (ssODN)   using   Lipofectamine®   3000   transfection   kit  
(Thermo   Fisher   Scientific),   following   the   manufacturer’s   instructions.  
Cells  were  washed  after  16-­20  h  post-­transfection  with  PBS  and   fresh  
medium   was   added.   Cells   were   processed   48   h   post-­transfection   for  
cell  sorting.  
3.3  Production  of  lentiviral  particles    
To  generate   lentiviral  particles  stocks,  HEK-­293T  cells  were  seeded  at  
a   density   of   2.5x106   in   100-­mm  plates   and   transfected  with   3.4   μg   of  
pCMV-­VSV-­G   envelope   plasmid,   6.3   μg   of   pCMV-­dR8.91   packaging  
construct  and  9.8  μg  of   the  specific   transfer  plasmid  using  the  calcium  
phosphate  precipitation  method.  Fresh  DMEM  medium  was  added  24  h  
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post-­transfection,   and   the   lentivirus   containing   supernatant   was  
harvested  at  48  h  and  72  h  post-­transfection.  The   lentivirus-­containing  
supernatant  was  centrifuged  at  1,000xg   for  10  min  at  4°C  and   filtered  
through  0.45  μm  filters  (Millipore).  Viral  particles  were  concentrated  by  
centrifuging   the  media   at   20,000   rpm   for   2   h   at   4°C   using   a   SW32Ti  
rotor  in  a  Beckman  Coulter  centrifuge,  and  the  pellet  was  resuspended  
in  PBS  and  stored  at  -­80°C.  
3.4.  Cell  transduction  with  lentiviral  particles  
Cells  were  trypsinized  and  resuspended  in  growth  medium  containing  5  
μg/ml  of  hexadimethrine  bromide  (Polybrene,  Sigma).  The  concentrated  
virus   was   added   to   cells   in   suspension   at   variable   concentrations  
depending  on  the  viral  titers  obtained.  The  cells  were  washed  with  PBS  
24  h  post-­infection  and  fresh  medium  was  added.  Finally,  the  cells  were  
processed   72h   post-­infection,   according   to   the   purpose   of   the  
experiment.  
3.5.  Generation  of  CRISPR-­Cas9-­edited  clones  
EN  and  HEC59  cells  transfected  with  specific  sgRNA-­Cas9  vector  and  
ssODN  were  trypsinized  and  centrifuged  at  300xg  for  5  min.  Cell  pellets  
were   resuspended   in   growth   medium   supplemented   with   5   µg/ml   of  
4’,6-­diamino-­2-­phenylindole   (DAPI;;   Roche).  GFP+   cells  were   selected  
by   fluorescence-­activated   cell   sorting   (FACS),   using   the   FACSAria  
SORP   or   the   Influx   cell   sorters   (Becton   Dickinson),   at   the   CRG/UPF  
Flow  Cytometry  Core  Facility.  The  sorted  cells  were  seeded   in  MW96  
plates,  previously  filled  with  conditioned  medium,  at  1  cell/well  density.  
Dead  cells,   identified  as  DAPI+,  were  excluded.  The  cells  were  grown  
for   2-­3  weeks   until   the  wells  were   fully   confluent.  Colonies  were   then  
split  1:2  in  two  wells,  one  for  genotyping  and  the  other  for  maintenance.  
The   conditioned   medium   was   prepared   by   collecting   media   from   2-­3  
days-­growing  EN  and  HEC59  cells.  Media  were  centrifuged  at  1,000xg  
for  10  min  and  filtered  using  0.45  µM  filters,  to  remove  cells,  cell  debris  
and  possible  contaminants.  
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3.6.  Colony  formation  assays  
The  ability  of  HEC59  and  EN  cell  lines  to  divide  and  form  colonies  was  
determined   by   clonogenic   assays.   Cells   were   seeded   at   low   density  
(1.0   -­   2.5x103   cells/well,   depending  on   the  cell   line)   in  MW6  plates,   in  
triplicate.   Cells   were   grown   for   3-­4   weeks   until   colonies   were   visible.  
Colonies   were   stained   with   methylene   blue   (Sigma;;   0.2%   [w/v]  
methylene  blue  in  50%  [v/v]  methanol)  for  10  min  and  washed  with  H2O.  
The  number  of  colonies  was  determined  using   the   image  software  Fiji  
(Schindelin  et  al.,  2012).  
3.7.  Cell  growth  assays  
To  assess  HEC59  and  EN  cell  proliferation   rate,  cells  were  seeded   in  
MW6   plates   at   2.0x105   cells/well   density,   in   triplicate.   Cells   were  
counted   each   day   during   5   days,   using   an   automatic   cell   counter  
(Countess,   Invitrogen).  Growth   curves  were   generated   by   normalizing  
all  counts  to  the  values  obtained  the  first  day.  
3.8.  FACS  analysis  of  cell  cycle  parameters  
EN   and   HEC59   cells   at   50-­70%   confluency   (0.5   -­   1x106)   were  
trypsinized  and  washed  in  PBS  by  centrifugation  at  300xg   for  5  min  at  
room  temperature.  Cell  pellets  were  fixed  by  adding  dropwise  500  μl  of  
cold   70%   (v/v)   ethanol   while   vortexing   and   stored   at   -­20ºC.   Samples  
were  processed  after,  at  least,  24  h:  cells  were  centrifuged  and  washed  
with  PBS   to   remove   residual  ethanol,  and  DNA  staining  performed  by  
resuspending  the  pellet  in  400-­800  μl  of  DAPI  solution  (5  μg/ml  DAPI  in  
PBS).   Cells   were   analyzed   with   a   LSR-­II   flow   cytometer   (Becton  
Dickinson)   using   the   FACSDiva   Software   v6.1.2   (Becton   Dickinson).  
The   cell   cycle   profile   was   determined   with   the   program   ModFit   v3.2  
(Verity  Software).  
To  determine  the  population  of  dead  cells  in  the  HEC59-­derived  clones,  
the   same   protocol   was   applied,   but   the   growth   media   were   also  
harvested  to  also  include  floating  dead  cells.  
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3.9.  Mouse  xenografts  
The   HEC59   parental   cell   line   and   the   CRISPR-­derived   clones   were  
used   for   xenografts   experiments   in  mice.   2x106   cells   were   inoculated  
subcutaneously   into   the   flanks  of  athymic  nude-­Foxn1nu  mice   (Envigo)  
in   collaboration   with   Giulia   Raimondi   (Cristina   Fillat's   group,   Institut  
d'Investigacions   Biomèdiques   Pi   i   Sunyer,   Barcelona).   Tumors   were  
measured  every  3-­4  days  and  tumor  volume  was  determined  using  the  
formula:   volume=   π/6   ×   length   ×   width2.   Relative   tumor   growth   was  
calculated   normalizing   every   measure   with   the   first   value   recorded.  
Statistical  analysis  was  applied  to  end-­point  data.  Mice  were  sacrificed  
at  35  days  after  cell  inoculation,  and  tumors  were  removed.  Each  tumor  
was   cut   in   half   and   either   fixed   with   4%   paraformaldehyde   and  
embedded   in   paraffin   or   quickly   frozen   in   liquid   nitrogen   for   further  
analysis.  
  
4.  Techniques  for  protein  analysis  
4.1.  Preparation  of  cell  lysates  
Total  cell  lysates  were  obtained  by  resuspending  the  cells  in  SDS  buffer  
(25  mM  Tris-­Cl   pH  7.5,   1%   [w/v]   sodium  dodecil   sulfate   [SDS],   1  mM  
EDTA,   10   mM   sodium   pyrophosphate   [Na-­PPi],   20   mM   β-­
glycerolphosphate)  and  boiling  at  98ºC  for  20  min.  
Soluble   extracts   were   prepared   by   resuspending   the   cells   in   HEPES  
lysis   buffer   (50  mM   4-­[2-­hydroxyethyl]-­1-­piperazineethanesulfonic   acid  
[HEPES]   pH   7.4,   150  mM  NaCl,   2  mM  EDTA,   1%   [v/v]  Nonidet   P-­40  
[NP-­40]   [Sigma]),   supplemented   with   a   protease   inhibitor   cocktail  
(complete  Mini;;   Roche  Diagnostic)   and   phosphatase   inhibitors   (2  mM  
sodium  orthovanadate,  30  mM  Na-­PPi,  and  25  mM  NaF).  Cell   lysates  
were   incubated  at   4ºC   for  30  min  and  centrifuged  at  maximum  speed  
for  30  min  at  4ºC,  to  separate  insoluble  cellular  components.  
Protein  quantification  was  done  with  the  BCA  Protein  Assay  Kit  (Pierce  
-­  Thermo  Scientific),  following  manufacturer’s  instructions.  
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4.2.  Western  Blot  (WB)  assay  
Protein  extracts  were  denatured  by  adding  6x   loading  buffer   (350  mM  
Tris-­HCl   pH   6.8,   30%   [v/v]   glycerol,   10%   SDS,   600   mM   dithiothreitol  
[DTT],  0.012%   [w/v]  bromophenol  blue)  and   incubation  at  98ºC   for  10  
min.  Proteins  were  resolved  by  SDS-­polyacrylamide  gel  electrophoresis  
(SDS-­PAGE),   using   different   acrylamide   percentage   gels   (depending  
on  the  molecular  weight  of  the  proteins  to  detect)  at  130  V  in  1x  running  
buffer   (25  mM  Tris-­base,   200  mM  glycine,   0.1%  SDS).   Proteins  were  
transferred   onto   Hybond-­ECL   nitrocellulose   membranes   (Amersham  
Biosciences)  at  400  mA  for  1  h  at  4ºC  in  1x  transfer  buffer  (25  mM  Tris-­
HCl  pH  8.3,  200  mM  glycine,  20%  [v/v]  methanol).  Protein  trapping  on  
nitrocellulose  membranes  was  confirmed  by  Ponceau  (Sigma)  staining.  
Membranes   were   then   blocked   with   10%   (w/v)   non-­fat   milk   (Cell  
Signaling  Technologies)  diluted  in  TBS-­T  (10  mM  Tris-­HCl  pH  7.5,  100  
mM  NaCl,   0.1%   [v/v]   Tween-­20   [Sigma])   for   1   h   at   room   temperature  
and   incubated   with   the   primary   antibody   (Table  MM.5),   diluted   in   5%  
(w/v)   non-­fat  milk,   overnight   at   4ºC.  Membranes  were   then  washed   3  
times   with   TBS-­T   (10  min   each   at   room   temperature),   and   incubated  
with   horseradish   peroxidase   (HRP)-­conjugated   secondary   antibodies  
(Table   MM.6),   diluted   in   5%   (w/v)   non-­fat   milk,   for   1   h   at   room  
temperature.   After   three   TBS-­T   washes,   membranes   were   incubated  
with  ECL  Western  Lightning®  Plus  ECL  (Perkin  Elmer)  and  exposed  in  
a   LAS-­3000   image   analyzer   (Fuji   PhotoFilm)   with   the   LAS3000-­pro  
software,  to  detect  protein  signal.  Signal  intensities  were  quantified  with  
Fiji   Software.   Relative   protein   levels   were   calculated   using   α-­tubulin  
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Table  MM.5  Properties  and  working  dilutions  of  the  primary  antibodies  used  in  this  work.  
Primary  antibody   Host   Dilution   Commercial  brand  
DYRK1A   Mouse   1:500   Santa  Cruz  (RR.7;;  sc-­100376)  
DYRK1A   Rabbit   1:1000   Sigma  (D1694)  
HA   Mouse   1:2000   BioLegend  (901501)  
GFP   Mouse   1:20000   Clontech  (632380)  
α-­Tubulin   Mouse   1:10000   Sigma  (T6199)  
  
Table  MM.6   Properties   and   working   dilutions   of   the   secondary   antibodies   used   in   this  
work.  
Secondary  antibody   Host   Dilution   Commercial  brand  
Anti-­Mouse   Rabbit   1:2000   Dako  (P0260)  
Anti-­Rabbit   Goat   1:2000   Dako  (P0448)  
  
4.3.  Immunoprecipitation  assay  
Immunoprecipitations   (IP)   were   carried   out   using   magnetic   beads  
coupled   to   Protein   G   or   Protein   A,   depending   on   the   host   of   the  
antibody  used  (Protein  G  for  mouse  antibodies  and  Protein  A  for  rabbit  
antibodies).  Beads  were  incubated  with  the  specific  antibody  or  control  
immunoglobulins  G   (IgGs)   (Table  MM.7)   for   1  h  at   room   temperature.  
Extracts  were  incubated  with  antibody-­bead  complexes  for  3  h  at  room  
temperature  or  overnight  at  4ºC.  The  beads  were  then  washed  3  times  
with   a   washing   buffer   (50  mM  HEPES   pH   7.4,   150  mM  NaCl,   2  mM  
EDTA,  1%  NP-­40);;  a   last  wash  was  performed  without  detergent.  The  
immunoprecipitated   proteins   were   finally   resuspended   in   2x   loading  
buffer  (100  mM  Tris-­HCl  pH  6.8,  200  mM  DTT,  4%  SDS,  20%  glycerol,  
0.2%  bromophenol  blue)  and  boiled  10  min  at  98ºC   for  WB  assays  or  
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Table  MM.7  Properties  and  working  dilutions  of  the  antibodies  used  for  IP.  
Antibody   Host   Amount   Commercial  brand  
Anti-­HA   Mouse   1  µg   Biolegend  (901501)  
Anti-­DYRK1A   Rabbit   3  µg   Abcam  (69811)  
Anti-­DYRK1A   Rabbit   3  µg   Sigma  (D1694)  
IgGs   Rabbit   3  µg   Cell  Signaling  (2729)  
  
4.4.  In  vitro  kinase  assay  
In  vitro  kinase  (IVK)  assays  were  carried  out  using  either  endogenous  
or  ectopically  expressed  DYRK1A  immunoprecipitated  from  cell  lines  as  
source  of  enzyme.  After  the  IP  washes,  the  beads  were  split  1:2.  Thus,  
an  aliquot  was  resuspended  in  loading  buffer  2x  and  analyzed  by  WB  to  
assess   the   relative  amount  of   immunoprecipitated  kinase.  The  second  
half  was   resuspended   in   kinase  buffer   (12.5  mM  HEPES,  pH  7.4,   2.5  
mM   MgCl2,   2.5   mM   MnCl2,   0.25   mM   DTT)   and   50   μM   ATP   in   the  
presence  of  2.5  μCi   [γ32P]-­ATP  (3000  Ci/mmol,  Perkin  Elmer)  and  200  
µM  of  the  “DYRKtide”  substrate,  an  optimal  substrate  peptide  for  DYRK  
kinases   (Himpel   et   al.,   2000).   This   reaction  mix  was   incubated   for   20  
min   at   30ºC.   The   reaction   was   then   dotted   in   triplicates   onto   P81  
Whatmann   cellulose   papers   and   washed   4   times   with   5%   (v/v)  
orthophosphoric  acid  to  eliminate  non-­incorporated  [γ32P]-­ATP.  The  32P  
incorporated   on   DYRKtide   molecules   was   measured   using   a  
scintillation   counter,   and   the   signal,   given   as   counts   per   minutes  
(cpms),   was   normalized   to   the   immunoprecipitated   kinase   levels  
evaluated  by  WB.  
To  evaluate  DYRK1A  autophosphorylation,  the  enzyme  molecules  were  
eluted   from   the   beads   in   loading   buffer   2x,   denatured   at   98ºC   for   10  
min,  and  fractionated  by  SDS-­PAGE.  The  gel  was  then  dried  for  1  h  at  
80ºC  and  exposed   to  a   film  or  Phosphoimager  screen  (revealed  using  
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the  GE  Typhoon  Trio  imager).  The  signal  was  normalized  to  the  kinase  
amounts  evaluated  by  WB.  
4.5.  Mass  spectrometry  analysis  
Label-­free  quantitative  mass  spectrometry  (MS)  was  used  to  define  and  
compare   the   whole   proteome   and   phospho-­proteome   of   the   HEC59  
parental  cell  line  and  the  CRISPR-­derived  clones.  Cells  were  seeded  in  
p100   plates   and   lysed   in   Urea   buffer   (6   M   urea-­100   mM   ammonium  
bicarbonate  [ABC]).  The  protein  amount  was  quantified  with  the  BCA  kit  
and   lysates   were   diluted   with   Urea   buffer   in   order   to   obtain   the  
concentration  corresponding  to  4x106  cells/ml.  Sample  preparation  and  
MS  analysis  were  performed  at  the  CRG/UPF  Proteomics  Unit.  
4.5.1.  Sample  preparation  
Four  independent  samples  for  each  cell  line  were  used.  Samples  (4x106  
cells,  ~1  mg)  were  reduced  with  DTT,  alkylated  with  iodocetamide,  and  
digested  with   trypsin   (Promega)   and   Lys-­C   (Wako)   proteases.   Tryptic  
peptide  mixtures  were  desalted  using  C18  Hypersep  columns  (Thermo  
Fisher   Scientific).   Phosphorylated   peptides   were   enriched   using   an  
immobilized  metal-­affinity  TiO2  protocol,  as  described   (Sebe-­Pedros  et  
al.,  2016).  
4.5.2.  Chromatographic  and  MS  analysis  
Samples  were  analyzed  by  liquid  chromatography  (LC)-­MS/MS  using  a  
LTQ   Orbitrap   Fusion   Lumos   mass   spectrometer   (Thermo   Fisher  
Scientific)   coupled   to   EASY-­nLC   1000   (Thermo   Fisher   Scientific,  
Proxeon).  Peptides  were  separated  by  reversed-­phase  chromatography  
using  a  50-­cm  column  with  an  inner  diameter  of  75  μm,  packed  with  2  
μm   C18   particles   spectrometer   (Thermo   Scientific).   Chromatographic  
gradients   started   at   95%   buffer   A   (0.1%   formic   acid   in   H2O)   and   5%  
buffer  B  (0.1%  formic  acid  in  acetonitrile)  with  a  flow  rate  of  300  nl/min  
for  5  min  and  gradually  increased  to  22%  buffer  B  and  78%  A  in  79  min  
and  then  to  35%  buffer  B  and  65%  A  in  11  min.  After  each  analysis,  the  
column  was  washed  for  10  min  with  10%  buffer  A  and  90%  buffer  B.  
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The  mass  spectrometer  was  operated   in  positive   ionization  mode  with  
nanospray   voltage   set   at   2.4   kV   and   source   temperature   at   275°C.  
Ultramark   1621   was   used   for   external   calibration   of   the   FT   mass  
analyzer  prior   the  analyses,  and  an   internal  calibration  was  performed  
using   the   background   polysiloxane   ion   signal   at   m/z   445.1200.   The  
acquisition  was  performed  in  data-­dependent  acquisition  mode  and  full  
MS  scans  with  1  micro  scans  at  resolution  of  120,000  were  used  over  a  
mass  range  of  m/z  350-­1500.  Auto  gain  control   (AGC)  was  set   to  1E5  
and   charge   state   filtering   disqualifying   singly   charged   peptides   was  
activated.   In   each   cycle   of   data-­dependent   acquisition   analysis,  
following  each  survey  scan,  the  most  intense  ions  above  a  threshold  ion  
count   of   10,000   were   selected   for   fragmentation.   The   number   of  
selected  precursor   ions   for   fragmentation  was  determined  by   the   “Top  
Speed”   acquisition  algorithm  and  a  dynamic   exclusion  of   60   seconds.  
Fragment   ion   spectra   were   produced   via   high-­energy   collision  
dissociation   at   normalized   collision   energy   of   28%   and   they   were  
acquired   in   the   ion   trap  mass  analyzer.  AGC  was   set   to   1E4,   and  an  
isolation  window  of   1.6  m/z   and   a  maximum   injection   time   of   200  ms  
were  used.  All  data  were  acquired  with  Xcalibur  software  v4.1.31.9.  
Digested  bovine   serum  albumin   (New  England  Biolabs)  was  analyzed  
between  each  sample  to  avoid  sample  carryover  and  to  assure  stability  
of   the   instrument;;   QCloud   (Chiva   et   al.,   2018)   was   used   to   control  
instrument  longitudinal  performance  during  the  project.  
  
5.  Techniques  for  RNA  analysis  
5.1.  RNA  purification  and  reverse  transcription  
Total   RNA   was   extracted   using   the   QIAGEN   RNeasy   extraction   kit  
(Qiagen)  or  the  TRIzol  reagent  (Ambion),  depending  on  the  purpose  of  
the   experiment,   and   following   manufacturer’s   instructions.   Samples  
were   treated   with   DNase   I   (Ambion,   2   U/μl)   for   30   min   at   37ºC   to  
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eliminate   the   remaining   genomic   DNA,   and   RNA   samples   were  
quantified  with  NanoDrop.  
For  reverse   transcription,  cDNA  was  generated  by   incubating  0.5-­1  μg  
RNA  with  Superscript  II  Reverse  Transcriptase  (Invitrogen)  and  random  
primers   as   recommended   by   the   manufacturer’s   instructions.   Total  
cDNA  from  EN  and  HEC59  cells  was  used  to  check   the  expression  of  
DYRK1A  wild  type  (wt)  and  mutant  alleles.  
5.2.  RNA-­Seq  
Libraries  for  RNA-­Seq  were  prepared  at  the  CRG  Genomics  Unit.  Only  
RNA  with  RNA  integrity  number  values  over  8  was  used.  Libraries  were  
prepared   using   the   TruSeq   Stranded   mRNA   Sample   Prep   Kit   v2  
according  to  the  CRG  Genomics  Unit  internal  protocols.  Briefly,  poly(A)-­
mRNA   selection   was   carried   out   on   1   µg   of   total   RNA   using  
streptavidin-­coated   magnetic   beads;;   the   selected   RNA   was  
subsequently   fragmented   to   approximately   300   bp.   cDNA   was  
synthesized   using   Superscript   II   RT   (Invitrogen)   and   random   primers.  
For  the  synthesis  of  the  second  strand  of  the  cDNA,  dUTP  was  used  in  
place  of  dTTP.  and  dsDNA  was  subjected  to  A-­tailing  and  ligation  of  the  
barcoded  Truseq  adapters.  Library  amplification  was  performed  by  PCR  
using   the  primer  cocktail  supplied   in   the  kit.  All  purification  steps  were  
performed  using  AMPure  XP  beads  (Beckman).  
The   libraries  were   analyzed   using  Agilent  DNA  1000   chip   to   estimate  
the  quantity  and  check  size  distribution,  and  quantified  by  qPCR  using  
the   KAPA   Library   Quantification   Kit   (Kapa   Biosystems)   before  
amplification   with   Illumina’s   cBot.   Libraries   were   sequenced   on   an  
Illumina  GAIIx  sequencer  (HiSeq  sequencing  v4  chemistry)  to  a   length  
of   50   bp   single-­ended.   Around   4-­6x107   reads  were   obtained   for   each  
library   with  more   than   97%   aligned   reads   in   all   cases,   and   biological  
triplicates  were  used  for  the  analysis.  
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6.  CRISPR-­Cas9-­based  genome  editing  
6.1.  Oligonucleotides  and  reagents    
CRISPR-­Cas9  technology  was  used  to   target  DYRK1A-­mutant  sites   in  
the  HEC59  and  EN  cell  lines  and  revert  them  to  wt.  The  design,  cloning  
and   T7   test   of   specific   sgRNAs   was   performed   in   collaboration   with  
Carlo  Carolis  (CRG  Protein  Technologies  Unit).  
For   the   nucleotide-­specific   editing,   a   combination   of   sgRNAs   for  
targeting   and   single   strand   oligonucleotides   as   templates   was   used  
(Bialk  et  al.,  2015).  Three  sgRNAs  targeting  the  EN  mutant  site  and  two  
sgRNAs   targeting   the   HEC59   mutant   site   were   designed   and   cloned  
into   PX458   vector   (Table   MM.2).   In   addition,   two   specific   120-­mer  
ssODN   were   designed   by   C.   Carolis   and   purchased   from   Integrated  
DNA   Technologies   (Table   MM.8).   Later   on,   a   new   ssODN   was  
designed   to   optimize   the   technique.   The   new   ssODN   harbored  
phosphorothioate  bonds  at  the  5’  and  3’  ends,  a  CRISPR/Cas-­blocking  
mutation   targeting   the   PAM   sequence   (Paquet   et   al.,   2016),   and  
additional  single-­nucleotide  mutations   to  allow  screening  of   the  clones  
by   restriction   digestion   (Table  MM.8).   The  RS-­1   reagent   (Sigma)  was  
kindly   gifted   by   Valeria   Di   Giacomo   (ZeClinics),   and   it   was   used   to  
enhance  CRISPR  genome  editing  efficiency.  
  
Table  MM.8  ssODNs  used  for  genome  editing  of  EN  and  HEC59  cell  lines.  














The  target  codon   is  highlighted   in  bold.  *,   indicates  a  phosphorothioate  bond.  Additional  
mutations  in  ssODN-­HEC59_new  are  indicated  in  lowercase.  
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6.2.  sgRNAs  T7  test  
The  sgRNAs  were  tested  for  their  efficiency  to  promote  Cas9  cleavage  
on  DYRK1A  mutant  site  by  the  T7  assay  (Guschin  et  al.,  2010).  EN  and  
HEC59  cells  were   transfected  with   their   respective   sgRNA-­expressing  
plasmids  and  GFP+  cells  were  sorted  and  grown  as  single  cell  clones.  
A   PCR   reaction   was   performed   on   gDNA   to   amplify   the   fragment  
containing   the   target  site   (Table  MM.9   for  primer  sequences),  and   the  
PCR   products   were   digested   with   T7   endonuclease   I   (New   England  
BioLabs,   M0302),   following   manufacturer’s   instructions.   Digestion  
products   were   resolved   by   1%   agarose   gel   electrophoresis   and  
sgRNAs   efficiency   was   determined   by   quantification   of   the   cleaved  
product  vs  the  PCR  fragment  bands  (Figure  MM.1).  
  
Table  MM.9.  Primers  for  target  site  amplification  PCR.  
Primer   Sequence  
EN_FW   5’-­ACAAGGCATTTTGGTAGCACTG-­3’  
EN_RV   5’-­ATAAGCATCCTGTAATTGCCTCTA-­3’  
HEC59_FW   5’-­ACGCTGAGAAATACATTGTTTGGG-­3’  
HEC59_RV   5’-­GTAGACATCTTTGCCTAAAAACAACT-­3’  
  
  
Figure  MM.1  T7  test.  PCR  products  from  gDNA  were  digested  and  fractionated  with  their  
respective  digestion  controls  (no  T7).  Orange  arrows  point  to  the  bands  produced  by  the  
T7  cut.  Percentages  of  targeting  efficiency  are  included.  NT:  non  transfected.  
  
T7 






EN - PCR 760 bp HEC59 - PCR 673 bp
41% 44% 56% 35% 16% 
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Based  on   the  T7   test   results,   sgRNA63  was   selected   for  EN  genome  
editing.  For  HEC59,  sgRNA86  was   initially  selected,  but   later   replaced  
by   sgRNA76,   since   sgRNA76   showed   mutant   allele-­specificity   during  
additional   tests,   which   probably   explains   the   reduced   efficiency  
observed  in  the  T7  assays.  
6.3.  Clone  screen  
Clones   were   initially   screened   by   gDNA   extraction,   PCR   and  
sequencing.  For  a  second  round  of  reverted  clone  identification,  a  new  
strategy   was   designed   to   screen   HEC59   clones   by   using   restriction  
enzymes.  After  gDNA  extraction,  amplification  of  the  fragment  carrying  
the  target  site  was  performed  with  HEC59_FW  and  HEC59_RV  primers  
(Table   MM.9).   The   PCR   products   were   then   digested   with   two  
restriction  enzymes,  BcoDI  and  BstEII  (Figure  MM.2A-­B).  The  digested  
PCR  products  were  separated  in  1%  agarose  gels  and  the  band  profile  
was  analyzed  to  distinguish  among  the  different  possible  editing  events,  
as  illustrated  in  Figure  MM.2C.  A  reverted  clone  should  lose  the  BcoDI  
restriction  site  and  gain  a  BstEII  site.  Clones  that  showed  a  “no  event”  
profile   were   then   digested   with   BsaI,   to   avoid   losing   false   negatives,  
result   of   a   reverted  wt/wt   genotype   without   a   BstEII   site   gain   (Figure  
MM.2C).  The   reliability   of   the   strategy  was  demonstrated  by  digesting  
two   PCR   products   from   different   sources   of   gDNA   with   the   three  
enzymes:   parental   HEC59   (wt/mut)   and   EN   (wt/wt   for   the   considered  
gDNA   fragment)   (Figure  MM.2D).   Finally,   a   positive   control   for   BstEII  
digestion   was   needed   and   therefore,   a   genomic   fragment   on   the  
DYRK1A   locus,  containing  a  BstEII  recognition  site,  was  identified  and  
amplified  by  PCR  (primers  in  Table  MM.10;;  Figure  MM.2E).  
  
Table  MM.10  Primers  for  BstEII  recognition  site  amplification  PCR.  
Primer   Sequence  
BstEII  D1A  site_FW   5’-­CCCTGGATATGTGTTATAGATGC-­3’  
BstEII  D1A  site_RV   5’-­TCCCTATGCTTTCATTGTGATTT-­3’  






Figure   MM.2   Screen   strategy   for   HEC59   CRISPR-­clones.   A)   Differential   activity   of  
BcoDI,   BsaI   and   BstEII   on   wt,   mutant   and   a   potential   reverted   allele   on   the  DYRK1A  
target  site.  B)  Recognition  sites  of  BcoDI,  BsaI  and  BstEII.  C)  Predicted  digestion  profiles  
of  BcoDI,  BsaI,  BstEII  and  not  digested  (ND),  considering  all  possible  editing  events.  D)  
Screen   test   using   PCR   products   obtained   from   HEC59   gDNA   and   EN   gDNA,   which  
correspond   to   the   genomic   scenarios   indicated.   E)   BstEII   positive   control   profile   and  
digestion  test.  
  
7.  Computational  analysis  
7.1.  Analysis  of  open-­access  tumor  sequencing  data  
Bioinformatic   analysis   of   publicly   available   data   from   cancer   patients  
was   mainly   performed   by   Carlota   Rubio   Pérez   (Nuria   López   Bigas’s  
group,  Institut  de  Recerca  Biomédica-­IRB,  Barcelona;;  previously  at  the  
Research   Unit   of   Biomedical   Informatics,   IMIM-­UPF),   as   a   part   of   a  
collaboration   started   at   the   beginning   of   this   thesis   project.   All   tumor  
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(CNAs)  and  gene  expression  (from  RNA-­Seq  RSEM  gene-­normalized),  
belonging   to   the  TCGA  project  was  considered.  Sequencing  data  was  
downloaded   from   the   most   recent   version   of   FireBrowse   server  
(firebrowse.org;;   2016_01_28   version).   Additionally,   tumor   sequencing  
data   from   the   IntOGen  platform  (www.intogen.org,   (Gonzalez-­Perez  et  
al.,  2013))  was  also  considered  for  the  somatic  mutation  analysis.  
To   identify   differences   in   the   expression   of   DYRK   genes   in   tumor  
samples,   the   expression   levels   of   DYRK   genes   transcripts   were  
compared  with  the  ones  in  paired  healthy  tissue  samples.  Of  note,  the  
number  of  cancer  types  with  sequenced  paired  healthy  tissue  samples  
in   TCGA   was   limited,   and   therefore   only   cancer   type   cohorts   with   at  
least   10   paired   samples   sequenced   were   considered.   A   gene   was  
considered   to   be   significantly   differentially   expressed   in   tumors   if  
Wilcoxon   test   showed   an   adjusted   p-­value   <   0.05.   P-­values   were  
adjusted  according  to  Benjamini-­Hoechberg  correction.	  
To   investigate  CNAs   in  DYRK  genes,   the  FireBrowse  portal  was  used  
to   download   outputs   of   TCGA  exome   sequencing   and  whole   genome  
sequencing   data   computed   with   the   GISTIC2   module   (Mermel   et   al.,  
2011).   Differential   gene   expression   analysis   was   also   performed   to  
assess   whether   DYRK   CNAs   were   associated   to   changes   in   gene  
expression.  Groups  were  set  as  GISTIC  =  2   (multiple  amplification)  or  
GISTIC  =  -­2  (homozygous  deletion),  and  GISTIC  =  0  (diploids)   tumors  
were  used  as  control  group.  Only  cancer  types  cohorts  with  at  least  10  
genes   in  samples  per  group  were  considered.  A  gene  was  considered  
to  be  significantly  differentially  expressed  in  tumors  if  Mann-­Whitney  U  
test   showed   an   adjusted   p-­value   <   0.05   and   a   log2-­fold   change  
(log2FC)  with  values:  Log2FC  <  -­1  or  Log2FC  >  1.  
The  profile  of  somatic  mutations  of  DYRK  tumor  samples  was  dissected  
to  assess  whether  DYRK  genes  carry  signals  of  positive  selection;;   the  
analysis   aimed   to   determine   if   the   mutational   patterns   deviated   from  
what   is   expected   by   chance   following   described  methodology   (Rubio-­
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Perez   et   al.,   2015).   Thus,   we   searched   for   complementary   signals   of  
positive   selection   in   the   somatic   mutational   patterns   of   DYRK   genes,  
across  each  cancer  type  cohort,  by  employing  three  different  methods:    
-­   OncodriveFM:   the   score   given   by   this   method   is   based   on   the  
bias   towards   the   accumulation   of   mutation   with   high   predicted  
functional  impact  (Gonzalez-­Perez  and  Lopez-­Bigas,  2012).  
-­   OncodriveCLUST:   the   score   is   based   on   the   bias   towards  
regional  clustering  of  mutations  (Tamborero  et  al.,  2013).  
-­   MutSigCV:   the   score   is   based   on   the   overall   mutation   rate,  
compared  with  a  background  model  (Lawrence  et  al.,  2013).  
7.2.  Analysis  of  the  RNA-­Seq  data  
RNA-­Seq  data  analysis  was  performed   in  collaboration  with  Chiara  Di  
Vona.  Sequences  obtained  from  each  sample  were  mapped  against  the  
human  genome   (hg38  genome  assembly  version)  using  STAR   (Dobin  
et  al.,  2013).  Reads  that  could  not  be  mapped  as  unique  regions  were  
discarded.  Differential  gene  expression  was  determined  by  normalizing  
data   using   the   trimmed   mean   of   Mvalues   normalization   method  
(Robinson   and   Oshlack,   2010),   and   filtering   genes   that   had   >10  
average  normalized  counts  per  million  with  the  DEseq2  package  (Love  
et  al.,  2014).  Statistical  analysis  was  performed  in  RStudio  by  fitting  an  
exact   test   with   the   negative   binomial   distribution   for   each   set   of  
conditions   and   testing   for   differential   gene   expression   utilizing   the  
DEseq2  package  (Love,  et  al.,  2014).  
7.3.  Analysis  of  the  proteomics  data  
Proteome   and   phospho-­proteome   acquired   data   were   analyzed   in  
collaboration   with   CRG/UPF   Proteomics   Unit   and   Chiara   Di   Vona.  
MaxQuant   v1.6.1.0   was   used   for   peptide   identification   and  
quantification.   Raw   data   was   searched   with   Andromeda   (Cox   et   al.,  
2011)  against  SwissProt  human  database  (as  in  October  2018)  with  the  
most   common  contaminants  as  defined   in  MaxQuant.  A  precursor   ion  
mass  tolerance  of  4.5  ppm  at  the  MS1  level  was  used,  and  up  to  three  
miscleavages   for   trypsin   were   allowed.   The   fragment   ion   mass  
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tolerance  was  set  to  0.5  Da.  Carbamidomethylation  on  Cys  was  set  as  
fix  modification;;   oxidation   of  methionine   and   protein   acetylation   at   the  
N-­terminal  were  defined  as  variable  modification,  and  in  the  case  of  the  
phospho-­enriched   samples,   phosphorylation   on   serine,   threonine   and  
tyrosine   were   also   considered   as   variable   modifications.   Data   was  
filtered  using  a  false  discovery  rate  (FDR)  <  5%  threshold  at  the  peptide  
spectrum  match  and  protein  levels.  
Proteins  abundances  were  estimated  using  MaxQuant  LFQ  (Cox  et  al.,  
2014)   and   phosphosite   quantification   data   was   retrieved   from   the  
corresponding   precursor   ion   intensities,   log2   transformed   and  
normalized.  The  protein  and  phosphosite  quantitative  values  were  used  
to  calculate  fold-­changes  and  their  corresponding  adjusted  p-­values  (q-­
values)   with   the   Storey   method   (Storey   and   Tibshirani,   2003).  
Significant  differences  were  considered   for  an  adjusted  p-­value  <  0.01  
for   both   the   proteome   and   phospho-­proteome   analysis.   For   protein  
differential  expression  analysis,  we  considered  a  log2FC  <  -­0.7  or  >  0.7,  
including  also  proteins   identified   in  only  one  condition.  To  alleviate   the  
“missing   value”   problem   (NAs),   in   the   case   of   the   phospho-­proteome  
analysis,  we  filtered  for  peptides  identified   in  at   least  two  replicates  for  
parental  HEC59  data   and   the  DYRK1A   reverted   clone;;   in   the   case  of  
the  DYRK1A-­/-­  knockout  clone,  we  also  consider  phosphorylation  events  
that  were  completely  absent  in  this  condition.  
7.3.  Other  computational  tools  and  databases  
Principal   component  analysis   (PCA)  and  heatmaps  were  generated   in  
collaboration   with   Chiara   Di   Vona.   PCA   of   RNA-­Seq   data   was  
performed  using  the  integrated  function  of  DESeq2  (Love,  et  al.,  2014),  
whereas  heatmaps  were  generated  using  the  package  ComplexHetmap  
in  R  (Gu  et  al.,  2016).  For  RNA-­Seq  data,   log-­normalized  counts  were  
z-­scored,  while  in  the  case  of  phospho-­events,  we  used  the  already  log-­
transformed   intensity   values.   In   both   cases   k-­means   clustering   was  
performed   and  NAs   values  were   treated   as   explained   in   the   previous  
section.  
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The   algorithm   FoldX   (Guerois   et   al.,   2002;;   Schymkowitz   et   al.,   2005)  
was   used   in   collaboration   with   Javier   Delgado   (Luis   Serrano’s   group,  
CRG)   to   predict   the   impact   of   DYRK1A   cancer  mutations   on   the   free  
energy   potential   (ΔG)   and   thus   on   the   stability   of   the   protein.   The  
YASARA   simulator   platform   was   used   to   easily   perform   FoldX  
commands;;   the   file   2VX3   containing   information   on   DYRK1A   crystal  
structure  was  downloaded  from  the  Protein  Data  Bank  (www.rcsb.org).  
Gene   ontology   (GO)   were   performed   using   EnrichR  
(amp.pharm.mssm.edu/Enrichr;;   (Kuleshov   et   al.,   2016))   web   server.  
Heatmaps  of  RNA-­Seq  and  MS  data  were  generated  using  R.  
Additional   sources   of   cancer   data   used   in   this   thesis   work   were:  
COSMIC   (cancer.sanger.ac.uk/cosmic;;   (Tate   et   al.,   2019)),   cBioPortal  
(www.cbioportal.org;;  (Cerami  et  al.,  2012;;  Gao  et  al.,  2013)),  and  ICGC  
(International   Cancer   Genome   et   al.,   2010).   The   Cancer   Cell   Line  
Encyclopedia   (CCLE)   (portals.broadinstitute.org/ccle;;   (Barretina   et   al.,  
2012))  was  interrogated  to  identify  and  obtain  information  about  cancer  
cell  lines  mutated  in  the  DYRK1A  gene.  
In  addition  to  cancer  databases,  other  sources  of  public  data  were  used  
in  this  work.  Gene  expression  data  of  DYRK  family  members  in  human  
tissues   was   obtained   from   the   GTEx   portal   (www.gtexportal.org).  
Protein   and   DNA   sequences   were   searched   and   analyzed   by   using  
public   databases  of   the  National  Centre   for  Biotechnology   Information  
(NCBI,   www.ncbi.nlm.nih.gov)   and   Ensembl   (ensembl.org).  
Bibliography   references  were  queried  with   the  database  PubMed   from  
NCBI.   The   Exome   Aggregation   Consortium   (ExAC,  
exac.broadinstitue.org;;  (Lek  et  al.,  2016)),  was  used  to  review  DYRK1A  
mutations   found   in   the   normal   population   and   to   compare   ExAC  
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8.  Statistical  analysis  
Box-­plots  and  scatter  plots  were  generated  using  R  Studio  software  and  
the  R  package  ggplot2  (Wickham,  2009).  For  box  plots,  the  bottom  and  
top  of  the  box  represent  the  first  and  third  quartiles,  and  the  line  inside  
the  box   is   the  second  quartile   (the  median).  The  ends  of   the  whiskers  
represent   the   lowest   datum  still  within   1.5   interquartile   range   (IQR)   of  
the   lower   quartile,   and   the   highest   datum   still   within   1.5   IQR   of   the  
upper  quartile.  Any  data  not  included  between  the  whiskers  is  plotted  as  
an  outlier  with  a  dot.  Medians  comparison  was  computed  through  either  
a   two-­tailed   unpaired   Student’s   t-­test,   or   a   two-­tailed   Mann-­Whitney  
test.  Scatter  plots  were  used  for  correlation  analysis,  where  regression  
lines  and  equation  were  indicated.  Significant  correlation  was  assessed  
with  a  Spearman  test.  
Bar   graphs   were   generated   with   Microsoft   Excel   v19.01.   Statistical  
significance  was   calculated  with   a   two-­tailed   unpaired  Student’s   t-­test  
(Microsoft  Excel  v15.33).  The  data  in  the  graphs  represent  the  mean  ±  
standard   deviation   (SD)   of   independent   experiments.   A   p-­value<0.05  
was  considered  significant   (*p<0.05;;   **p<0.01;;   ***p<0.001),  with   some  
exceptions   (sometimes   a   p<0.01   was   considered   necessary   for  
significance).   All   experiments   were   performed   independently   at   least  
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1.  DYRK1A  is  a  potential  tumor  driver  
1.1.  In  silico  analysis  of  TCGA  data  
To  understand  to  what  extent,  and  in  which  cellular  context,  alterations  in  
DYRK   genes   contribute   to   carcinogenesis   and   tumor   progression,   a  
systematic   in  silico  analysis  was  performed,   in  collaboration  with  Carlota  
Rubio  Pérez  (Nuria  López  Bigas’  group,  IRB,  Barcelona).  
Publicly  available  data  from  TCGA  were  interrogated  to  define  the  profile  
of   DYRK   genes   in   tumor   samples,   considering   different   layers   of   gene  
alterations:   differential   gene   expression,   CNAs   and   somatic   mutations  
(Figure   R.1).   An   initial   analysis   was   performed   on   the   TCGA   release  
available   on   2015,   which   included   a   smaller   number   of   tumor   samples  
than  the  current  one  (n  =  4,068  covering  16  tumor  types  (Cancer  Genome  
Atlas   Research   et   al.,   2013;;   Rubio-­Perez   et   al.,   2015)).   This   analysis  
gave   indications  of  alterations   in  DYRK  genes.  The   results  presented   in  
this   Thesis   work   correspond   to   a   second   analysis   performed   using   the  
last  TCGA  release  (Pan-­Cancer  Atlas,  April  2018),  containing  information  
extracted   from  more   than  10,000   tumor  samples   included   in  33  different  
tumor  types  (Hoadley  et  al.,  2018).  Moreover,  the  list  of  somatic  mutations  
was   obtained   from   the   former   TCGA  dataset   (August   2014),   plus   2,724  
additional  samples  derived   from  other   large  sequencing  cancer  projects,  
including   the   ICGC   cohort,   covering   28   tumor   types   and   obtained   from  
Intogen  (see  Materials  and  Methods  section).  
For   the   purpose   of   this   thesis   work   only   the   last   analysis   will   be  
presented,  since   it  gave  a  wider  profile  of  DYRK  genes  status   in  cancer  
(more   tumor   types   included)  and  more   robust   results   (increased  number  
of   samples).   The   cancer   types   considered   in   this   study   and   their  










Figure  R.1  Overview  of  the  in  silico  analysis  of  DYRK  genes  in  tumor  samples.  TCGA  
data  from  the  Pan-­Cancer  Atlas  project  were  analyzed,  focusing  on  DYRK  family  of  genes.  
The  study  aimed  to  understand  whether  any  of  the  members  of  DYRK  family  could  represent  
a   potential   tumor   driver,   by   interrogating   gene   expression   data,   CNAs   and   somatic  
mutations.  
  
1.2.  DYRK  genes  are  differentially  expressed  in  cancer  
Differential   gene   expression   at   the   mRNA   level   was   assessed   by  
analyzing  TCGA  RNA-­Seq  data   from   those   tumor   types  with  at   least  10  
available  paired  healthy-­tumor  samples.  This  filter  reduced  the  number  of  
tumor   types   to   be   analyzed   to   15   (Table   R.1   and   Figure   R.2).   DYRK  
genes  were   found   either   down-­regulated   or   up-­regulated,   depending   on  
the   tumor   type,   with   members   of   the   family   showing   a   conserved   pan-­
cancer   trend.   Indeed,  DYRK1A  was   found   to  be  down-­regulated   in  most  
of  the  tumor  types  analyzed  (Figure  R.2A),  whereas  its  closest  paralogue  
DYRK1B   was   found   mainly   up-­regulated   (Figure   R.2B).   The   class   II  















10,000 samples, 33 tumor types
GENE EXPRESSION (mRNA) COPY-NUMBER VARIATIONS
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expression   levels   in   most   of   the   tumor   types   considered   in   the   study  
(Figure   R.2C).   On   the   contrary,  DYRK3   and  DYRK4   did   not   follow   any  
particular  trend  (Figure  R.2D-­E).  Therefore,  the  analysis  indicated  that  the  
expression   of   DYRK   family  members   is   altered   in   tumors   at   the  mRNA  
level.  
  
Table   R.1   TCGA   cancer   types.   A   total   of   32   cancer   types   from   the   TCGA   Pan-­Cancer  
project   and   their   respective   symbols.   Colon   adenocarcinoma   (COAD)   and   rectal  
adenocarcinoma  (READ)  cohorts  were  considered  as  a  unique  tumor  type  (COADREAD).    
  
*tumor  types  used  for  the  DE  (differential  expression)  analysis;;  the  number  of  samples  with  














Lymphoyd neoplasm diffuse large B cell lymphoma
THYM Thymoma
OV Ovarian cancer
UCEC Uterine corpus endometrial carcinoma
CESC Cervical squamous cell and endocervical adenocarcinoma
UCS Uterine carcinosarcoma
BRCA Breast invasive carcinoma
PRAD Prostate adenocarcinoma
TGCT Testicular germcell tumors
BLCA Bladder carcinoma
KIRC Kidney renal clear cell carcinoma
KIHC Kidney chromophobe




LIHC Liver hepatocellular carcinoma
PAAD Pancreatic ductal adenocarcinoma
CHOL Cholangiocarcinoma
LUAD Lung adenocarcinoma
LUSC Lung squamous cell carcinoma
MESO Mesothelioma
GBM Glioblastoma multiforme
LGG Brain lower-grade glioma
SKCM Skin cutaneous melanoma
UVM Uveal melanoma
HNSC Head and neck squamous cell carcinoma
SARC Sarcoma
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Figure  R.2  The  DYRK  genes  are  differentially  expressed  in  cancer.  A-­E)  DE  analysis  of  
DYRK1A  (A),  DYRK1B  (B),  DYRK2  (C),  DYRK3  (D)  and  DYRK4  (E)  genes  using  RNA-­Seq  
data   obtained   from   TCGA   paired   healthy/tumor   samples   (see   Table   1   for   the   number   of  
samples  used  for  each  tumor  type).  Tumor  types  are  ranked  following  log2FC  values,  which  
are  indicated  when  significant  (Wilcoxon  test,  adjusted  p-­value  <  0.05).  
1.3.  DYRKs  copy  number  alterations  (CNAs)  
Changes   in   gene   expression   can   arise   as   the   consequence   of  
deregulated  transcriptional  cis-­  or  trans-­  mechanisms  or  they  might  result  
from   alterations   at   the   genomic   DNA   sequence.   Among   the   somatic  
alterations   occurring   in   tumor   cells,   copy   number   alteration   (CNAs)   are  
defined   as   big   modifications   of   genomic   DNA   (>   1   kb)   generated   by  








CNAs,   in   particular,   gene   amplification,   are   relatively   frequent   events   in  
cancer  genomes  (Santarius  et  al.,  2010).  Analysis  of  TCGA  data  with  the  
GISTIC   method   (Mermel   et   al.,   2011)   indicated   that   DYRK   genomic  
regions  appear  amplified/deleted  in  tumor  cohorts  (Figure  R.3).  To  better  
define   the   driver   potential   of   DYRK   family   genes,   we   next   aimed   to  
determine   whether   DYRK   CNAs   correlate   with   changes   in   gene  
expression.   The   analysis   is   based   on   the   assumption   that   gene  
amplifications/deletions  occurring  in  tumor  driver  genes  will  be  associated  
to   coherent   expression   changes,   and,   in   fact,   the   integration   of   gene  
expression   and   CNA   data   has   been   used   to   identify   potential   tumor  
drivers  (Ohshima  et  al.,  2017;;  Rubio-­Perez,  et  al.,  2015;;  Santarius,  et  al.,  
2010).  Therefore,  a  DE  analysis  was  carried  out  on   tumor  samples  with  
amplifications   (GISTIC   =   2)   or   homozygous   deletions   (GISTIC   =   -­2)   in  
each   of   the   DYRK   genes,   using   tumor   samples   diploid   for   each   of   the  
genes  (no  CNAs,  GISTIC  =  0)  as  control  groups.  
Coherent   with   the   results   described   in   the   previous   section,   analysis   of  
DYRK   CNAs   pointed   at   the   class   I   member  DYRK1B   and   the   class   II  
member  DYRK2   as   frequently  amplified-­overexpressed   in  specific   tumor  
cohorts   (Figure  R.3B-­C),   suggesting   a   possible   role   as   tumor   drivers   in  
these   specific   cancer   types.   In   particular,   DYRK1B   and   DYRK2   were  
found   significantly   amplified   respectively   in   7   and   9   TCGA   cohorts.   No  
significant  CNAs-­derived  expression  changes  were  observed  for  DYRK1A  
(Figure  R.3A);;  while,  DYRK3  and  DYRK4   showed  alterations   in  1  and  2  
TCGA  cohorts,   respectively   (Figure  R.3D-­E).  These   results  only  partially  
explain  the  upregulation  of  DYRK1B  and  DYRK2  expression  observed  in  
tumors  since  only  2  out  of  9  DYRK1B-­overexpressing  (BRCA  and  BLCA)  
and   5   out   of   10   DYRK2-­overexpressing   cancer   types   (BRCA,   BLCA,  
LUSC,  LUAD  and  HNSC)  showed  also  multiple  amplifications.  Therefore,  
alternative  mechanisms  such  as  promoter  methylation  or   altered  activity  
of  transcription  factors  might  be  responsible  for  the  differential  expression  
observed   for   those   tumors   in   which   DYRK1B   and   DYRK2   are   not  
amplified,  and  of  course  for  DYRK1A,  DYRK3  and  DYRK4.  
Results  










Figure   R.3   DYRK   family   members   CNAs   in   cancer   samples   vs   gene   expression.  
DYRK1A  (A),  DYRK1B  (B),  DYRK2  (C),  DYRK3  (D)  and  DYRK4  (E)  gene  expression  values  
are  plotted  for  each  tumor  type.  Each  dot  represents  a  tumor  sample.  Multiple  amplification  
(GISTIC   =   2)   and   homozygous   deletions   (GISTIC   =   -­2)   are   represented   as   red   and   blue  
dots,   respectively.   Only   tumors   with   RNA-­seq   data   and   CNA   values   in   each   cohort   were  
used.   DE   analysis   was   performed   using   diploid   samples   (grey   dots)   as   controls.   Cohorts  
with  significant  coherent  expression  changes  are  indicated  with  arrows  (Mann-­Whitney  test,  
adjusted  p-­value  <  0.05;;  Log2FC  <  -­1;;  Log2FC  >  1).    
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1.4.  DYRK1A  shows  signals  of  positive  selection  
To  better   evaluate   if   any  of   the  DYRK  genes   is   a   tumor  driver,  we  also  
analyzed   the   profiles   of   somatic   mutations   in   tumor   samples,   following  
approaches   previously   described   (Rubio-­Perez,   et   al.,   2015;;   Tamborero  
et  al.,  2013).  These  studies,  and  others,  consider  that  a  gene  is  a  cancer  
driver  if  it  bears  signals  of  positive  selection.  Signals  of  positive  selection  
are   identified   by   means   of   the   study   of   the   pattern   of   accumulation   of  
somatic  mutations  (including  single-­nucleotide  variations  [SNV]  and  small  
insertions/deletions   [indels])   and   how   they   deviate   from   models   of  
expected  random  distribution  of  mutations.  These  methods  are  based  on  
the   assumption   that   mutations   occurring   in   tumor   driver   genes   provide  
survival   advantages   and   are   thus   positively   selected   during  
carcinogenesis.  Hence,   this  selection   leaves  “signals”   that  can  be  traced  
in  tumor  cohorts.  Here,  we  used  three  different  methods  to  reveal  signals  
of  positive  selection  to  identify  driver  genes,  following  the  pipeline  used  in  
(Rubio-­Perez,  et  al.,  2015)  (Figure  R.4A):  OncodriveFM  (Gonzalez-­Perez  
and  Lopez-­Bigas,  2012),  OncodriveCLUST  (Tamborero  et  al.,  2013)  and  
MutSigCV   (Lawrence   et   al.,   2013).   However,   none   of   the   DYRK   family  
members   had   a   mutation   profile   that   could   be   computed   with  
OncodriveCLUST   in  any  cohort,   since  no   recurring   variant  was   found   in  
any  tumor  type.	  
Among  all  the  members  of  the  family,  DYRK1A  was  the  only  gene  scoring  
for  signals  of  positive  selection  (Figure  R.4B).  In  particular,  we  obtained  a  
significant   score   with   OncodriveFM   in   three   cohorts,   corresponding   to  
three  different  tumor  types:  liver  hepatocellular  carcinoma  (LIHC),  uterine  
corpus   endometrial   carcinoma   (UCEC)   and   esophageal   carcinoma  
(ESCA).  Moreover,  we  found  a  further  signal  given  by  MutSigCV  in  UCEC  
(Figure  R.4B)  
The  profile  of  somatic  mutations  provides  also  information  on  the  putative  
function   played   by   the   tumor   driver   genes.   In   particular,   oncogenes   are  
often   characterized  by  activating  mutations   clustering   in   specific   residue  




show   a   strong   incidence   of   LoF   mutations   (frameshifts   and   nonsense),  
and  they   lack  hotspots,  with  mutations  more  randomly  distributed  across  
the   gene   sequence   (Davoli   et   al.,   2013).   As   mentioned   above,   the  
analysis  identifies  the  class  I  member  DYRK1A  as  a  putative  tumor  driver  
and  furthermore,  the  profile  of  somatic  mutations  (Figure  R.4C)  indicates  
a  potential   tumor-­suppressive   role.  This  hypothesis   is  also  supported  by  
the  DE   results,  which   rendered   a   very   clear   trend   for  DYRK1A   towards  
downregulation  in  tumor  samples  (Figure  R.2A).  
  
  
Figure  R.4  DYRK1A  shows  signals  of  positive  selection.  A)  Schematic  description  of  the  
three   methods   used   to   detect   signals   of   positive   selection   (see   Materials   and   Methods).  
Adapted  from  (Tamborero,  et  al.,  2013).  B)  DYRK1A  showed  signals  of  positive  selection  in  
three  TCGA  cohorts:   liver  hepatocellular  carcinoma  (LIHC),  esophageal  carcinoma  (ESCA)  
and  uterine  corpus  endometrial  carcinoma  (UCEC).  C)  Distribution  of  LoF  mutations  (upper  
scheme)  and  missense  mutations  (lower  scheme)  in  DYRK1A  reported  in  cBioPortal  (April,  
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2.  DYRK1A  mutations  identified  in  tumors  are  LoF    
2.1   Generation   of   DYRK1A   cancer   variants   for   functional  
analysis  
The   outcome   of   the   analysis   of   TCGA   data   suggested   that   loss   of  
DYRK1A,   by   either   down-­regulation   of   at   the   mRNA   level   or   gene  
mutation,  is  positively  selected  in  cancer.  However,  no  functional  data  on  
the   DYRK1A   somatic   mutations   was   available,   so   the   question   was  
whether   the  amino  acid  changes  negatively  or  positively  affect  DYRK1A  
activity.  
We  first  looked  at  the  mutations  described  at  that  moment  and  found  that  
the  proportion  of  LoF  in  DYRK1A  was  higher  than  expected.  The  number  
of  DYRK1A  somatic  mutations  has  increased  since  then,  and  at  the  time  
of  writing   this  Thesis  manuscript,  we  manually  curated  a  comprehensive  
list  of  DYRK1A  cancer  missense  mutations  by  reviewing  different  cancer  
repositories   and   additional   public   data   generated   by   cancer   genomic  
studies.  The  list  has  been  included  in  the  manuscript  as  Annex  II.  Somatic  
mutations   in  DYRK1A  gene   include  missense   (77%),   nonsense   (12.5%)  
and   indels   resulting   in   frameshifting   (8.8%).   In   the   latter   cases,  most   of  
the   mutations   are   located   before   the   end   of   the   catalytic   domain,   and  
therefore  they  will  generate  truncated  proteins  devoid  of  catalytic  activity.  
For   the   missense   mutations,   they   are   found   all   along   the   primary  
structure,  including  the  non-­catalytic  N-­terminus,  the  catalytic  domain  and  
the  non-­catalytic  C-­terminus.  
To   assess   the   impact   that   DYRK1A   cancer-­associated   missense  
mutations  observed  in  tumor  tissues  could  have  on  DYRK1A  activity,  we  
selected  a  pool  of  27  DYRK1A  missense  variants  from  cancer  databases  
to  perform  functional  assays  (Table  R.2).  Most  of  the  variants  map  in  the  
catalytic   domain,   with   some   exceptions   (Figure   R.5   and   Table   R.2).   In  
some   cases,   the  mutation   is   found   in   several   samples   (E160K,  R467Q,  




S311P,  S311Y).  Finally,  many  of   the  mutated  residues  are  also  mutated  
in  other  members  of  the  DYRK  family  (Table  R.2).  
  
Figure  R.5  Distribution  of   the  selected  DYRK1A  cancer  variants.  27  DYRK1A  cancer-­
associated  variants  were  selected  among  all  the  mutations  found  in  cancer  databases.  Their  
distribution  along  the  catalytic  domain  is  shown.  The  scheme  shows  the  secondary  structure  
of  the  catalytic  domain  based  on  Protein  Data  Bank  accession  2WO6.  
  





















































































































































Variant Cancer Tissue Sample ID Domain Other DYRKs
DYRK1A Y147C (2x)
DYRK3 Y197C
Ovary (cell line) TOV21
Large intestine TCGA-AG-A002-01









K188N Lung MU11199963 DYRK1B K140T
Large intestine DFCI_3010
Large intestine (cell line) HT115
L207V Lung TCGA-33-4533 Catalytic: alpha C DYRK1A L207P/L207I
D247H Endometrium TCGA-FI-A2EW
D247N Upper aerodigestive TCGA-CR-5248
L261R Hematopoietic and Lymphoid Broad_CLL007 Catalytic: alpha E DYRK3 L311S
DYRK1A A277P
DYRK1B A229S





S311F Skin CSS-35-T DYRK1B S263Q
S311P Endometrium (cell line) EN
S311Y Endometrium TCGA-B5-A0JY
DYRK3 R348C*/R348H (2x)
Y147H Endometrium TCGA-D1-A103 DH box

























DYRK1A Cancer Variants selected for functional screens
Catalytic: alpha D
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*ExAC  variant  (exac.broadinstitue.org;;  (Lek  et  al.,  2016))  
  
Each  of  the  27  DYRK1A  cancer  variants  were  introduced  into  a  vector  to  
express   HA-­tagged   DYRK1A   by   site-­directed   mutagenesis,   to   generate  
expression   plasmids   in   mammalian   cells   that   allow   to   screen   them   for  
their  impact  on  protein  functionality.  
2.2.   DYRK1A   cancer   variants   negatively   affect   the   enzymatic  
activity  
Since   DYRK1A   is   a   protein   kinase,   the   first   functional   screen   aimed   to  
determine   the   impact   of   the   mutation   on   the   enzymatic   activity.   Thus,  
HEK-­293T  cells  were  used  as  hosts  for   transient  expression  of  DYRK1A  
WT  and  the  cancer  variants.  The  enzymatic  activity  was  measured  in  anti-­
HA  IPs  used  for  IVK  assays,  and  two  different  aspects  were  investigated  
in  these  assays.  On  the  one  hand,  the  ability  to  phosphorylate  a  substrate  
Variant Cancer Tissue Sample ID Domain Other DYRKs
DYRK1A Cancer Variants selected for functional screensS311P Endometrium (cell line) EN
S311Y Endometr um TCGA-B5-A0JY
Q313L Lung TCGA-85-8070 Catalytic: beta 9 -





Endometrium (cell line) HEC-59
S346F Large Intestine (cell line) MDST8 Catalytic: alpha F DYRK2 S407C
Skin Broad_MEL-Ma-Mel-55
Lung TCGA-05-4396
R438H Stomach STC291 Catalytic: CMGC insert DYRK1A R438C (2x)
















































peptide   with   a   specific   consensus   sequence   for   DYRK   kinases  
(“DYRKtide”   (Himpel   et   al.,   2000))  was   assessed   (Figure  R.6A).  On   the  
other   hand,   the   capacity   of   the  DYRK1A  mutants   to   autophosphorylate,  
either   in  cis   or   in   trans,  was   also   analyzed   although   to   a   smaller   set   of  
mutants   (22  mutants)   (Figure   R.6A).   In   the   former   case,   the   amount   of  
phosphorylated   peptide   was   assessed   by   measuring   the   incorporated  
radioactive   ATP   using   a   scintillation   counter   (Figure   R.6B),   whereas  
autophosphorylated  DYRK1A  proteins  were  detected  by  SDS-­PAGE  and  
autoradiography   (Figure   R.6C).   As   shown   in   Figure   R.6D,   the  
experiments   revealed  a  partial   or   total   loss  of   enzymatic  activity   caused  
by  most  of  the  DYRK1A  cancer  variants  screened;;  moreover,  none  of  the  
mutants   analyzed   led   to   significant   increased   activity.   Some   of   the  
variants  presented  an  enzymatic  activity  close   to   that  of   the  WT  protein,  
as   it   was   the   case   of   R158H   or   R559C,   which   we   later   found   to   be  
variants   present   in   the   human   population   as   they   are   collected   in   the  
ExAC   database   (Lek,   et   al.,   2016).   A   correlation   analysis   showed   that  
there   was   a   positive   correlation   between   the   two   types   of   enzymatic  
activity   (Figure   R.6E),   suggesting   that   when   the   catalytic   activity   is  
altered,  both  aspects  are  affected   in   the  same  manner.  Given  the  model  
of  DYRK1A  activation,   the   results  might  also   indicate   that   the  mutations  
affect  the  activation  of  the  kinase  preventing  the  authophosphorylation  in  
the  T-­loop.  Therefore,  activity  on  substrate  was  chosen  as  the  main  assay  
















Figure  R.6  DYRK1A  cancer  variants  show  partial  or  total  loss  of  activity.  A)  Schematic  
representation   of   the   screen.   B)   Substrate   phosphorylation   showing   the   results   of   a  
representative  experiment,   in  which  DYRK1A  WT  protein  and  a  mutant   in   the  ATP  binding  
site   (K188R,   KD)   are   included.   The   plot   shows   radioactivity   incorporation   (cpms)   into  
DYRKtide  (mean  ±  SD  of  technical  replicates).  The  amount  of  DYRK1A  IP  assessed  by  WB  
is   shown   in   the   lower   panel.   C)   DYRK1A   autophosphorylation   showing   the   results   of   a  
representative  experiment.  The  densitometric  values  of   the  autoradiography  are  plotted  as  
percentages  of  the  WT  protein  value,  set  as  100.  D)  Summary  of  the  characterization  of  the  
DYRK1A   catalytic   activity   on   the   DYRKtide   substrate   for   each   mutant:   the   radioactivity  
signals  were  normalized  to  the  amount  of  DYRK1A  detected  in  the  IPs  by  anti-­HA  WB  and  
plotted  as  a  the  percentage  of  the  WT  protein  value,  set  as  100  (the  dashed  line  marks  this  
value).  The  box-­plot  represents  the  distribution  of  activity  values  from  at  least  3  independent  
experiments.  E)  Correlation  between  the  relative  values  from  the  substrate  phosphorylation  
assays  and  autosphosphorylation   levels,  normalized  by  setting  the  WT  values  as  100.  The  
Spearman  correlation  coefficient  and   the  p-­value  are  shown.  The  values   for  DYRK1A  WT,  
the  kinase  inactive  mutant  KD  and  the  mutant  Y321C  are  shown  in  colors.  
  
The   mutant   Y321C   deserves   a   special   mention,   since   it   was   the   only  
outlier,  with  a  strong  autophosphorylation  rate,  despite  of  a  low  activity  on  
the  exogenous  substrate  (Figure  R.6E).  As  explained  in  the  Introduction,  
Y321   is   the   residue   of   the   activation   loop   that   is   autophosphorylated  
during   the   protein   synthesis,   and   this   event   is   required   for   full   kinase  
activation   (Himpel   et   al.,   2001).   Even   though   the   retention   of   in   vitro  
enzymatic  activity  for  certain  Y321  mutants  (Y321H  or  Y321Q  in  contrast  
to   the  death  kinase  mutant  Y321F)  has  already  been  shown   (Adayev  et  
al.,   2007),   it  was  quite   surprising   to   observe   such  enhanced   radioactive  
signal  in  the  autophosphorylation  assay  (almost  2-­fold  of  the  WT  protein).  
One   possible   interpretation   of   these   results   is   that   the   substitution   has  
altered   the   substrate   specificity,   and   the   kinase   does   not   longer  
phosphorylate   efficiently  DYRKTide  but   it   is   able   to   phosphorylate   other  
residues  when  it  uses   itself  as  substrate.  Alternatively,   the  change  might  
promote  autophosphorylation  events  instead  of  the  use  of  an  exogenously  
substrate.  Further  experiments  are   required   to  explore   the  nature  of   the  
high  autophosphorylation  activity  of  the  mutant  Y321C  and  what  happens  
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2.3.  DYRK1A  cancer  variants  negatively  affect  protein  stability  
Another   important   aspect   to   explore   in   order   to   determine   whether  
DYRK1A   cancer   variants   affect   protein   function   is   represented   by   the  
stability  of  the  protein.  Protein  accumulation  levels  in  live  cells  depend  on  
many   factors,   including   the   rate   of   protein   degradation   and   the   intrinsic  
stability   of   the   folded   protein   structure.   This   feature   acquires   special  
significance  in  the  case  of  DYRK1A,  which  it  is  a  dosage-­sensitive  gene,  
and  little  fluctuations  in  protein  amounts  strongly  affect  cell  behavior  (see  
Introduction).  
To  explore  how  the  cancer  variants  affected  the  stability  of  the  protein,  the  
HA-­tagged   versions   were   expressed   in   HEK-­293T   cells   together   with   a  
GFP-­expressing   vector   to   correct   for   transfection   efficiency.   The   protein  
accumulation   levels   depend   on   the   balance   between   protein   synthesis  
and   degradation   rate.  Given   that   the  DYRK1A   variants  were   ectopically  
expressed   using   the   same   vector   and   under   the   same   experimental  
conditions,  we  attributed  any  change  in  the  protein  accumulation  levels  to  
variation  in  protein  stability.  
Total   cell   lysates  were  prepared  48  h  post-­transfection  by   resuspending  
the   cell   pellets   in   loading   buffer   to   avoid   interferences   with   changes   in  
protein  solubility,  and  the  DYRK1A  and  GFP  protein  levels  were  assessed  
by  WB  (Figure  R.7A  and  B).  The  results  shown  in  Figure  R.7C  indicated  
that   the  mutations   affect   the   stability   of  DYRK1A   to   different   extent,   but  
compared   to   DYRK1A   WT,   lower   levels   of   protein   accumulation   were  







Figure   R.7   DYRK1A   cancer   variants   show   reduced   stability.   A)   Schematic  
representation   of   the   screen.   B)   Results   of   a   representative   experiment:   the   values  
generated  with   the  densitometric  analysis  of   the  anti-­HA  signals   in   the  WB  were  corrected  
for  transfection  efficiency  (anti-­GFP  WB)  and  plotted  as  percentages  of  the  WT  protein,  set  
as   100.  C)   Summary   of   the   characterization   of   the   protein   stability   for   each   mutant:   the  
accumulation   levels   were   plotted   as   the   percentage   of   the  WT   protein   value,   set   as   100  
(marked  with  a  dashed  line).  The  box-­plot  represents  the  distribution  of  activity  values  from  
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2.4.  Changes  in  DYRK1A  stability  caused  by  cancer  mutations  
are  linked  to  aberrant  folding  and  loss  of  activity  
Missense  mutations  can  lead  to  a  switch  in  the  thermodynamic  properties  
of   a   protein   and   thus   impair   normal   folding   during   protein   synthesis.  
Misfolded  proteins  are  more  susceptible  to  degradation,  thanks  to  cellular  
proteolytic   systems   that   are   sensitive   to   aberrant   folding   (reviewed   in  
(Waters,   2001).   To   gain   more   insight   about   the   thermodynamic  
contribution  to  the  stability   loss  for  DYRK1A  cancer  variants,  we  decided  
to  use  the  FoldX  program  (foldxsuite.crg.eu/about).  FoldX  is  a  force  field  
algorithm  based  on  the  calculation  of  free  energy  (ΔG)  of  macromolecules  
with   a   high-­resolution   3D   structure,   which   can   be   used   to   predict   the  
impact   of   mutations   in   the   folding   and   stability   of   proteins   and   nucleic  
acids   (Guerois   et   al.,   2002;;   Schymkowitz   et   al.,   2005).   Such   effect   is  
defined  by  the  differential  ΔG  (ΔΔG);;  thus,  negative  values  are  associated  
with  a  gain  in  stability,  whereas  positive  values  mean  a  loss  of  stability.  
Using   available   information   on   the   DYRK1A   crystal   structure  
(Soundararajan  et  al.,  2013),  ΔΔG  values  were  calculated  using  FoldX  for  
DYRK1A   cancer-­associated   variants   and   compared   with   the   levels   of  
protein   accumulation   obtained   through   the   functional   screens   described  
above.   The   free   energy   variations   for   Y321C   and   R559C   could   not   be  
computed  because  Y321  phosphorylation   in   the  PDB   file   interfered  with  
FoldX  calculation,  and  because  R559C  was  not  included  in  the  DYRK1A  
3D   structure   (aa   127-­485).   A   significant   correlation   between   the   FoldX-­
predicted   values   and   the   experimental   ones   was   found   (Figure   R.8A;;  
Spearman’s   test,   p-­value   <   0.001),   suggesting   that   FoldX   represents   a  
useful  tool  to  predict  the  impact  of  DYRK1A  cancer-­associated  mutations  
on   DYRK1A   protein   stability.   However,   FoldX   did   not   predict   a   high  
variation   in   free  energy  value   for   some  of   the   low-­stability   variants   (6  of  
the  17  examined).  These   findings  could   indicate   that  other   factors  might  
control   DYRK1A   stability,   and   the   autophosphorylation   of   specific  
residues  could  be  one  of  them  since  phosphorylation  has  a  regulatory  role  




2013).   In   fact,  DYRK1A  autophosphorylation  on  S97  has  been  shown  to  
regulate   DYRK1A   protein   stability   (Kii   et   al.,   2016).   In   line   with   these  
results,   we   observed   a   positive   correlation   between   kinase   activity   and  
protein   accumulation   for   DYRK1A   cancer-­associated   variants   (Figure  
R.8B),   supporting   the   hypothesis   that   DYRK1A   activity   and   stability   are  
functionally   linked.   It   should   be  mentioned   that   such   positive   correlation  
has   been   also   shown   by   our   group   when   analyzing   missense   mutants  




Figure  R.8  The  lower  stability  of  DYRK1A  cancer  variants  is  linked  to  misfolding  and  
loss   of   activity.   A)   Correlation   analysis   between   the   stability   values   obtained   in   the  
experimental   tests   and  FoldX-­predicted  ΔΔG   values.  ΔΔG  ≤   -­1.5:   gain   of   stability;;   ΔΔG  ≥  
1.5:  loss  of  stability;;    -­1.5  <  ΔΔG  <  1.5:  no  effect.  B)  Correlation  analysis  between  the  kinase  
activity  of  the  variants  and  their  stability  values.  Three  groups  can  be  distinguished,  WT-­like  
mutants  (orange  dots)  with  activity  and  stability  values  close  to  100%,  LoF  mutants  (purple  
dots)  with   low  activity  and  stability   values,  and  mutants  whose  activity  and  stability  do  not  
correlate  (grey  dots).   In  A  and  B,   the  Spearman  correlation  coefficient  and  the  p-­value  are  
shown.  
  
In   conclusion,   these   functional   studies   suggested   that   DYRK1A   cancer  
mutations  are  LoF  mutations,  since  most  of  the  variants  analyzed  (21/27)  
led  to  impaired  catalytic  activity  and/or  reduced  protein  stability  (Figure  9  
and  Table  3).  
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Table  R.3  Summary  of  DYRK1A  cancer  variants  activity  and  stability.  LoF  parameters  
set  as:  activity  <  70%  of  WT,  p-­value  <  0.01  and/or  stability  <  50%  of  WT,  p-­value  <  0.01  (n  
≥  3  independent  experiments,  Student’s  t-­test).  
  
  
Mean (%) p-value Mean (%) p-value
WT 100 - 100 - -
Y147H 28 4.98E-06 33 2.91E-03 YES
R158C 84 8.87E-02 54 8.77E-04 NO
R158H 84 0.275 31 2.08E-04 YES
E160K 58 1.83E-03 43 1.49E-03 YES
K188N 2 2.89E-08 31 8.71E-04 YES
K188T 4 1.53E-08 34 4.51E-05 YES
L207V 69 8.85E-03 94 0.598 YES
D247H 61 6.74E-03 43 1.31E-03 YES
D247N 41 2.40E-03 93 0.441 YES
L261R 71 0.289 85 0.321 NO
A277V 10 1.57E-04 46 3.46E-03 YES
I283V 36 1.03E-04 87 0.417 YES
C286Y 0 7.40E-18 23 3.50E-05 YES
R300H 118 0.369 131 0.226 NO
R300P 33 2.51E-04 76 0.167 YES
S311F 0 7.40E-18 13 1.81E-05 YES
S311P 0 4.52E-10 32 4.96E-03 YES
S311Y 4 1.64E-08 6 3.87E-10 YES
Q313L 80 0.197 73 0.185 NO
Y321C 12 8.65E-08 117 0.167 YES
R328L 4 8.94E-08 73 0.456 YES
R328Q 2 8.37E-09 31 1.88-05 YES
S346F 3 3.97E-07 3 6.38E-07 YES
G348W 2 2.33E-08 26 8.46E-04 YES
R438H 78 8.63E-02 121 0.672 NO
R467Q 3 8.73E-08 18 4.20E-06 YES
R559C 118 0.546 63 4.74E-02 NO







Figure   R.9   DYRK1A   cancer   variants   are   LoF.   Schematic   representation   of   the   results  
obtained  in  the  functional  screens.  Color  code:  green  =  no  significant  effect;;  orange  =  partial  
effect  on  activity/stability;;  red  =  strong  effect  on  activity/stability  and  total   loss  of  enzymatic  
activity.  
  
3.   DYRK1A   acts   as   a   tumor   suppressor   in   endometrial  
cancer  cell  lines  
3.1.   HEC59   and   EN   are   heterozygous   DYRK1A-­mutated   cell  
lines  of  endometrial  carcinoma  
According   to   the   results   obtained   analyzing   the   TCGA   data,   DYRK1A  
emerged  as  a  potential  tumor  driver.  Among  the  three  TCGA  tumor  types  
in   which   signals   for   positive   selection   were   detected,   Uterine   Corpus  
Endometrial   Carcinoma   (UCEC)   was   the   only   set   revealing   two  
independent   signals   (Figure   R.4B),   and   DYRK1A   also   showed   reduced  
expression   in   UCEC   tumor   samples   compared   with   paired   healthy  
samples   (Figure   R.2A).   In   addition,   by   manually   reviewing   all   DYRK1A  
mutations   in   cancer   samples   annotated   in   distinct   cancer   databases  
(Annex   II),  we  provided  additional  clues  supporting  a   role   for   this  kinase  
as   tumor   driver   in   endometrial   cancer.   First,   endometrial   cancer   shows  
the   higher   percentage   of   truncating   mutations   (nonsense   and   indels  
causing   frameshift;;   Figure   R.10),   with   all   of   them   appearing   before   the  
end   of   the   catalytic   domain.   Additionally,   while   DYRK1A   missense  
mutations   seem   to  map   in   equal   proportion   to   the   catalytic   domain   and  
the  non-­catalytic  N-­  and  C-­terminal  regions  in  cancer  tissues  (205  vs  192,  
410   aa   vs   403   aa),   uterine   cancer   samples   show   a   trend   towards  
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FoldX  method   to  all   the  DYRK1A  cancer  variants  mapping   in   the  crystal  
structure   of   the   kinase,   we   observed   an   enrichment   of   destabilizing  
mutations  in  uterine  tumors,  when  compared  with  the  tendency  observed  
in  the  Pan-­Cancer  cohort  (Table  R.4).  
  
Table  R.4  DYRK1A  missense  mutations  in  cancer  tissues.  DYRK1A  missense  mutations  
reported   in  cancer  databases  where  manually   reviewed   (Annex   II).  Numbers  are   indicated  
for  each  category.  For  the  stability  analysis,  ΔΔG  ≤  -­1.5:  gain  of  stability  (GoS);;  ΔΔG  ≥  1.5:  
loss  of  stability  (LoS);;    -­1.5  <  ΔΔG  <  1.5:  no  effect.  
    
     
Therefore,  all   this  evidence  pointed  out  endometrial  cancer  as  a  suitable  
model   to   investigate   whether   DYRK1A   drives   tumor   formation   and/or  
progression.   To   this   purpose,   we   interrogated   the   CCLE  
(portals.broadinstitute.org/ccle;;  (Barretina  et  al.,  2012))  and  identified  two  
endometrial   cancer   cell   lines,   HEC59   and   EN,   harboring   missense  
mutations   in   the  DYRK1A  gene,  which  could  be  used  as  cellular  models  
(Figure  R.11).  
Catalytic Non-Catalytic LoS No effect GoS
PanCancer 397 205 192 47 64 1
Breast 19 6 13 2 4 0
Lung 28 17 11 7 9 0
Liver 36 20 16 11 5 0
Pancreas 7 2 5 1 2 0
Prostate 9 5 4 1 3 0
Upper aero-dig 21 12 9 3 8 0
Ovary 5 3 2 1 2 0
Skin 54 17 37 7 10 0
Stomach 26 19 7 10 8 0
Uterus 56 38 18 23 14 0
Thyroid 3 0 3 0 0 0
Urinary tract 20 8 12 4 3 0




Blood 25 16 9 5 9 0
Brain 12 4 8 2 2 0
Cervix 11 6 1 13
Kidney 4 2 2 1 1 0





HEC59   and   EN   are   two   cell   lines   isolated   from   the   biopsies   of   two  
advanced,   poorly   differentiated,   endometrioid   adenocarcinomas   taken  
from   Japanese   patients   (Isaka   et   al.,   2003).   EN   and   HEC59   are  
heterozygous   for   DYRK1A   point   mutations   that   result   in   the   protein  
variants  S311P  and  R328Q,  respectively.  Both  variants  were   included   in  
the  functional  screens  described  in  the  previous  section  and  both  of  them  
were  LoF,  with  a  complete  loss  of  kinase  activity  (Figure  R.6D).  
  
  
Figure.   R.10   Distribution   of   DYRK1A   cancer   mutations   across   tissues.   Number   of  
cancer   missense   and   truncating   mutations   collected   across   different   cancer   browsers  
(Annex  II),  across  different  tissues.  Boundaries  for  the  DYRK1A  catalytic  domain  were  set  to  
aa   140-­500,   based   on   the   results   of   kinase   assays   using   truncated   DYRK1A   variants  
obtained  by  our  laboratory  and  other  groups  (Arranz,  et  al.,  2019;;  Himpel,  et  al.,  2001)  
  
The  DYRK1A  genotype  was  confirmed  by  sequencing  the  mutation  site  in  
the   genomic   DNA   of   both   cell   lines   (Figure   R.12A,   upper   panels).   The  
expression  of  both  alleles  at  mRNA,  wt  and  mutated,  was  also  confirmed  
by   sequencing   of   the   transcript   (Figure   R.12A,   lower   panels),   and  
DYRK1A  was  expressed  at  the  protein  level,  with  its  characteristic  pattern  
of  3  bands  (Figure  R.12B).  Finally,  in  order  to  confirm  loss  of  function,  IVK  
assays   were   performed   on   immunoprecipitated   endogenous   DYRK1A,  
which   showed   that   the  DYRK1A  protein   pool   isolated   from  both  HEC59  
and  EN  cell  lines  had  almost  50%  of  the  catalytic  activity  when  compared  
with   HeLa   cells,   a   DYRK1Awt/wt   cervical   carcinoma   cell   line   (Figure  
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having   kinase   activity.   Thus,   these   results   demonstrate   that   the  
alterations   observed   at   the   gene   and   transcript   levels   result   in   a   LoF  
phenotype.  
  
Figure   R.11   EN   and   HEC59   are   two   DYRK1A-­mutated   endometrial   carcinoma   cell  
lines.  Phase  contrast  photographs  of  EN  and  HEC59,  two  heterozygous  DYRK1A-­mutated  
endometrial   carcinoma   cell   lines,   carrying   the   missense   mutations   S311P   and   R328Q,  




Figure   R.12   Characterization   of   the   endometrial   cancer   cell   lines   with  mutations   in  
DYRK1A.  A)  The  DYRK1A  mutation   loci  of  EN  and  HEC59  cell   lines  were  PCR-­amplified  
using   genomic   DNA   (upper   panels)   and   total   cDNA   (lower   panels)   as   templates,   and  
sequenced.  The  heterozygous  sequences  are  visible  as  two  overlapping  peaks,  highlighted  
with  a  red  square.  B)  The  expression  of  DYRK1A  in  EN  and  HEC59  was  assessed  by  WB.  
C)  Functional  validation  of  DYRK1A-­functional  loss  in  HEC59  and  EN  cell  lines.  Endogenous  
DYRK1A  was  IP  and  evaluated  using  IVK  assays.  HeLa  cells  were  used  as  a  DYRK1Awt/wt  
control   cell   line.   Both   the   levels   of   authophosphorylation   (left   panel)   and   the   ability   to  

























































































3.2.   DYRK1A   overexpression   impairs   proliferation   of   EN   and  
HEC59  cells  
After   confirming   that   EN   and   HEC59   cells   were   bona   fide   DYRK1A-­
dysfunctional   cancer   models,   the   next   experiments   were   aimed   to  
investigate  whether  this  loss  of  functional  DYRK1A  was  responsible,  or  at  
least   contribute,   for   the   malignant   phenotype   in   the   two   cell   lines.   To  
address   this   question,  DYRK1A  was   ectopically   expressed   as   a   gain   of  
function   experiment.   Cells   were   transduced   with   lentiviral   vectors   to  
express  GFP-­DYRK1A,   to  allow  for  selection  of   the  DYRK1A  expressing  
cells   based   on   GFP   detection.   Thus,   cells   were   FACS-­sorted   and  
screened  in  colony  formation  assays  to  assess  for  cell  self-­renewal  ability  
(Figure   R.13A).   The   expression   of   GFP-­DYRK1A   was   confirmed   by  
DYRK1A   immunoblotting,   using   pre-­sorted   cell   lysates   (Figure   R.13B).  
The  experiments  showed  that  overexpression  of  DYRK1A  reduced  colony  
formation   in   both   HEC59   and   EN   compared   with   control   cells   (Figure  
R.13C-­D).  
3.3.   A  HEC59-­derived  DYRK1A  wt/wt   “reverted”   clone   shows  
reduced  proliferation  
3.3.1.  CRISPR-­based  genome  editing  in  endometrial  cancer  cell  lines    
Given   that   DYRK1A   overexpression   led   to   a   strong   reduction   in   the  
clonogenic  capabilities  of  the  two  endometrial  cancer  cell  lines,  this  could  
mean   that   restoring   functional   DYRK1A   protein   amounts   led   to   an  
impairment  in  their  proliferative  ability.  However,  such  effect  could  be  the  
consequence   of   cell   cycle   perturbations   due   to   a   massive   DYRK1A  
expression   as   described   in   other   cell   types,   and   based   on   a   G1-­arrest  
induced   by   DYRK1A-­dependent   degradation   of   Cyclin   D1   (Chen   et   al.,  
2013).  Therefore,  another  approach  was  explored.  The  strategy  consisted  
in  “correcting”  the  mutation  on  the  DYRK1A  gene  to  the  WT  sequence  by  
targeted   CRISPR/Cas9-­mediated   genome   editing   (Figure   R.14A),  
restoring  thereby  a  DYRK1Awt/wt  genotype.  
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Figure  R.13  DYRK1A  overexpression  reduces  HEC59  and  EN  clonogenic  capacity.  A)  
Schematic   representation   of   the   experiment:   HEC59   and   EN   cells   were   transduced   with  
lentiviral  particles  to  express  a  GFP-­DYRK1A  fusion  protein  or  with  a  bicistronic   lentivector  
to   express  DYRK1A   and  GFP.  GFP+   cells  were   FACS-­sorted   and   seeded   for   clonogenic  
assays.  B)  WB   of   total   lysates   of   the   transduced   cells   to   check  DYRK1A   overexpression  
prior  to  sorting.  A  130  kDa  band  corresponding  to  the  molecular  weight  of  the  GFP-­DYRK1A  
fusion  protein  appears  in  both  EN  and  HEC59  extracts,  confirming  ectopic  expression.  C,  D)  
Colony  formation  assays  for  HEC59  (C)  and  EN  (D).  The  barplots  (left)  show  quantification  
of  a  representative  experiment  (mean  ±  SD  of  experimental  triplicates).  Boxplots  (right)  were  
generated   by   plotting   results   from   n   =   3   independent   experiments.   The   medians   were  








































































































































Figure  R.14  Genome  “correction”   to  DYRK1Awt/wt   in  endometrial  cancer  cell   lines.  A)  
Design   of   the   CRISPR/Cas9-­based   strategy   to   revert   DYRK1A-­mutated   alleles   to   wt   in  
HEC59  ad  EN  cell   lines.  B)  Scheme  for   the  experimental  procedure:  HEC59  and  EN  cells  
were   transfected  with   sgRNA-­Cas9-­GFP   expressing   vectors   and   a   specific   ssODN.  GFP-­
expressing   cells   were   FACS-­sorted   in   MW96   plates   at   single-­cell   density.   After   colony  
growth,  the  clones  were  genotyped.  
  
EN  and  HEC59  cells  were  transfected  with  a  sgRNA-­Cas9  vector  and  the  
ssODN   (see   Materials   and   Methods   for   details).   The   RS-­1   drug   is   a  
RAD51  stimulator  (Jayathilaka  et  al.,  2008),  and  it  was  added  to  the  cells  
to   increase   the   frequency  of  homologous  recombination  events  (Song  et  
al.,   2016).   Next,   GFP+   cells   were   sorted   and   clones   were   grown  
individually   and   screened   to   identify   positive   “reverted”   clones   with   a  
DYRK1Awt/wt  genotype  (Figure  R.14B).  
After  the  first  unsuccessful  screens,  the  procedure  was  improved  trying  to  
increase   the   knock-­in   efficiency   and   also   to   set   up   a   faster   and   easier  
screening   protocol.   Furthermore,   HEC59   was   selected   as   the   only   cell  
model   for   genome   editing,   since   EN   cells   resulted   very   difficult   to  
manipulate,   due   to   their   slow   growth   and   the   low   percentage   of   clone  
recovering   after   cell   sorting   and   single-­cell   plating.   Thus,   a   new   ssODN  
was   designed   for   HEC59   DYRK1A   gene   editing   with   several  
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boundaries,   to   increase  the  knock-­in  efficiency  and  precision  (Renaud  et  
al.,   2016).   Second,   additional   sequence   modifications   were   introduced  
aimed  to  introduce  silent  mutations  in  the  HEC59  genome  to:  i)  disrupt  the  
PAM  sequence,  therefore  preventing  further  cleavage  events  after  correct  
editing,  and   ii)   change   the   restriction  profile  of   the  genome   locus,  which  
allowed  clone  screening  by   restriction  digestion   (Figure  R.15A-­B;;  details  
are  found  in  the  Materials  and  Methods  section).  Figure  R.15B  shows  an  
example   of   one   of   the   screens   to   identify   positive   clones.   One   of   the  
clones   (#123.B2)   showed   a   restriction   pattern   that   suggested   the  
occurrence  of  a  correct  knock-­in  (Figure  R.15B).  Hence,  we  proceeded  to  





Figure   R.15   Modification   of   the   CRISPR-­cas9   genome   editing   to   increase   precise  
knock-­in  efficiency  and  speed  up  the  screening  step.  A)  Structure  of  the  new  ssODN  for  
precise   HEC59   genome-­editing.   The   sgRNA   mapping   on   the   DYRK1A-­mutated   allele   is  
represented  and   the   target  PAM   is  also  highlighted.  The  WT  codon  sequence   is  shown   in  
green  and  additional  mutations  are  indicated  in  blue.  B)  Example  of  a  screening  with  BcoDI  
and  BstEII  restriction  enzymes.  The  mutation  site  was  amplified  with  PCR  and  the  digested  
product  with  the  indicated  enzymes  are  loaded  in  1%  agarose  gel.  The  parental  HEC59  cell  
line  and  a  BstEII  positive  control  are  also   loaded.  The  #123.B2  clone  shows   the  expected  
profile  of  a  positive-­reverted  clone  (the  cleavage  by  BstEII  enzyme  generated  the  fragment  





























































3.3.2.   The   HEC59-­derived   clone   #123.B2   is   a   DYRK1Awt/wt   reverted  
clone  
Correct   genome   editing   and   a   restored   DYRK1Awt/wt   genotype   in   the  
HEC59-­derived   clone   #123.B2,   with   the   incorporation   of   the   additional  
silent  mutations  included  in  the  ssODN,  was  confirmed  by  genomic  DNA  
and   transcript   sequencing   (Figure   R.16A).   Next,   to   determine   if   the  
reverted  genotype  was  linked  to  a  gain  in  DYRK1A  activity,  an  IVK  assay  
was   performed   on   immunoprecipitated   endogenous   DYRK1A   proteins,  
which  showed  that  the  DYRK1A  protein  obtained  from  #123.B2  presented  
a  2-­fold  increase  in  substrate  phosphorylation  capacity  compared  with  the  
activity   levels   of   parental  HEC59  DYRK1A   (Figure  R.16B-­C),   confirming  
that  the  reversion  was  also  occurring  at  the  functional  level.  
  
  
Figure  R.16  HEC59-­derived  clone  #123.B2  is  a  positive,  functionally  restored,  DYRK1A  
wt/wt   clone.   A)   Genomic   and   cDNA   sequencing   of   the  mutation   site   of   HEC59   #123.B2  
clone  confirms  the  reverted  DYRK1Awt/wt  genotype  (the  reverted  nucleotide  is  indicated  in  the  
red  square).  Additional  mutations  incorporated  through  the  engineered  ssODN  are  indicated  
with   black   arrows.  B)   Expression   analysis   of   DYRK1A   by  WB   in   the   indicated   clones.  C)  
Functional  validation  of  the  activity  gain  in  the  reverted  clone:  the  IVK  was  performed  using  
immunoprecipitated  DYRK1A   from  HEC59  parental   cells  and   its  derived  clone  #123.B2  on  
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3.3.3.  The  HEC59  reverted  clone  exhibits  reduced  proliferation  
Next,   we   aimed   to   assess   whether   restoring   a   DYRK1Awt/wt   genotype  
caused  any  changes  in  the  behavior  of  HEC59  cancer  cells,   focusing  on  
their   proliferation   ability.   Clonogenic   assays   revealed   that   the   HEC59  
#123.B2   clone   had   a   diminished   clonogenicity,   compared   with   the  
parental  HEC59  cells,  with  a  7-­fold  reduction   in  colony  formation  (Figure  
R.17A).   The   reduced   proliferation   rate  was   also   observed   in   cumulative  
growth   experiments,   although   to   a   less   extent   (Figure   R.17B).   These  
results   indicate   that   the  gain  of   the   full  DYRK1A  content  has  a  negative  
impact  on  the  proliferation  of  the  tumor  cells.  
  
Figure  R.17  HEC59-­derived  DYRK1Awt/wt  clone  shows  reduced  proliferation.  A)  Colony  
formation   assay   using   parental   HEC59   and   its   derived   #123.B2   clone:   the   bar-­plot   (left)  
shows  colony  quantification   from  a  representative  experiment   (mean  ±  SD  of  experimental  
triplicates);;   the   box-­plot   (right)   was   generated   with   results   from   n   =   6   independent  
experiments  in  triplicates  (****,  p  ≤  0.0001,  Mann-­Whitney  test).  B)  Cumulative  growth  curve  
of  parental  HEC59  and   its  derived  #123.B2  clone:   the  cell  numbers  at  day  1  were  set   to  1  
(mean  ±  SD,  n  =  3  independent  experiments;;  **,  p  ≤  0.01,  Student’s  t-­test,  only  comparisons  
















































































3.3.4.   Non-­edited   HEC59-­derived   CRISPR   clones   do   not   show  
differences  in  proliferation  
To  reinforce  the  proposal  that  reduced  proliferation  was  specifically  due  to  
functional  DYRK1A  gain  in  HEC59-­derived  clone  #123.B2,  another  clone,  
which   did   not   undergo   genome   editing   in   the  DYRK1A   locus   (parental-­
like),   was   isolated   and   characterized.   As   shown   in   Figure   R.18,   the  
DYRK1A   genotype   of   the  HEC59-­derived   clone   #123.D5  was   the   same  
as   the   parental   cell   line   (Figure  R.18A),   and   in   agreement,   no   changes  
were  observed  in  the  kinase  activity  levels  associated  to  the  endogenous  
protein  (Figure  R.18B).  
  
  
Figure  R.18  Characterization  of  HEC59-­derived  CRISPR/Cas9  clones.  A)  Genomic  and  
cDNA   sequencing   of   the   parental   HEC59   cell   line   and   the   parental-­like   clone   #123.D5  
(DYRK1Awt/R328Q).  B)  Expression  analysis  of  DYRK1A  by  WB  in  the  indicated  HEC59-­derived  
clones:   #123.B2,   DYRK1Awt/wt;;   #123.D5,   DYRK1Awt/R328Q;;   #123.D8,   DYRK1Amur/R328Q.   C)  
Functional   validation   of   HEC59   CRISPR   clones.   Endogenous   DYRK1A   was  
immunoprecipitated   and   assessed   by   Western   blot   (left)   and   IVK   assays   on   DYRKtide  
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The  characterization  of  HEC59  clone  #123.D5  showed  that  it  displayed  a  
significant   increase   in   colony   formation   capacity   compared   with   the  
parental  cell   line  in  clonogenic  assays  (Figure  R.19A),  with  no  significant  
differences  in  cumulative  growth  assays  (Figure  R.19B).  
  
  
Figure  R.19  Proliferation   capabilities  of  HEC59  parental-­like   clones   (DYRK1Awt/R328Q).  
A)  Colony   formation  assay  using  parental  HEC59  and   its  derived  clone  #123.D5.  The  bar-­
plot   (left)   shows   colony   quantification   from   a   representative   experiment   (mean   ±   SD   of  
triplicates);;   the   box-­plot   (right)   was   generated   with   results   from   n   =   5   independent  
experiments,  in  triplicates  (***p  ≤  0.001,  Mann-­Whitney  test).  B)  Cumulative  growth  curve  of  
parental  HEC59  and  its  derived  #123.D5  clone,  in  which  the  cell  numbers  at  day  1  were  set  
to  1  (mean  ±  SD  of  n  =  3  independent  experiments;;  ns  =  not  significant,  Student’s  t-­test,  only  
comparisons  at  day  5  are  shown).  C)  Colony  formation  assay  using  parental  HEC59  and  its  
derived   clone   #109.A10.   The  bar-­plot  was   generated  with   results   from  n  =   2   independent  
experiments,  in  triplicates  (ns  =  not  significant,  Mann-­Whitney  test).  
  
Cancer  cell  lines  are  heterogeneous  biological  systems.  Their  behavior  is  
therefore  the  result  of  each  cell  contribution,  which  is  closely  linked  to  the  







































































































manipulation.   Such   variance   can   never   be   completely   recapitulated   by  
single  clones   isolated  from  the  cell   line   itself.  Hence,  we  argued  that   the  
small   difference   observed   in   colony   formation   capacity   between   the  
parental   HEC59   cell   line   and   the   parental-­like   clone   #123.D5   might   be  
clone-­specific.   To   confirm   this   hypothesis,   we   isolated   an   alternative  
parental-­like   clone   from   the   CRISPR   screen   to   perform   additional  
clonogenic   assays.   The   clone   #109.A10   did   not   show   any   sequence  
modification  on  the  mutated  DYRK1A  locus  and  kinase  assays  confirmed  
a   parental-­like   enzymatic   potential   (data   not   shown).   When   assayed   in  
clonogenic  assays,  this  parental-­like  clone  showed  a  proliferative  capacity  
similar   to   the   parental   HEC59   (Figure   R.19C),   suggesting   that   the  
differences   observed   in   clone   #123.D5   could   either   be   due   to   HEC59  
cellular   heterogeneity   or   to   off-­target   effects   induced   by   the   CRISPR  
procedure.  Nevertheless,  we  think  that  the  fact  that  “parental-­like”  clones  
did  not  show  diminished  clonogenic  capabilities  provide   robust  evidence  
supporting  that  the  proliferative  deficiency  displayed  by  the  reverted  clone  
is  actually  due  to  the  restored  DYRK1Awt/wt  genotype.  
3.3.5.   HEC59-­derived   clones   deficient   for   DYRK1A   show   increased  
clonogenicity  
As  shown  by  the  genomic  analysis,  HEC59  cells  are  heterozygous  for  the  
LoF   mutation   R328Q.   The   data   deposited   in   several   cancer   databases  
consulted  indicate  that  heterozygosity  is  a  recurrent  condition  in  DYRK1A-­
mutated  cancer  samples,  and  we  did  not   find  any  case  indicative  of   loss  
of   heterozygosity.   Our   working   hypothesis   is   that   DYRK1A  
haploinsufficiency   is   sufficient   to   promote   tumor   progression.   The  
absence   of   tumor   samples   with   total   depletion   of   DYRK1A   could  mean  
that   retention   of   functional   DYRK1A,   albeit   reduced,   is   essential   for   the  
cancer   cell   viability;;   alternatively,   total   DYRK1A   depletion   might   not  
provide  further  advantage  to  cancer  cells  and  it  does  not  undergo  positive  
selection.   To   explore   these   possibilities,   we   posed   to   characterize   the  
behavior  of  homozygous,  DYRK1A  functional  knock-­out  (KO)  cells.  Thus,  
we   isolated   HEC59-­derived   clones   that   went   through   “incorrect”   editing  
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events   on   both   alleles   during   the   CRISPR   screen,   mostly   due   to   Non-­
Homologous-­End-­Joining  (NHEJ)  DNA  repair  activity,  which  is  error-­prone  
and  tends  to  generate  frameshifts  (Ceccaldi  et  al.,  2016).    
Two   independent  clones  were   isolated,  #109.D8  and  #109.G5,  and   their  
genomic  identity  confirmed  by  sequencing  of  the  mutated  locus  (data  not  
shown),   which   indicated   that   they   were   homozygous   for   truncating  
mutations.   These   results   were   in   agreement   with   the   lack   of   detectable  
DYRK1A  protein  expression  or  associated-­kinase  activity   (Figure  R.18B-­
C,  for  #109.D8).  The  two  clones  showed  increased  clonogenic  capabilities  
in   comparison   with   the   parental   HEC59   cells   (Figure   R.20A   and   C),  
although   no   significant   differences   were   observed   in   cumulative   growth  
curves   (Figure   R.20B   for   #109.D8).   These   results   suggested   that   total  
loss   of   DYRK1A   enhances   the   proliferative/survival   capacity   of   HEC59,  
when  assayed  in  single-­cell  colony  formation,  but  it  does  not  affect  global  
proliferation  rate.  
The   outcome   of   these   experiments   do   not   explain   why   DYRK1A  
homozygous   mutations   or   LOH   events   have   not   been   found   in   cancer  
samples,  which   is   the  expectation  by   considering   the   strong   increase   in  
clonogenic   capacity.   These   findings   thus   raise   the   interesting   possibility  
that   the   loss   of   DYRK1A   in   tumors   has   distinct   effects   than   those  
observed   in   tumor   cell   models,   and   further   suggest   that   DYRK1A  








Figure   R.20   Characterization   of   HEC59-­derived   DYRK1A   KO   (DYRK1A-­/-­)   clones.   A)  
Colony  formation  assay  using  parental  HEC59  and  its  derived  clone  #109.D8.  The  bar-­plot  
(left)   shows   colony   quantification   from   a   representative   experiment   (mean   ±   SD   of  
triplicates);;   the   box-­plot   (right)   was   generated   with   results   from   n   =   3   independent  
experiments,  in  triplicates  (***p  ≤  0.001,  Mann-­Whitney  test).  B)  Cumulative  growth  curve  of  
parental  HEC59  and  its  derived  #109.D8  clone,  in  which  the  cell  numbers  at  day  1  were  set  
to  1  (n  =  2  independent  experiments;;  ns  =  not  significant,  Student’s  t-­test,  only  comparisons  
at  day  5  are  shown).  C)  Colony  formation  assay  using  parental  HEC59  and  its  derived  clone  
#109.G5.  The  bar-­plot  was  generated  with   results   from  n  =  2   independent  experiments,   in  
triplicates  (***p  ≤  0.001,  Mann-­Whitney  test).  
  
3.4.   The   HEC59-­derived   DYRK1A   reverted   clone   shows  
increased  sub-­G1  cell  population  
Activated   cell   cycle   progression   and   repressed   apoptotic   program   are  
hallmarks  of  cancer  cells.  Among  the  cellular  factors  that  have  been  found  
phosphorylated   and   thereby   modulated   by   DYRK1A,   are   critical  
regulators  of  both  processes,  such  as  p53,  Cyclin  D1,  p27Kip1  or  Caspase  




































































































	   105  
2014).   In   this   regard,   the   results   shown   in   Figure   R.17   indicated   that  
reversion  of  DYRK1A   to  a  WT  status   induced  a   reduction   in   clonogenic  
assays  and,  to  a  lesser  extent,  in  cumulative  growth.  These  effects  could  
be  the  result  of  alterations  in  cell  proliferation  and/or  survival.  To  test  this  
hypothesis,  the  cell  cycle  profile  of  the  HEC59-­derived  DYRK1Awt/wt  clone  
was  monitored  and  compared  with  that  of  parental  HEC59  cells.  The  flow  
cytometric  analysis  showed  no  significant  differences  in  any  of  the  phases  
of   the   cell   cycle   (Figure  R.21A),   suggesting   that   the  DYRK1A   reversion  
does  not   causes  major   changes   in   cell   cycle  progression   in   this   cellular  
context.  Therefore,  we  speculated  that  reduction  in  the  cell  numbers  could  
be   due   to   decreased   cell   viability.   This   possibility   was   assessed   by  
measuring  the  sub-­G1  population  by  FACs  analysis.  As  shown   in  Figure  
R.21B,  the  DYRK1Awt/wt  cells  (#123.B2)  showed  a  significant  increment  in  
the   sub-­G1   population   when   compared   with   the   parental   HEC59   cells,  
indicating   that   restoring   normal   DYRK1A   levels   led   to   increased   cell  
death.   Interestingly,   the   HEC59-­derived   clone   deficient   in   DYRK1A  
(#109.D89)   displayed   an   opposite   trend,   with   a   reduction   in   cell   death  
(Figure  R.21B).  Of  note,  this  type  of  assay  does  not  allow  to  discriminate  
between   different   types   of   cellular   death;;   thus,   we   cannot   ascribe   the  
differences   in   the   sub-­G1   population   to   alterations   in   the   apoptotic  
program   or   necrotic   processes.   Together,   these   data   suggest   that  
restoring  a  normal  functional  DYRK1A  protein  dosage  in  the  endometroid  
carcinoma  HEC59  cells  either  enhanced  the  response  to  programmed  cell  
death   or   reduced   the   overall   cell   fitness,   leading   to   an   increment   in   the  
non-­viable   cell   fraction.   Notably,   this   effect   appears   to   correlate   with  
variations  in  the  DYRK1A  dosage,  with  the  total  loss  of  DYRK1A  having  a  
protective  effect.  The  alteration  in  the  survival  potential  in  response  to  the  
DYRK1A   dosage   would   explain,   at   least   in   part,   the   results   of   the  





Figure   R.21   The   HEC59-­derived   clones   with   DYRK1A   dosage   modifications   show  
differences  in  cell  death  rate.  A)  Flow  cytometry  analysis  of  cell  cycle  phases  in  parental  
HEC59  and  the  reverted  DYRK1Awt/wt  #123.B2  clone.  The  graph  shows  mean  ±  SD  of  n  =  2  
independent  experiments.  B)  Flow  cytometry  analysis  of   the  sub-­G1  population   in  parental  
HEC59,  the  reverted  #123.B2  clone  and  the  KO  #109.D8  clone.  The  percentage  of  the  sub-­
G1  values  was  normalized  to  the  values  of  the  parental  cell  line  set  as  1.  The  graph  shows  
the  results  of  3  independent  experiments  performed  in  triplicate.  
  
3.5.  Alteration  of  DYRK1A  dosage  in  endometroid  tumor  cells  
affects  tumor  growth  in  vivo  
The   results   obtained   so   far  with   the   endometrial   cancer   cellular  models  
suggest   that   restoring   functional   DYRK1A   expression   in   DYRK1A-­
deficient   endometrial   cancer   cell   lines   leads   to   impaired   proliferative  
capacity  (Figure  R.17)  most  likely  linked  to  decreased  cell  survival  (Figure  
R.21),   suggesting   a   role   for   DYRK1A   as   tumor   suppressor   in   this  
biological   context.   To   evaluate  DYRK1A   contribution   to   tumor   formation  
and   progression,   we   decided   to   analyze   the   behavior   of   the   HEC59-­
derived  cell   lines  with  different  dosage  of  DYRK1A  in  mouse  xenografts.  
Although   we   are   aware   of   the   limitations   of   tumor   xenograft   models   by  
using   immunocompromised   animals   and   the   growth   of   the   cells   outside  
the   proper   tumor   environment,  we   thought   that   this   type   of   experiments  
might   provide   information   beyond   the   tumor   cell   itself   growing   in  
controlled  tissue  culture  conditions.  The  HEC59  parental  cell  line  and  the  
genome-­edited  clones  were   inoculated  subcutaneously   into   the   flanks  of  
nude   mice,   and   the   tumor   growth   followed.   Tumors   generated   by   the  
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parental-­like   clone   #123.D5.  On   the   contrary,   xenografts   of   the  HEC59-­
derived  clone  with  the  reversion  in  DYRK1A  showed  a  clear  growth  delay  
and  a   strong   reduction   in   the   size  of   the   tumors  at   the  experiment  end-­
point   (Figure  R.22A-­C,   clone  #123.B2).  Strikingly,   and   in   contrast   to   the  
phenotype  observed   in   the  cell  cultures  assays,  xenografts  derived   from  
the  clone  deficient   in  DYRK1A  showed  a  slower  tumor  growth  compared  
to   the  parental   cell   line   (Figure  R.22A-­C,  clone  #123.D8),   indicating   that  
the   total   loss   of   DYRK1A   in   the   tumor   cells   represents   an   unfavorable  
condition   for   the   tumor   proliferation   in   animal   hosts,   and   further  




Figure   R.22   Characterization   of   the   tumor   growth   of   HEC59   and   its   derived   clones  
with   different   dosages   of   DYRK1A.   A)   Follow-­up   of   tumor   growth   after   subcutaneous  
inoculation   in  nude  mice  of   the  HEC59  parental  cell   line  and   its  derived  clones.  The  tumor  
volumes  were  measured  and  normalized  by  the  first-­point  value  (set  as  0).  The  graph  shows  
mean  ±  SEM  of  n  =  12  tumors  per  group.  For  the  statistical  analysis  only  comparisons  at  day  
35   are   shown   (*p   ≤   0.05,   ns   =   not   significant,   Mann-­Whitney   test).   B)   Plot   representing  
relative  tumor  growth  values  at  end-­point  (day  35).  The  graph  shows  mean  ±  SEM  of    n=12  
(*p≤0.05,   ns=   not   significant,   Mann-­Whitney   test).   C)   Photographs   showing   three  







































































4.   An   integrated   proteomic-­transcriptomic   analysis  
reveals   enhanced   STAT1   activation   and   an   interferon  
signaling   pathway   signature   in   the   HEC59-­derived  
DYRK1A-­WT  clone  
4.1.   Proteome   profiling   of  DYRK1Awt/wt   and  DYRK1A-­/-­   HEC59  
clones  reveals  a  DYRK1A  dose-­dependent  enrichment  in  type  
I  Interferon  (IFN-­I)  response  factors  
To   gain   further   insight   on   the   molecular   changes   provoked   by   the  
restoration   of   DYRK1A-­WT   in   the   HEC59-­derived   #123.B2   clone,   we  
implemented   a   proteomic   approach   based   on   free-­label   quantitative  MS  
to   evaluate   whether   differential   protein   expression   could   provide   some  
clues  on  the  biological  mechanisms  responsible  for  the  observed  changes  
in  phenotype.  The  HEC59-­derived  DYRK1A-­KO  clone  #109.D8  was  also  
included  in  the  analysis  to  monitor  changes  in  global  proteome  linked  to  a  
complete   loss   of   DYRK1A.   Total   protein   extracts   were   prepared   in  
quadruplicates  and  all   samples  were  analyzed  by  LC-­MS/MS.  A   total   of  
4,525   proteins   were   identified   in   the   experiment,   including   DYRK1A,  
which   was   absent   in   the   DYRK1A-­KO   clone.   PCA revealed   that   the  
proteome   of   each   clone   cluster   tightly   and   is   distinct   from   the   others  
(Figure  R.23A),   indicating  that  each  clone  possesses  a  unique  proteome  
signature.  The  analysis  rendered  a  total  number  of  259  proteins  that  were  
up-­regulated   or   down-­regulated   in   the   HEC59-­derived   clones   when  
compared  with  the  parental  protein  profile  (Figure  R.23B).  GO  enrichment  
analysis  showed  no  particular  enrichment  for  the  downregulated  proteins  
in   the   DYRK1A-­WT   clone   or   the   upregulated   ones   in   the   DYRK1A-­KO  
clone.  However,  enrichment   in  Type   I   Interferon   (IFN-­I)   signaling-­related  
GO   terms   in   the   upregulated   group   in   the   DYRK1A   WT   cells   and   the  
downregulated  group   in   the  DYRK1A-­KO  cells  when   compared  with   the  
parental   HEC59   cells   was   observed   (Figure   R.23C),   which   includes  
downstream   targets   of   the   pathway   such   as   MX1,   OAS2,   OAS3,   or  
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ISG15.   IFN   signaling   has   been   extensively   described   as   a   master  
regulatory   network   modulating   immune   cells,   mostly   in   response   to  
microbial   and   viral   infection,   stimulating   anti-­proliferative   transcriptional  
programs   (Gonzalez-­Navajas   et   al.,   2012).   IFNs   exhibit   important  
antineoplastic   effects,   reflecting   both   direct   antiproliferative   responses  
mediated   by   IFN   receptors   expressed   on   malignant   cells,   as   well   as  
indirect  immunomodulatory  effects  (Borden,  2019;;  Dunn  et  al.,  2006;;  Fish  
and  Platanias,   2014).   Lack   of   several   key   effectors   of   the   IFN   signaling  
cascade  has  been  observed  in  different  type  of  tumors,  which  has  led  to  
the   proposal   that   loss   of   responsiveness   to   IFNs   may   be   a   critical  
component  of  the  host  response  to  tumors  (Cheon  et  al.,  2014).    
  
  
Figure   R.23   Proteomic   analysis   of   HEC59   parental   cells   and   its   derived   DYRK1A-­
edited  clones.  A)  Principal   component  analysis  of   the  proteomic  data.  Four   replicates   for  
each  condition  were  used.  B)  Number  of  differentially  expressed  proteins   in   the  DYRK1A-­
edited   clones   in   comparison   to   the   HEC59   parental   cells.   Threshold:   log2FC   ≤   -­0.7  
(downregulated)   or   log2FC  ≥  0.7   (upregulated)   and  adjusted   p-­value  <  0.01.  The  proteins  
detected   in   one   of   the   clones   but   absent   in   the   parental   cells   (or   vice   versa)   were   also  
included.   C)   GO   term   analysis   of   the   differentially   abundant   protein   indicated   in   the  
DYRK1A-­edited  clones,  ranked  by  p-­values  according  to  the  Enrich-­R  software  (Kuleshov  et  
al.,  2016).  
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Therefore,   the   results   obtained   with   the   proteome   analysis   defined   the  
protein   expression   profiles   of   the   HEC59   DYRK1A-­edited   clones   and  
provided   new   hints   on   molecular   changes   caused   by   variations   in  
functional   DYRK1A   protein   abundance,   as   it   is   the   case   of   proteins  
encoded  by  IFN-­responsive  genes  (Figure  R.23C).  
4.2.   DYRK1A   gain   drives   STAT1   activation   and   coherent   IFN-­
response  gene  expression  in  HEC59  cells  
The   changes   observed   at   the   protein   level   could   be   due   to   gene  
expression   changes,   to   post-­transcriptional   regulatory   mechanisms,   or  
both.   To   explore   these   possibilities,  we   generated   a   phospho-­proteomic  
profile   to   identify   gain/loss   of   phosphorylation   events   in   the   DYRK1A-­
modified   HEC59   clones.   The   analysis   yielded   more   than   6,000   unique  
phosphosites  identified,  mapping  to  2,441  proteins.  
Hierarchical   cluster   analysis   highlighted   different   groups   of   unique  
phosphorylation   events,   with   distinct   patterns   across   the   three   different  
conditions   (Figure   R.24A).   To   better   understand   which   groups   of  
phospho-­events   could   be   directly   or   indirectly   boosted   by   DYRK1A  
activity,   we   focused   the   analysis   on   those   clusters   whose   intensity  
changed   following   a   “DYRK1A-­increasing-­dosage”   (DID)   pattern,   i.e.  
showing   increased   phosphorylation   from   the   DYRK1A   (-­)   null   condition  
(KO  clone)  to  the  normal  DYRK1A  amount  (+/+)  condition,  represented  by  
the   reverted   clone,   with   the   parental   HEC59   cells   serving   as   an  
intermediate   (+/-­)   state   (Figure  R.24A).   The   phosphorylation   of   S727   of  
Signal   transducer  and  activator  of   transcription  1   (STAT1)  was   identified  
as   one   of   these   events   (Figure   R.24B).   STAT   proteins   are   the   ultimate  
effectors   of   IFN   and   other   crucial   signaling   pathways,   getting   activated  
through   phosphorylation,   which   in   turn   allows   their   translocation   to   the  
nucleus  and  the  promotion  of  the  transcription  of  specific  gene  signatures  
(Ivashkiv   and   Donlin,   2014;;   Majoros   et   al.,   2017).   STAT1   is  
phosphorylated   by   different   upstream   kinases,   in   response   to   several  
types   of   extracellular   signals;;   multiple   phosphorylation   sites   have   been  
identified,  but  phosphorylation  of  Y701  represents  the  key  activation  event  
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and  phosphorylation  of  S727  is  also  required  for  full  transcriptional  activity  
(Horvath,  2000;;  Wen  et  al.,  1995).    
  
  
Figure   R.24   Phospho-­proteome   profiling   of   HEC59   DYRK1A-­edited   clones.   A)  
Hierarchical   cluster   analysis   of   unique   phosphorylation   events   (peptides);;   only   peptides  
detected  in  at  least  two  of  the  four  replicates  in  both  parental  and  reverted  clone  were  used.  
The   median   intensity   of   the   replicates   in   each   condition   was   z-­scored   and   coloured   as  
shown  in  the  scale  bar.  The  cluster  responding  to  DYRK1A  dosage  is  marked  with  squares.  
B)   STAT1   p-­Ser727   log2(FC)   in   reverted   #123.B2clone,   Parental   cells   and   KO   #109.D8  
clone,  normalized   to  parental   values   (mean  of  parental   condition   replicates  set  as  1).  The  
graph  also  includes  the  mean  ±  SD  for  each  group.  
  
To  assess  whether  the  changes  in  activated  STAT1  had  consequences  at  
the   transcriptional   level,   we   integrated   the   proteomic   and   phospho-­
proteomic   data   with   RNA-­Seq   data.   The   analysis   showed   that   the  
DYRK1A-­WT   and   -­KO   clones   had   profound   changes   in   transcript  
abundances  when  compared  with  HEC59  parental  cells.  Intriguingly,  total  
loss  of  DYRK1A  led  to  more  dramatic  gene  expression  rewiring  than  that  
associated   to   the   gain   in   DYRK1A   (Figure   R.25A).   Following   the   same  
criteria   as   for   the   phospho-­proteomic   analysis,   we   zoomed   into   those  
genes   that   appeared   to   have   a   DID-­like   behavior   (increasing   from  
DYRK1A-­KO   clone   to   DYRK1A-­WT   clone)   to   determine   which  
transcriptional   programs   were   boosted   by   increased   DYRK1A   dosage  




































indeed   enriched   in   STAT1   and   STAT2   targets   (Figure   R.25C,   upper  
panel).   In   agreement,   GO   terms   analysis   unveiled   a   significant  
enrichment   for   IFN   signaling-­associated   genes   (Figure   R.25C,   lower  
panel),  providing  additional  robustness  to  our  results.  
  
Figure  R.25  Gene  expression  analysis  of  HEC59  DYRK1A-­edited  clones.  A)  Correlation  
heatmap   of   the   different   biological   replicates   used   for   the   RNA-­seq   analysis.   Euclidean  
distance  was  calculated  across   replicates;;   this  analysis  gives  an  overview  over  similarities  
and   dissimilarities   between   samples.  B)   Genes  were   grouped   into   eleven   clusters   on   the  
basis   of   the   similarity   of   expression   (clustering   type:   K-­means   clustering).   The   DYRK1A-­
increasing  dosage  (DID)  cluster  is  marked  with  a  square.  The  median  intensity  of  the  three  
biological  replicates  in  each  condition  was  z-­scored  and  coloured  as  shown  in  the  scale  bar.  
C)  Analysis  of  the  transcription  factor  enrichment  based  on  ENCODE  ChIP-­seq  data  (upper  
panel)   and   of   GO   Terms   Biological   Processes   enrichment   (lower   panel)   of   the   genes  
extracted   from   the   DID   cluster,   filtered   for   those   showed   adjusted   p-­value   <   0.01.   The  
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In   summary,   the   integrated   transciptomic/proteomic/phospho-­proteomic  
study  performed  on  the  HEC59  parental  cell  line  and  the  DYRK1A-­edited  
derived  clones  has  uncovered  multiple  molecular  changes,  generated  by  
the   sole   DYRK1A   gene   correction/deletion.   Moreover,   we   identified   a  
DYRK1A  dosage-­dependent  event  affecting  IFN-­I  signaling,  which  is  most  
likely  mediated  by  STAT1  activation.  The  link  between  DYRK1A  gain/loss  
and  the  IFN  signaling  response  and  whether  this   interplay   is  responsible  
for   the   observed   anti-­proliferative   effect   caused   by   functional   DYRK1A  
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1.   Identification   of   DYRK   family  members   as   potential  
tumor  drivers  
The   aim   of   this   Thesis   project   was   to   dissect   the   potential   of   DYRK  
protein   kinases   as  molecular   tumor   drivers   in   specific   tumor   contexts.  
Although   isolated   reports   had   revealed   altered   expression   of   single  
DYRK   members   in   tumors,   this   study   represents   the   first  
comprehensive   research   effort   of   multi-­type   alterations   of   the   whole  
DYRK  family  of  kinases  in  cancer  samples.  
As   a   parallel   project   of   my   PhD,   I   also   carried   out   a   study   in  
collaboration   with   Cristina   Fillat’s   group   (IDIBAPS,   Barcelona),   where  
we  investigated  the  role  of  DYRK1A  and  DYRK1B  in  pancreatic  cancer.  
The  article,  published  in  Gut  journal  in  October  2018,  has  been  included  
in   this  manuscript   as  Annex   I,   and   it  will   be  discussed   in-­depth   in   the  
following  sections.  
Although   the  Thesis  work   focused  on  DYRK1A,  we  also  provide   initial  
evidence   that   other   two   members   of   the   DYRK   family   of   kinases,  
DYRK1B  and  DYRK2,  may  function  as  tumor  drivers  in  several  cancer  
types.   More   specifically,   they   show   a   tendency   towards   gene  
amplification   and   overexpression   in   specific   tumor   types,   indicating   a  
potential  role  for  these  two  kinases  as  oncogenic  factors.  
1.1.   DYRK1B   is   amplified   in   tumors   and   plays   pro-­tumorigenic  
functions  in  pancreatic  cancer  
By  looking  at  the  tumor/healthy  DE  analysis,  DYRK1B  turned  out  to  be  
overexpressed   in   BLCA,   UCEC,   PRAD,   KICH,   KIRP,   THCA,   BRCA,  
LIHC   and  KIRC   (Figure  R.2B).   Amplification   of   the  DYRK1B   genomic  
region   with   coherent   overexpression   was   observed   in   BLCA,   BRCA,  
LUSC,  SARC,  CESC,  OV  and  PAAD   (Figure  R.3B).   The   last   4   tumor  
cohorts   were   not   in   the   DE   analysis,   since   the   number   of   paired  
healthy-­tumor   samples   did   not   pass   the   threshold   used,   so   no  
correlations   could   be   established;;   however,   the   results   indicate   that  
overexpression  in  BRCA  and  BLCA  could  be  due  to  gene  amplification  
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(Figure   R.3B-­C).   Our   analysis   confirms   previously   reported   DYRK1B  
amplification/overexpression   in   ovarian   cancer   (Gao   et   al.,   2009)   and  
pancreatic   cancer   (Deng   et   al.,   2006),   and   DYRK1B   upregulation   in  
breast   tumor   tissues   (Chen   et   al.,   2017).   Moreover,   we   provide  
additional  information  on  a  potential  oncogenic  role  played  by  DYRK1B  
in   other   tumor   tissue   types   such   as   uterus   (UCEC),   bladder   (BLCA),  
kidney   (KICH,   KIRP   and   KIRC),   liver   (LIHC)   and   thyroid   (THCA).  
However,   experimental   work   is   needed   to   confirm   DYRK1B  
overexpression   in   independent  cohorts  and  to  study  how   it  contributes  
to  tumorigenesis   in  these  biological  contexts.  In  the  case  of  pancreatic  
ductal   adenocarcinoma   (PDAC),  we   provide   further   experimental   data  
by   using   the   cell   line   PANC-­1,   which   presents   19q13.2   amplification  
(Kuuselo  et  al.,  2007;;  Miwa  et  al.,  1996),  and  overexpresses  DYRK1B  
(Deng,   et   al.,   2006).   We   demonstrate   that   DYRK1B   knockdown  
drastically  reduced  cell  proliferation,  motility  and  invasion  in  this  cell  line  
(Luna   et   al.,   2018)(Annex   I).   These   results   suggest   that   targeting  
DYRK1B   in   DYRK1B-­overexpressing   pancreatic   tumors   might  
represent  a  good  therapeutic  strategy.  We  also  show  that   treatment  of  
PANC-­1   with   the   DYRK   inhibitor   harmine   strongly   reduced   cell  
proliferation   and   tumor   growth   in   the   Ela-­myc   PDAC   mouse   model  
(Luna,  et  al.,  2018)(Annex  I).  Given  that  harmine  targets  both  DYRK1A  
and   DYRK1B   (Bain   et   al.,   2007),   the   inhibitor-­dependent   antitumor  
effects   could   be   the   consequence   of   DYRK1A   inhibition,   DYRK1B  
inhibition,   or   both.   Although   specific   DYRK1B   inhibitors   not   targeting  
DYRK1A,  or  vice  versa,  would  be  needed  to  evaluate  the  independent  
effects  of  each  kinase,  the  dual  targeting  ability  could  be  also  envisaged  
as   an   advantage   for   treating   tumors   with   overexpression   of   the   two  
class  I  kinases.    
1.2.  DYRK2  is  a  potential  oncogene  
Another   member   of   the   DYRK   family   that   deserves   additional  
consideration  is  DYRK2.  Compared  with  the  respective  healthy  tissues,  
we   found   DYRK2   overexpressed   in   8   tumor   cohorts:   BRCA,   STAD,  
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LIHC,   BLCA,   KIRC,   LUAD,   LUSC,   ESCA   and   KIRP   (Figure   R.2C).  
Analysis   of   CNAs   demonstrated   that   the   up-­regulation   is   associated  
with   gene   amplification   in   BRCA,   LUAD,   LUSC,   BLCA   and   STAD.  
Significant   DYRK2-­overexpression   was   also   observed   in   OV,   SKCN,  
SARC   and   HNSC   (Figure   R.3C).   As   for  DYRK1B,   the   results   of   the  
analysis  of   the  TCGA  cohorts  are  consistent  with  previous  reports  that  
showed   DYRK2   amplification/overexpression   in   different   cohorts   of  
esophageal   carcinoma,   lung   adenocarcinoma   (Miller   et   al.,   2003)   and  
gastric   adenocarcinoma   (Gorringe   et   al.,   2005).   The   BRCA   cohort   is  
included  among  the  TCGA  cohorts  where  DYRK2  is  found  upregulated  
(Fig  R.2C);;  of  note,  several  publications  have  studied  the  role  played  by  
DYRK2   in   breast   cancer   with   conflicting   results.   Our   results   may  
indicate  that  DYRK2  amplification/overexpression   is  positively  selected  
in  breast  cancer  cells.  This  hypothesis  would  be  in  agreement  with  the  
pro-­tumorigenic   role  proposed  by  previous  studies,  which  showed   that  
DYRK2   inhibition   impaired   cell   proliferation   and   breast   tumor   growth  
(Banerjee   et   al.,   2018;;   Guo   et   al.,   2016).   However,   no   evidence   of  
increased   DYRK2   expression   was   provided   in   these   works.   On   the  
contrary,   Taira   and   colleagues   reported   decreased   protein   expression  
levels   in   tissue   microarrays   of   several   tumor   types,   including   breast,  
even   though   no   statistical   analysis   is   provided,   and   increased  
tumorigenic   potential   when   DYRK2   was   silenced.   These   authors   did  
show   significant   correlation   between   low   levels   of   DYRK2   expression  
and   tumor   aggressiveness   (Taira   et   al.,   2012).   These   results   are   not  
necessarily   in  discordancy  with  our  findings,  since  we  did  not  consider  
differences   in   tumor   stages   or   grade   of  malignancy   in   the   analysis   of  
the   TCGA   data;;   moreover,   we   analyzed   exclusively   RNA-­Seq   data,  
which   could  mean   that   transcript   levels  might   be   not   recapitulated   by  
protein  staining.  Finally,  although  the  research  works  mentioned  above  
showed   opposite   outputs   of  DYRK2   silencing,   it   should   be   observed  
that   different   cell   lines   were   used,   thus   suggesting   that   DYRK2  
oncogenic  or  tumor  suppressive  function  in  breast  cancer  may  depend  
on  the  genetic  background  of  the  breast  cancer  cells.    
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Further   lines   of   investigation   are   required   to   study   in-­depth   how  
DYRK1B  and  DYRK2  participate  in  cancer-­promoting  processes.  
  
2.  DYRK1A  cancer-­associated  mutations  are  LoF  
DYRK1A  was  identified  as  a  putative  tumor  driver  with  multiple  methods  
of  analysis  of  somatic  mutation  patterns  (Figure  R.4B),  and  it  was  found  
downregulated  at  the  transcript  level  in  most  of  the  TCGA  tumor  cohorts  
considered   (Figure   R.2A).   These   results   suggest   that   the   loss   of  
DYRK1A  either  by   inactivating  mutations  or  by  reduction  in  expression  
could  be  selected  in  tumor  cells.  In  this  regard,   it   is  worth  noticing  that  
DYRK1A  belongs   to  a  class  of  genes  defined  as  LoF-­intolerant  by   the  
ExAC   large-­scale   study,   which   collected   and   reviewed   exome   and  
whole  sequencing  data  from  more  than  60,000  human  samples  (Lek  et  
al.,  2016).  The  result  is  extremely  interesting,  since  it  may  indicate  that  
different   genetic   and  molecular   landscapes   create   the   conditions   that  
allow   a   higher   mutation   burden   on  DYRK1A   gene   in   cancer   cells.   In  
other   words,   while   DYRK1A   LoF   is   poorly   tolerated   at   the   germline  
level,   it   may   be   not   only   well   tolerated   in   tumor   cells   but   positively  
selected,   as   indicated   by   the   results   obtained   with   computational  
methods   (Figure  R.4C).   Indeed,   by   comparing   the   profile   of   DYRK1A  
missense  variants  obtained   from  the  ExAC  browser  and   the  pattern  of  
DYRK1A   cancer-­associated   variants,   it   is   evident   that   the   overall  
mutation   frequency   is   lower   in   the   normal   population   and   the  
distribution   of   the   variants   in   the   coding   sequence   is   different   (Figure  
D.1).  Amino  acid  changes  reported  in  ExAC  are  localized  mainly  in  the  
non-­catalytic   C-­terminal   part   of   the   protein,   with   fewer   changes  
mapping   in   the   catalytic   domain   (Figure   D.1),   indicating   that   most  
residues   in   this  domain  are   important   for  protein   functionality.  Of  note,  
the  only  variant  annotated  as  LoF  is  a  change  affecting  a  splice  donor  
site   (not   included   in   the   figure),  which  would   affect   the   splicing   of   the  
last   coding   exon.  On   the   contrary,   nonsense  mutations   and   frameshit  
indels  in  tumor  samples  are  accumulated  within  the  N-­terminus  and  the  
Discussion  
  
	   121  
kinase   domain   (Figure   R.4C),   suggesting   positive   selection   for  
truncation-­causing   changes,   whereas   missense   mutations   are  




Figure  D.1.   Distribution   of   DYRK1A  mutations   in   normal   and   cancer   samples.   All  
DYRK1A  missense  mutations  listed  in  ExAC  browser  (upper  panel)  and  cBioPortal  cancer  
browser   (lower   panel)   are  mapped   along   the   primary   structure   of   the  DYRK1A  protein.  
The   height   of   the   sticks   does   not   reproduce   the   allelic   frequency,   and   varies   only   for  
illustrative   reasons.   Indeed,   the   Figure   does   not   intend   to   compare   allele   frequencies  
since  the  number  of  individuals  analyzed  in  each  study  is  very  different.  DYRK1A  protein  
domains  are  as  described  in  Figure  I.2.  
  
All   these   observations   fit   with   our   speculation   that   DYRK1A   somatic  
alterations   are   positively   selected   in   tumors.   Indeed,   the   results  
obtained   in   this   Thesis   work   provide   experimental   evidence   for   this  
hypothesis,  because   the  majority  of   the   representative  group  of   tumor  
somatic  missense  variants  analyzed  for  functional  impact  (21  out  of  27)  
dramatically  affect  protein  function  and  stability,  and  they  are  therefore  
LoF   mutations   (Figure   R.9   and   Table   R.3).   Of   note,   the   ExAC   study  
was   published   after   the   choice   of   the   DYRK1A   missense   cancer  
variants,  and  we  noticed   that  3  of   them  were  also   found   in   the  normal  
population,  R158H,   I283V  and  R559C   (Table  R.2).   In   agreement  with  
the   LoF   intolerance   of   DYRK1A   in   normal   population,   none   of   these  
mutants   shows   total   loss   of   activity   and   R559C   is   functionally   a   WT  
protein   (Table   R.3).   Therefore,   they   might   represent   passenger  







The   results   generated   by   our   functional   analysis   resemble   what   has  
been   shown   for   the   protein   kinase   C   family   of   kinases,   where   a   an  
extensive   functional   characterization   of   PKC   cancer-­associated  
mutations   was   performed,   showing   that   most   are   LoF   (Antal   et   al.,  
2015),  thus  questioning  the  assumption  that  cancer  mutations  in  kinase  
genes   previously   described   to   act   as   oncogenes   are   activating  
mutations.  
Despite   these   observations,   DYRK1A   inactivation   through   LoF  
mutations   remains   a   low-­frequency-­event,   in   the   vast   landscape   of  
tumor   genetic   alterations.   In   this   sense,   we   speculate   that   loss   of  
DYRK1A   function   is   positively   selected   only   under   specific  
circumstances.   As   discussed   by   many   authors,   the   low-­penetrance  
genes,   although   harder   to   identify,   might   represent   determinants   of  
intratumor  and   intertumor  heterogeneity   (Garraway  and  Lander,   2013;;  
Wood   et   al.,   2007),   and   a   source   of   tumor-­specific   targets   to   be  
exploited  for  personalized  therapies.  Thus,  uncovering  the  “addiction”  of  
low-­penetrance   tumor   driver   genes   to   specific   molecular   context   is   a  
very   important   aspect   in   current   cancer   research;;   this   aspect   will   be  
further  discussed  in  chapter  4.  
2.1.  Recurrence  of  LoF  mutations  in  cancer  and  in  DHS  
The   relevance   of   DYRK1A   in   neuronal   development   and   in   the  
regulation  of  basic  cellular  processes  in  multiple  adult  cell  lineages  has  
been   extensively   proved   (Arbones   et   al.,   2019).   It   was   not   then  
surprising,   the   scarceness   of   DYRK1A   non-­silent   mutations   in   the  
general   population   reported   by   the   ExAC   study   (Figure   D.1   and  
associated   text).  Normal   levels  of  DYRK1A  active  protein  are   required  
for  proper  developmental  processes  and,  in  fact,  heterozygous  de  novo  
mutations   in   DYRK1A   gene   have   been   associated   to   a   specific   ASD  
syndromic   form,   the  DYRK1A   haploinsufficiency   syndrome   (DHS),   or  
MRD7   (OMIM:614104)   (van   Bon   et   al.,   2016).   While   for   truncating  
mutations  DYRK1A  LoF   is  easily  predictable,  no   information  about   the  
effect  on  DYRK1A  function  was  provided.  A  first  study  filled  the  gap  by  
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screening   a   small   group   of   these   variants   (Widowati   et   al.,   2018).  
Additionally,   our   group   and   collaborators   published   a   comprehensive  
biochemical   screen   on   the   whole   list   of   DYRK1A   de   novo   missense  
mutations   reported   to   date   to   confer   functional   significance   to   these  
changes   and   give   proper   information   to   ascribe   those   cases   as   DHS  
(Arranz   et   al.,   2019).   Figure   D.2   shows   all   mutations   assayed   in   our  
screens,   the  cancer  group   included   in   this  Thesis  work  and   the  group  
associated   to   DHS.   Both   functional   screens   examined   the   functional  
impact   of   the   mutations   following   the   same   procedure,   that   is   by  
assessing   catalytic   activity   and   protein   accumulation   levels.  
Interestingly,  many   of   the   residues  mutated   in  DHS  are   also   found   in  
cancer   samples,   in   some   cases   with   the   same   amino   acid   change,  
suggesting   the   existence   of   LoF-­hotspots   in   the   DYRK1A   sequence.  
Moreover,   several   of   the   detected   indels   are   also   shared   by   the   two  
situations   (data   not   shown),   further   pointing   to   the   existence   of  
hotspots.   Germline   mutations   in   tumor   suppressor   genes   are   often  
associated   to   proliferative   disorders,   which   are   characterized   by   an  
increased   risk   of   developing   specific   types   of   cancers   (Payne   and  
Kemp,  2005).  DHS   individuals  are   young   in  age   so  no   information  on  
tumor  burden   is  available,  but   these  results  might  point   to  an   increase  




Figure   D.2.   DYRK1A   pathological   mutations.   Comparison   of   the   functional   impact  
indicated  with   a   color   code   (see  Figure  R.9)   of   reported  DYRK1A  missense   variants   in  

























































































































































































































































2.2.  Hints  on  DYRK1A  biochemistry:  the  activity-­stability  link  
To   assess   the   impact   of   cancer   somatic   mutations   on   DYRK1A  
function,  we  analyzed  two  very  important  features  of  a  cellular  enzyme:  
the  intrinsic  catalytic  activity  and  stability  in  vivo,  interpreted  as  levels  of  
protein   accumulation.   Given   the   strong   dosage-­dependence   of  
DYRK1A,   the   last   feature   could   be   also   very   relevant.  We   found   that  
most  of  the  screened  mutations  had  profound  effects  on  both  DYRK1A  
kinase   activity   (Figure   R.6)   and   protein   accumulation,   which   we  
assumed  to  depend  almost  entirely  on  protein  degradation  rates  (Figure  
R.7).   Notably,   the   functional   characterization   of   DYRK1A   cancer  
variants   also   provided   information   about   the   biochemical   connection  
between   DYRK1A   activity   and   stability   (Figure   R.8B).   Inactivating  
mutations   are   not   destabilizing   per   se,   as   demonstrated   by   other  
studies   characterizing   cancer-­related   mutations   on   other   cellular  
enzymes  (Gaboriau  et  al.,  2015;;  Kugel  et  al.,  2015;;  Li  et  al.,  2016),  but  
in   the   case   of   DYRK1A   we   found   a   significant   correlation   between  
stability   and   activity   (Figure  R.8B).   This   outcome   has   been   confirmed  
also  by  the  functional  analysis  of  DHS  de  novo  mutations  (Arranz,  et  al.,  
2019),  indicating  that  it  is  a  DYRK1A  specific  property  regardless  of  the  
pathological  context.  Thus,  we  argue  that  regulatory  mechanisms  might  
exist   by   which   dysfunctional   DYRK1A   proteins   are   detected   and  
degraded   faster   by   the   cells.   We   show   that   the   DYRK1A   inactive  
mutants   are   unable   to   phosphorylate   a   substrate   and   also   lack  
autophosphorylation   activity.   It   is   therefore   possible   that   some   of   the  
autocatalytic   events   might   be   responsible   for   preventing   proteasome-­
targeted   degradation.   In   this   regard,   and   as   previously   mentioned,  
autophosphorylation   of   S97   by   a   catalytic   active   intermediate   during  
protein   synthesis   has   been   proposed   as   a   crucial   step   hampering  
DYRK1A  degradation  (Kii  et  al.,  2016).  
We   noticed   that   some   of   the   variants   escaped   the   linear   correlation  
activity/stability.  Among  them,  the  mutant  Y321C  in  the  activation  loop-­
tyrosine   was   especially   interesting,   since   it   showed   a   dramatic  
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decrease   in   kinase   activity   on   substrate   but   retained   high  
autophosphorylation   activity;;   the   protein   accumulation   levels   of   this  
mutant   were   highly   variable   levels,   although   close   to   the   WT-­level  
median   (Figure   R.6D   and   R.7C).   This   higher   autophosphorylation  
activity   would   produce   a   more   complex   autophosphorylation   profile,  
which   might   explain   the   high   variability   in   stability   assays.   These  
observations  suggest  that  there  could  be  unique  biochemical  features  in  
vitro,   with   unforeseen   consequences   in   vivo,   for   DYRK1A   mutations  
that   deserve   further   exploration.   We   should   also   mention   that   the  
biochemical  characterization  of   the  DYRK1A  variants  was  restricted   to  
those  variants  appearing  in  the  catalytic  domain.  It  is  therefore  possible  
that   other   cancer-­associated   variants   outside   this   domain   might   also  
impact   DYRK1A   properties   (subcellular   localization,   substrate   choice,  
etc.,)   rendering   them   LoF   from   a   biological   viewpoint.   The   lack   of  
knowledge   on   key   sequences   determining   these   features   has   limited  
further  exploration.  
  
3.   Good   or   evil?   The   dual   role   of   the   dual-­specificity  
kinase  DYRK1A  as  tumor  driver  
The   word   “dual”   has   never   been   more   appropriate   for   the   kinase  
DYRK1A.  Beyond  its  dual  substrate  residue-­specificity,  DYRK1A  seems  
to   play   a   dual   role   as   tumor   driver.   Indeed,   our   results   suggest   that  
DYRK1A   function   in   tumor   cells   is   context-­dependent,   in   agreement  
with  previous  reports.  
As  previously  mentioned,  our  results  support  the  hypothesis  that  loss  of  
DYRK1A  expression  or  function  is  positively  selected  in  cancer.  Indeed,  
our  DE  analysis  showed  significant  DYRK1A  downregulation   in  11  out  
of   the   15   tumor   types   considered:   ESCA,   LUSC,   KIRP,  COADREAD,  
THCA,  HNSC,  STAD,  UCEC,  LIHC,  KIRC  and  LUAD  (Figure  R.2A).  No  
upregulation  was  detected  in  any  tumor  cohort.  Lower  DYRK1A  mRNA  
levels  have  been  found  by  other  group  in  AML  samples  (not  included  in  
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our  DE  analysis),  which  was  more  apparent  in  relapsed  patient  samples  
(Liu   et   al.,   2014).   DYRK1A   downregulation   was   also   reported   in   the  
BRCA   TCGA   cohort   (Kim   et   al.,   2016),   a   result   that   we   could   not  
reproduce  (Figure  R.2A),  probably  due  to  the  use  of  different  statistical  
analysis  (paired  Wilcoxon  test   in   this  work  vs  unpaired  Student’s   t-­test  
in   Kim   et   al.,   2006).   Distinct   molecular   mechanisms   could   be  
responsible  for  DYRK1A  downregulation  in  tumor  cells.  First,  alterations  
in   the   activity/levels   of   the   transcription   factors   already   described   to  
promote  DYRK1A  expression  (Kim,  et  al.,  2016;;  Lee  et  al.,  2009;;  Lu  et  
al.,  2011;;  Maenz  et  al.,  2008),  or  of  unknown  transcriptional  regulators  
in  the  tumor  cells.  Second,  epigenetic  changes  at  the  promoter  locus,  or  
at  other  regulatory  regions,  might  occur;;   this  aspect  could  be  explored  
by  crossing  DNA  methylation  data  with  gene  expression  data  in  TCGA  
samples.   Finally,   post-­transcriptional   mechanisms   affecting   steady-­
state   mRNA   levels   by   miRNAs   or   RNA   binding   proteins   might   be  
involved  as  well.  
In   addition   to   reduced  DYRK1A   expression   in   tumors,   the   analysis   of  
somatic  mutations  revealed  signals  of  positive  selection  in  three  cancer  
types,  LIHC,  ESCA  and  UCEC,  and  we  provide  experimental  prove  that  
DYRK1A  cancer  missense  mutations,   including  several   found   in   these  
tumor  types,  are  bona  fide  LoF  mutations.    
Despite  these  results,  our  work  on  pancreatic  cancer,  together  with  data  
from  others,  suggest   that   the  role  of  DYRK1A  in  cancer   is  much  more  
complex.  Thus,  contrary  to  the  general  trend  observed  in  DE  analysis  of  
TCGA  data,  we  found  that  DYRK1A  was  upregulated  in  PDAC  samples  
at  the  mRNA  level  in  3  independent  cohorts  (Luna,  et  al.,  2018)(Annex  
I).  Similar  behavior  was  reported  in  glioblastoma  and  in  head  and  neck  
squamous   cell   carcinoma   (Pozo   et   al.,   2013;;   Radhakrishnan   et   al.,  
2016).  Of  note,   the  PAAD   (pancreatic  adenocarcinoma)  and   the  GBM  
(glioblastoma)  TCGA  cohorts  were  not   included   in  our  DE  analysis   for  
not  reaching  the  minimum  number  of  paired  samples.  However,  we  did  
observe   downregulation   of   DYRK1A   in   the   HNSC   TCGA   samples  
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(Figure  R.2A).   These   contradictory   results   could   be  due   to   the  use  of  
different  cohorts  in  the  two  studies;;  alternatively,  the  fact  that  DYRK1A  
overexpression   was   observed   at   the   protein   level   (Radhakrishnan,   et  
al.,   2016)   could   mean   that   the   increase   is   caused   by   post-­
transcriptional   mechanisms,   despite   a   slight   but   significant  
downregulation  at  the  mRNA  level  (as  detected  in  the  TCGA  cohort).  
In   the  next  sections,   I  will  discuss  the  controversial   role  of  DYRK1A  in  
cancer  using  the  results  from  the  two  tumor  models  studied  in  this  work:  
pancreatic  adenocarnicoma  and  endometrial  carcinoma.  
3.1.   DYRK1A   plays   oncogenic   functions   and   promotes   tumor  
growth  in  pancreatic  adenocarcinoma  
Pancreatic  cancer  is  not  among  the  most  recurrent  cancer  types,  but  it  
certainly   represents   one   of   the   worse   malignancies   in   terms   of  
prognosis  and  increasing  incidence,  which  make  this  disease  the  fourth  
leading  cause  of  cancer-­related  death  in  United  States  and  prediction  to  
become   the   second  by   2030   (Rahib   et   al.,   2014;;  Siegel   et   al.,   2018).  
The   disease   groups   several   cancer   types,   but   PDAC   accounts   for  
almost   90%   of   all   cases   (Feldmann   et   al.,   2007).   Environmental   risk  
factors  are  strongly  related  with  lifestyle,  smoking,  alcohol  consumption  
and  obesity  among  the  modifiable  risk  factors  (McGuigan  et  al.,  2018),  
which  would  explain  why  its  incidence  is  increasing  mostly  in  developed  
countries.  Poor   outcomes  are  mainly   due   to   late   diagnosis,  with  most  
patients   presenting   advanced   stages   and   proximal   or   distant  
metastases.   Current   therapeutic   opportunities   are   limited;;   surgical  
resection   with   adjuvant   chemotherapy   represents   the   only   potential  
curative   procedure,   but   in   80%   of   cases   is   not   applicable   due   to   the  
advanced   stage   of   the   disease   at   time   of   presentation   (Ilic   and   Ilic,  
2016).   The   treatment   for   advanced,   metastatic   PDAC   consists   of  
palliative  chemotherapy,  with  the  FOLFIRONOX  regime  the  most  widely  
accepted  protocol   (McGuigan,  et  al.,   2018).  Therefore,   the  high  grade  
of  malignancy  and  the  narrow  window  of  intervention  for  PDAC  patients  
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highlight  a  strong  need  for  prevention,  new  strategies  for  early  detection  
and  alternative  treatment  approaches.  
By  using  the  PDAC  cell   line  model  PANC-­1,  we  showed  that  DYRK1A  
silencing   with   specific   shRNAs   led   to   impaired   PANC-­1   cell   growth,  
migration  and  invasion  (Figure  2A  and  2C-­E  in  Annex  I).  Similar  results  
were   obtained   using   harmine,   which   strongly   hindered   PANC-­1  
proliferation  (Figure  2B  in  Annex  I).  Mechanistically,  DYRK1A  depletion  
led   to   decreased   stability   of   c-­MET   (Figure   7   in   Annex   I),   a   well-­
described   RTK   with   key   functions   in   development   and   organ   repair,  
whose  overexpression  or  hyperactivation  had  already  been  associated  
with  different   types  of   cancer,   including  PDAC.   Indeed,   targeting  MET  
or  its  ligand  HGF  has  been  proposed  as  a  potential  therapeutic  strategy  
for   PDAC   and   both   HGF   and   MET   inhibitors   are   under   evaluation   in  
clinical  trials  (Modica  et  al.,  2018;;  Rizwani  et  al.,  2015).  Notably,  PDAC  
was   poorly   represented   in   the   list   of   DYRK1A   mutations   in   cancer  
samples   (3   variants   in   the   catalytic   domain   and   only   1   appears   to   be  
destabilizing   according   to   FoldX;;   Table   R.4   and   Annex   II),   which  
concurs  with  a  need  for  PDAC  cells  to  preserve  DYRK1A  activity.  
This  work  thus  revealed  a  pro-­tumorigenic  role  for  DYRK1A  in  PDAC,  at  
least,   by   increasing   c-­MET   stability.   It   is   also   possible   that   additional  
mechanisms   exist   by   which   DYRK1A   promotes   PDAC   tumor   growth,  
and   preliminary   results   from   the   analysis   of   differentially   expressed  
genes  in  DYRK1A  silenced  PANC-­1  cells  suggest  that  the  secretion  of  
molecules  important  for  the  cross-­talk  between  the  neoplastic  cells  and  
other   cells   in   the   tumor   niche   is   also   affected   (data   not   shown).  
Coupling  harmine   treatment  with  c-­MET   inhibitors  will  probably  help   to  
unveil  eventual  c-­MET-­independent  DYRK1A  oncogenic  functions.  
Further   investigation   is   required   to   better   elucidate   how   DYRK1A  
participates   in  pancreatic   ductal   cells   transformation  and  PDAC   tumor  
progression.  Nevertheless,  our   results  suggest   that  DYRK1A  can  be  a  
potential  therapeutic  target  for  treating  c-­MET  “addicted”  PDAC  tumors.  
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3.2.  DYRK1A  represents  a  novel  tumor  suppressor  in  endometrial  
cancer  
Endometrial   cancer   represents   the   most   common   gynecological  
malignancy  in  Europe  and  United  States  and  its  incidence  is  increasing  
annually  (Henley  et  al.,  2018;;  Siegel,  et  al.,  2018).  Among  the  different  
histological  types  of  uterine  cancers  (Bokhman,  1983;;  Lax  and  Kurman,  
1997),  endometrioid  adenocarcinoma  is  the  most  frequent  (almost  70%)  
(Henley,  et  al.,  2018).  This  malignancy  presents  clear  symptoms  since  
its   onset,   and   it   is   thereby   diagnosed   at   early   stages   in   most   cases.  
Indeed,  most  patients  are  characterized  by  good  prognosis  and  a  high  
5-­year  survival  rate  (95.3%)  (Henley,  et  al.,  2018;;  Siegel,  et  al.,  2018).  
In  contrast,  patients  with  advanced  or  recurrent  endometrial  carcinoma  
have  poor  prognosis  and  a  very  low  5-­year  survival  rate  (16.2%).  Since  
the   mid-­1970s,   uterine   corpus   and   uterine   cervix   carcinomas   are   the  
only   cancer   types,   among   the  most   common   ones,   for   which   survival  
has   not   improved   (Siegel,   et   al.,   2018).   The   only   approved   targeted  
therapy   is   represented   by   hormonal   therapy   (Sommeijer   et   al.,   2013),  
whereas  current  chemotherapeutic  treatments  are  associated  with  high  
toxicity   and   limited   efficacy,   highlighting   a   strong   need   for   new  
therapeutic  approaches.  
The   results   obtained   in   this   Thesis   work   strongly   suggest   a   role   for  
DYRK1A   as   tumor   suppressor   in   endometrial   carcinoma.  On   the   one  
hand,   we   found  DYRK1A   significantly   downregulated   at   the   transcript  
level   in   the  UCEC  TCGA   cohort   (Figure  R.2A).  Moreover,   analysis   of  
somatic  mutations  in  UCEC  tumor  samples  revealed  signals  of  positive  
selection   with   two   independent   methods   (Figure   R.4B).   Finally,  
DYRK1A   deleterious   mutations   are   found   more   frequently   in  
endometrial  cancer  specimens  than  in  other  cancer  types  (Figure  R.10  
and   Table  R.4;;   see   also   Annex   II   for   the   full   list   of   DYRK1A   somatic  
mutations).  All   these   findings   suggest   that   endometrial   cancer  models  
would   be   very   appropriate   to   study   whether   and   how   DYRK1A  
mutations   drive   tumor   progression.   Fortunately,   we   found   two  
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endometrioid  carcinoma  cell   lines,  EN  and  HEC59,  with  LoF  mutations  
in   one   DYRK1A   allele,   which   displayed   reduced   DYRK1A   activity  
(Figure   R.12C),   thus   representing   useful   models   for   gain-­of-­function  
experiments.  
First,  we  showed  that  DYRK1A  overexpression  impaired  the  capabilities  
of   both   cell   lines   to   form   colonies   when   grown   in   diluted   conditions  
(Figure   R.13C-­D).   Second,   using   a   more   elegant   approach,   we   also  
showed  that  restoring  the  DYRK1Awt/wt  genotype  in  HEC59  cells  led  to  a  
strong  reduction  in  clonogenic  assays  (Figure  R.17A)  and  in  cumulative  
growth   (Figure   R.17B),   which   appears   be   due   to,   at   least,   reduced  
survival   of   the   reverted   cells   (Figure   R.21B).   More   importantly,  
xenograft   experiments   in   mice   using   the   DYRK1A-­reverted   clone  
showed  delayed  tumor  growth  compared  to  the  parental  cell  line  (Figure  
R.22),   indicating   that   reverting   the   DYRK1A   mutation   negatively  
affected   the  ability  of  HEC59  cells  of   surviving  and/or  dividing   in   vivo.  
Together,  these  findings  point  at  DYRK1A  as  a  novel  tumor  suppressor  
in   endometrial   cancer   and   further   suggest   that   DYRK1A  mutations   in  
endometrial   tumors   represent   driver   mutations.   Notably,   other  
endometrial  cancer  DYRK1A-­mutated  cell   lines  are  available  (HEC251  
and  SNGM,  portals.broadinstitute.org/ccle),  and  they  could  be  exploited  
to  extend  these  results  by  analyzing  the  behavior  of  the  corresponding  
reverted  clones.  
Given  the  limitations  of  mouse  xenografts  as  cancer  models  to  properly  
study   the   tumor   niche,   a   complementary   approach   should   involve  
alternative   in   vivo   strategies   using   endometrial   cancer   mouse  
transgenic   models.   Several   models   have   been   engineered   so   far,  
including  the  Mitogen-­inducible  gene  6  (Mig-­6)  model  (Kim  et  al.,  2017),  
the  Pten-­inducible  KO  model  (Mirantes  et  al.,  2013)  and  the  Pten/Lkb1-­
deficient  model   (Cheng   et   al.,   2014).  One   smart   strategy  would   be   to  
cross   these   mice   with   Dyrk1a+/-­   mice   (Fotaki   et   al.,   2002)   to   study  
Dyrk1a-­haploinsufficient   mouse   models   of   endometrial   carcinoma.   A  
conditional  Dyrk1a  KO  model  is  also  available  (Thompson  et  al.,  2015),  
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which   would   allow   to   target   specific   cell   types   to   further   dissect   the  
contribution  of  the  cellular  components  of  the  tumor  microenvironment.  
Another   possible   strategy   may   take   advantage   from   recent  
CRISPR/Cas9-­based   methods,   which   allow   multiple   genome-­editing  
events   to   generate   specific   cancer   mouse   models   (Gargiulo,   2018;;  
Oldrini   et   al.,   2018).   Thus,   introducing   specific  DYRK1A   mutations   or  
allele  deletions  through  sgRNAs  delivery  directly  into  the  uterus  of  adult  
animals  might   represent   an   elegant  way   to  mimic   a   specific  DYRK1A  
somatic   mutation   event   in   uterine   cells   and   to   investigate   how   such  
event  affects  tumor  development  in  the  endometrium.  
Finally,  we  are  aware   that  additional   research  work  would  be   required  
to   fully  support   the   involvement  of  DYRK1A   in  endometrial  carcinoma,  
apart   from   the   already  mentioned   studies   on   other   DYRK1A  mutated  
cell   lines.   The   experiments   should   include   evaluation   of   DYRK1A  
expression  changes   in  alternative,   independent  cohorts  of  endometrial  
tumor   samples   and   immunohistochemistry   analysis   on   endometrial  
cancer   patient   samples   to   provide   evidence   that   the   DYRK1A   loss  
observed  at  the  mRNA  level  is  mirrored  at  the  protein  level.  Identifying  
the   genetic   background   that   favors   the   selective   loss   of   DYRK1A  will  
also  help  to  stratify  endometrial  tumors  for  future  therapy  approaches.  
3.3.   A   multi-­level   approach   to   uncover   new   DYRK1A-­regulated  
cellular  pathways  in  endometrial  cancer  cells  
To   uncover   the   molecular   mechanisms   contributing   to   the   modified  
behavior   of   DYRK1A   reverted   HEC59   cells,   we   have   performed   a  
comprehensive  analysis  aimed  at  identify  changes  at  multiple  molecular  
levels.  The  most   relevant  aspects  of   the  outcome  of   this  study  will   be  
discussed  in  the  next  sections.  
3.3.1.   Increased   DYRK1A   dosage   activates   STAT1-­mediated   IFN  
response  
Whole  proteome  analysis  in  HEC59  parental  cells  and  CRISPR-­derived  
clones   revealed   the   upregulation   of   proteins   belonging   to   the   IFN-­I  
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signaling   pathway   in   DYRK1A-­WT   reverted   cells,   and   the  
downregulation   of   the   same   category   of   genes   in   DYRK1A-­KO   cells  
(Figure   R.23C).   Binding   of   the   IFN-­I   family   of   cytokines   to   their  
membrane   receptors  activate  signaling  cascades   in   target  cells,  which  
ultimately  induce  the  expression  of  IFN-­stimulated  genes  (ISG),  leading  
to   a   multitude   of   cellular   responses   that   ultimately   cause   enhanced  
cellular   protection   against   viral   and   bacterial   infection   and   activated  
immunosurveillance   (Ng   et   al.,   2016)   (Figure   D.3).   Interestingly,   the  
expression  of  IFN-­I  receptor  1  and  2  (IFNAR1-­2)  and  ISGs  changes  in  a  
stage-­dependent  manner  during  menstrual  cycle  in  mammalian  uterine  
cells  (Ozaki  et  al.,  2005;;  Shirozu  et  al.,  2017).  Moreover,  expression  of  
IFNα   is   upregulated   during   embryo   implantation   (Li   et   al.,   2001),  
suggesting  that  IFN  signaling  may  play  relevant  functions  in  controlling  
endometrial   physiologic   processes   and   during   gestation.   In   addition,  
IFN-­I   signaling   drives   the   immune   response   to   cancer   cells,   by  
stimulating   immune   cells,   preventing   tumor   cells   immune   escape   and  
inducing  cell  death  and  cell  cycle  arrest  in  neoplastic  cells,  although  the  
molecular   processes   orchestrating   this   response   are   not   fully  
understood  (Dunn  et  al.,  2006;;  Musella  et  al.,  2017)  (Figure  D.3).  
  
Figure  D.3.  Type  1  Interferon-­modulated  processes  in  response  to  virus  infection  
and  cancer.  Activation  of  I-­IFN  signaling  promotes  multiple  downstream  pathways,  in  the  
different  cell  types  within  the  infection/tumor  niche.  These  events  lead  to  immune  
response  activation  and  anti-­proliferative  effects  in  tumor  cells.  Adapted  from  (Snell  et  al.,  
2017).  
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STAT  proteins  are  a   family  of   transcription   factors  which  are  activated  
through   phosphorylation   in   response   to   many   diverse   stimuli;;   once  
activated  they  translocate  to  the  nucleus  and  promote  gene  expression,  
thus   modulating   crucial   cellular   processes,   from   cell   division   to  
apoptosis   and   defense   against   infection   (Levy   and   Darnell,   2002).   A  
few   reports   have   linked   DYRK1A   and   STAT   proteins.   Thus,  
phosphorylation  of  STAT3  by  DYRK1A  on   the  activating   residue  S727  
was  documented   in  a  screen  aimed  at   identifying  STAT3  kinases  and  
confirmed   by   co-­expression   in  mammalian   cells   (Matsuo   et   al.,   2001;;  
Wiechmann  et  al.,  2003).  Increased  STAT3  S727  phosphorylation  was  
observed   in   neuronal   progenitors   in   the   Ts1Cje   DS   mouse   model,  
which   was   attributed   to   elevated   DYRK1A   levels   in   this   model  
(Kurabayashi   et   al.,   2015).   However,   our   results   showed   changes   in  
STAT3   phosphorylation   on   S727   not   depending   on   the   DYRK1A  
dosage,  with  a  reduction  in  the  phosphosignal  by  both  gain  and  loss  of  
DYRK1A   (data  not  shown).  On   the  other  hand,   the  phosphorylation  of  
STAT1   on  S727  was   found   to   gradually   increased   following  DYRK1A  
dosage   differences   among   the   three   conditions   (Figure   R.24B);;  
however,  our  current  data  do  not  allow  us  to  formally  probe  that  STAT1  
is  a  direct  substrate  of  DYRK1A.  STAT1  homodimers  and  heterodimers  
with  STAT2  bind  to  DNA  and  activate  transcription  of  a  broad  panel  of  
genes,   affecting   many   cellular   processes   (Levy   and   Darnell,   2002).  
Importantly,  we   found  coherent  expression  of   IFN-­I   responsive  genes,  
supporting  functional  activation  of  STAT1  (Figure  R.25C).  
Opposing   roles   for   STAT1   and   STAT3   in   mediating   tumor   related  
processes   have   been   suggested.   In   particular,   STAT3   has   been  
described   to  promote  proliferation  and  survival   in   response  to  different  
growth   signals,   whereas   STAT1   has   been   found   to   mediate   anti-­
proliferative   cellular   mechanisms   and   increased   immune   response  
against   transformed   cells   (Avalle   et   al.,   2012).   The   activated   IFN  
response   might   explain   the   anti-­proliferative   behavior   of   HEC59  
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DYRK1A-­WT  reverted  cells,  and  attenuated  STAT1/IFN-­I  signaling  due  
to  DYRK1A  functional  loss  could  be  one  of  the  mechanisms  of  acquired  
survival  advantage  by  HEC59   tumor  cells.  Concurring  with   this  model,  
previous   studies   revealed   decreased   Interferon   regulatory   factor   1  
(IRF1)  levels  in  endometrial  carcinoma  samples,  compared  with  normal  
tissue   (Giatromanolaki   et   al.,   2004;;   Kuroboshi   et   al.,   2003).   STAT1-­
mediated   tumor  suppressive   functions  have  been   in  part  explained  by  
activation   of   genes   encoding   for   negative   regulators   of   cell   cycle  
checkpoints,   such  as  CDKN1A   (p21WAP),  CDKN1B   (p27KIP),  among  
others  (Chin  et  al.,  1996;;  Levy  and  Darnell,  2002;;  Mandal  et  al.,  1998).  
However,  we  did  not  observed  changes  at  the  transcript  or  protein  level  
for  most  of  these  genes,  which  agrees  with  the  lack  of  effect  on  the  cell  
cycle   profile   by   DYRK1A   dosage   changes   (Figure   R.21A).   It   is   likely  
that   the   advantage   gained   through   reduced   STAT1   signaling   is   also  
linked  to  tumor  niche-­related  mechanisms,  like  immunosuppression  and  
immune   escape   by   tumor   cells,   although   these   processes   cannot  
contribute   to   the   phenotype   we   observed   in   cell   culture   experiments  
and  immunosuppressed  mouse  models.    
In   summary,   our   analysis   discloses   a   new   regulatory   axis  
DYRK1A/STAT1/IFN  that  could  represent  an  anti-­neoplastic  pathway  in  
the   tumor   context   under   study,   and   which   surely   deserves   further  
investigation  in  other  biological  contexts.  
3.3.2.  Additional  clues  on  anti-­proliferative  molecular  mechanisms  
mediated  by  DYRK1A  
Although   the   enhanced   STAT1/IFN   response   may   contribute   to   the  
DYRK1A-­dependent  tumor  suppressive  phenotype,  it  is  most  likely  that  
additional  cellular  mechanisms  are  also  involved.  In  this  sense,  the  DID  
group   of   phosphorylated   proteins   (Figure   R.24A)   offers   an   excellent  
platform   for   identifying   cellular   pathways   differentially   regulated   by  
DYRK1A   dosage-­dependent   events.   Although   no   differences   were  
observed   in   the   cell   cycle   profile   as   result   of   changes   in   DYRK1A  
dosage,   our   results   indicate   that   cell   viability   is   indeed   affected.   The  
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increase  in  the  non-­viable  cell  population  may  be  caused  by  increased  
programmed   cell   death,   necrosis   or   any   other   type   of   cell   death.  We  
have   screened   our   high-­throughput   data   sets   searching   for   putative  
candidates  that  could  explain  the  observed  phenotype.  We  did   identify  
changes  in  S194  phosphorylation  in  the  apoptotic  factor  Fas  associated  
via  Death  Domain   (FADD),  a  modification   that   is   involved   in  cell  cycle  
regulation   by   FADD   rather   than   apoptosis   (Alappat   et   al.,   2003;;  
Tourneur   and   Chiocchia,   2010).   Phosphorylation   of   FADD   S194   was  
reported  to  happen  during  mitosis  and  to  mediate  FADD  localization  at  
spindle  poles  (Alappat  et  al.,  2005).  Interestingly,  we  identified  other  M  
phase-­specific  phosphorylation  events  in  the  DID  group  (Figure  D.4).  
The  DNA   damage-­associated   factor   p53   binding   protein   1   (53BP1)   is  
hyperphosphorylated  in  response  to  DNA  damage  by  the  kinases  ATR  
and  ATM,  thus  promoting  53BP1  recruitment  to  damage  foci  (Anderson  
et  al.,  2001;;  Jowsey  et  al.,  2007).  Additionally,  phosphorylation  events  
at  the  C-­terminus  of  53BP1  during  mitosis  have  been  causally  linked  to  
the   block   of   DNA   repair   process   that   cells   use   to   prevent   deleterious  
events   like   defective   chromosome   segregation   and   telomere   fusions  
(Heijink  et  al.,  2013;;  Orthwein  et  al.,  2014).  Several  C-­terminal  53BP1  
phosphorylated   residues   are   included   the  DID  group   (Figure  D.4).  No  
functional   roles   have   been   associated   to   any   of   these   sites,   so   it   is  
difficult  to  offer  further  insight,  but  some  of  them  are  SP  sites  and  they  
might   be   direct   targets   of   DYRK1A.   We   also   found   multiple  
phosphorylated  peptides  belonging  to  Cut  homeobox  protein  1  (CUX1)  
(Figure  D.4),  a   transcription   factor  whose  activity   is   inhibited  during  M  
phase   through   hyperphosphorylation   (Sansregret   et   al.,   2010)   and   to  
microtubule   associated   protein   1A,   1B,   1S   (MAP1A,   MAP1B   and  
MAP1S)   (Figure   D.4),   which   have   been   shown   to   coordinate  
microtubule  dynamics  in  several  cellular  mechanic  processes,  including  






Figure  D.4  M  phase-­associated  phospho-­events  in  the  DID  cluster.  Phospho-­events  
of   cellular   factors   for   which   hyperphosphorylation   has   been   described   enriched   during  
mitosis.  Log2FC  values  of  phospho-­peptide  intensities   in  parental  HEC59  cells,  reverted  
DYRK1A-­WT  and  DYRK1A-­KO   clones,   normalized   to  HEC59-­parental   values   (mean   of  
replicates   set   as   1)   are   represented.  The  graphs  also   include   the  mean  ±  SD   for   each  
group.  For  some  events,  no  peptides  were  detected  in  any  replicate  of  the  DYRK1A-­KO  
clone.  
  
Phosphorylation  dynamics  is  crucial  to  orchestrate  the  complex  network  
of   events   that   occur   during   cell   division   (Dephoure   et   al.,   2008).  
Alterations   in   this  delicate  regulation  might  cause  aberrant  mitosis  and  
consequently,  cell  death.  This  process,  known  as  mitotic  catastrophe,  is  
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2011).  The  M-­phase  associated  events  described  above  could  point  at  
a   prolonged   or   blocked  mitotic   process   in   reverted  DYRK1Awt/wt   cells.  
We   argue   that   increased   frequency   of   aberrant   mitosis   might   explain  
the   reduction   in   viable   cells   proportion   caused   by  DYRK1A   increased  
dosage   in   HEC59   cells.   Although   this   proposal   needs   to   be  
experimentally   addressed,   we   find   it   quite   attractive.   DNA   damage  
repair  processes  are  strongly  altered  in  cancer  cells,  as  indicated  by  the  
hypermutator  genetic  profile  and  heterozygous  LoF  mutations  in  crucial  
DNA  repair  genes  such  as  BRCA1  and  TP53BP1   itself   (data  available  
on   CCLE   browser,   portals.broadinstitute.org/ccle).   In   this   scenario,  
mitotic   checkpoint   inactivation   becomes   crucial   for   cancer   cells   to  
undergo   cell   division,   regardless   of   DNA   damage   status.   DYRK1A  
might   be   involved   in   the   regulation   of   mitosis-­associated   DNA   repair  
signaling   and   DYRK1A   LoF   could   have   equipped   endometrial   cancer  
cells   with   compensatory   mechanisms   to   overcome   cell   division  
blockade   and   escape   mitotic   catastrophe-­cell   death   program   (Figure  
D.5).  
3.4.  Targeting  DYRK1A:  therapeutic  opportunities  
At   this   point,   it   becomes   clear   that   the  DYRK1A   function   in   cancer   is  
complex   and   therefore,   it   prompts   for   rigorous   research   work   before  
designing   DYRK1A-­targeting   strategies.   The   use   of   the   currently  
available  DYRK1A   inhibitors  may   represent   an  attractive  approach   for  
treating   those   cases  when  DYRK1A   is   overexpressed  and/or   promote  
tumorigenic   processes,   as   in   the   case   of   PDAC,   as   we   have  
demonstrated   in   mouse   models   of   this   tumor   type   (Luna,   et   al.,  
2018)(Annex   I).   Since   c-­MET   has   been   extensively   associated   to  
resistance  to  chemotherapy,  with  emerging  evidence  also  in  pancreatic  
cancer  (Delitto  et  al.,  2014;;  Shah  et  al.,  2007),  combination  of  DYRK1A  
inhibitors   and   standard   adjuvant   therapies   might   represent   a   good  
strategy  to  overcome  MET-­mediated  chemoresistance  in  PDAC.  
In   the   case   of   endometrial   cancer,   or   other   cancer   types   where  
DYRK1A   is   found   to   play   tumor   suppressive   functions,   the   potential  
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therapeutic   opportunities   are   less   obvious.   Cancer   driver   genes   have  
been   revealed   to   be   more   frequently   tumor   suppressors   than  
oncogenes   (Vogelstein   et   al.,   2013),   and   in   these   cases   the   targeting  
strategies   are   more   complicated,   representing   a   significant   challenge  
for  modern  oncology  (Liu  et  al.,  2015;;  Morris  and  Chan,  2015),  as   it   is  
illustrated  by   the   fact   that  none  of  anticancer  agents  currently  used   in  




Figure   D.5   Model   of   DYRK1A-­mediated   tumor   suppressive   functions   in   HEC59  
reverted  DYRK1A-­WT  clone.  Schematic   representation   of   potential   tumor   suppressive  
mechanisms  mediated,  either  directly  or  indirectly,  by  DYRK1A  in  HEC59  cells.  Increased  
phosphorylation   of   STAT1   and   other   putative   factors   lead   to   IFN-­I   pathway   activation;;  
increased   phosphorylation   of   53BP1,   MAP   proteins,   CUX1   and   FADD   S194   might   be  
linked  to  dysregulation  of  mitotic  checkpoints  and  thus,  to  increased  frequency  of  mitotic  
death  events  in  reverted  HEC59  DYRK1A-­WT  cells.  Adapted  from  (Vitale,  et  al.,  2011).  
  
One  possibility   to   target   tumors  with  DYRK1A  LoF  could  be   to   identify  
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gene  therapy  with  viral  vectors  might  represent  a  strategy  for  targeting  
DYRK1A-­mutated   tumors,   although   only   modest   results   have   been  
achieved  so  far  for  other  tumor  suppressors  (Amer,  2014).  Alternatively,  
learning  from  DYRK1A  dosage-­sensitivity  might  help  to   identify  altered  
intracellular   signaling   pathways   for   which   inhibitors   are   available.  
Finally,  our  data  suggest  that  DYRK1A  inactivation  might  be  effective  in  
DYRK1A-­deficient   tumors,  given   that  complete   loss  of  DYRK1A   led   to  
significantly   impaired   tumor   growth   in   xenografts   (Figure   R.22).   This  
phenomenon   may   be   related   to   the   crosstalk   between   tumor   and  
stromal   cells   of   the   tumor  microenvironment,   since  DYRK1A-­KO   cells  
performed  better  than  the  parental   line  in  tissue  culture  assays  (Figure  
R.20A   and   R.20C).   In   this   regard,   the   pro-­angiogenic   properties   of  
DYRK1A  (Rozen  et  al.,  2018)  acquire  particular  relevance.  Of  note,  the  
DYRK1A   inhibitor   EGCG   suppresses   angiogenic   processes   during  
endometriosis   (Xu   et   al.,   2011),   a   common   pathological   process  
characterized  by  proliferation  of  endometrial  cells  outside  the  uterus.  In  
this  context,  a  recent  study  showed  the  inhibitory  effect  of  recombinant  
IFN  molecules  on  endometriotic  cells  growth  and  migration  (Dicitore  et  
al.,   2018).   Together,   these   pieces   of   research   make   us   proposed   a  
model  by  which  a  regulatory  IFN-­I/DYRK1A  axis  contributes  to  maintain  
a  benign  state  in  endometrial  cells.    
We  should  not  forget  that  DYRK1A  is  an  essential  gene  in  normal  cells.  
Thus,   although   cancer   cells   can   tolerate   and   even   being   selected   for  
DYRK1A   losses,   one   can   speculate   that   this   loss   is   not   for   free.  
Understanding   the   vulnerabilities   that   cancer   cells   experience   for  
maintaining  a  pool  of   functional  DYRK1A  may  help   to   identify   specific  
and  hopefully   targetable   synthetic   lethal   genes.  Synthetic   lethality   has  
been  extensively  studied  in  genetics,  but  only  recently  applied  to  cancer  
drug   discovery   (Nijman,   2011;;   O'Neil   et   al.,   2017).   The  most   famous  
case   of   such   application   is   the   use   of   poly(ADP-­ribose)   polymerase  
(PARP)   inhibitors   for   treatment   of   BRCA1/2   mutation-­carrier   breast  
cancer  patients   (Sonnenblick  et   al.,   2015).   In   this   regard,   results   from  
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our   laboratory  proposed  a  role   for  DYRK1A  in  regulating  the  response  
to  DNA  damage,  by  interacting  with  the  ubiquitin   ligase  ring  finger  169  
(RNF169)  (Roewenstrunk,  2016).  Indeed,  DYRK1A  depletion  increased  
sensitivity   to   ionizing   irradiation,   suggesting   that   DYRK1A-­deficient  
cancer  cells  might  be  more  sensitive  to  DNA  damage  agents.  However,  
we   observed   no   differences   in   sensitivity   to   DNA   damage-­inducing  
drugs  such  as  doxorubicin  and  cisplatin  between  parental  HEC59  cells  
and   the   reverted  DYRK1A-­WT   clone   in   preliminary   experiments   (data  
not  shown).  
  
4.  DYRK1A  in  cancer:  still  a  complex  picture  
The  complexity  of  the  role  played  by  DYRK1A  in  cancer  appears  to  be,  
largely   related   to   context-­specificity.   Indeed,   it   is   currently   widely  
accepted   that   context,   interpreted   as   the   genetic   and   molecular  
landscape   of   the   cell   of   origin  where   oncogenic   events   take   place,   is  
what   really   determines   whether   a   gene   will   contribute   to   tumor  
development   or   not   (Schneider   et   al.,   2017).   Thanks   to   the   great  
advances   in   cancer   genomics   field,   we   are   not   only   discovering   new  
drivers,   but   also   obtaining   more   precise   information   about   tissue-­
specificity  of  known  cancer  genes  (Haigis  et  al.,  2019).  Although  cancer  
genes   often   control   cellular   processes   that   are   considered   crucial   for  
homeostasis  maintenance,  regardless  of  the  cell  type,  they  do  not  give  
rise  to  cancer  in  every  cell  of  origin  when  altered.  A  striking  example  is  
represented   by   germline   mutations   in  BRCA1   and  BRCA2   genes;;   as  
they   control   genomic   stability,   they   are   expected   to   increase   tumor  
incidence  independently  of  cell   type,  but  they  have  been  associated  to  
higher  risk  exclusively  for  breast  and  ovarian  cancer  (Miki  et  al.,  1994;;  
Wooster  et  al.,  1995).  
Additional  aspects  that  determine  the  potential  of  a  given  gene  to  exert  
tumor  driver  functions  might  be  intrinsic  to  the  genetic  alterations  of  the  
cancer   cells.   In   this   regard,   a   high-­throughput   screening   aimed   at  
identifying   kinase   inhibition-­vulnerabilities   in   tumor   cell   lines   revealed  
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that   the   most   sensitive   cell   types   to   DYRK1A   inhibition   were   RB1-­
mutated  osteosarcoma  cell  lines  (Campbell  et  al.,  2016),  indicating  that  
DYRK1A  pro-­survival  function  in  this  tumor  type  may  be  dependent  on  
RB1  loss.  
Tissue-­specificity   can   also   be   related   to   differential   expression  
mechanisms,  at   least   for  cancer  genes  whose  expression   is   restricted  
to  specific  cell   lineages,  such  as   the  Estrogen   receptor  1,  which  plays  
tumorigenic   functions   only   in   estrogen-­responding   tumors.   However,  
even   for  ubiquitously  expressed,  dosage-­sensitive   tumor  driver  genes,  
differential  expression  profiles  might  affect  differently  their  driver-­tissue  
specificity.   Indeed,  DYRK1A  expression   levels   in  normal   tissues  might  
provide   clues   about   the   differences   in   functional   DYRK1A   dosage  
necessary   to   ensure   tissue   homeostasis.   Normal   uterus   is,   the   tissue  
expressing   the   highest  DYRK1A   transcript   levels   among   the   different  
human   tissues   analyzed   by   GeTX   (Figure   I.3).   On   the   other   hand,  
normal  pancreatic  DYRK1A  mRNA  levels  are  the  lowest,  right  after  liver  
(Figure   I.3).   Given   that   little   fluctuations   in   DYRK1A   dosage   have  
dramatic  effects  on  cellular  outcomes,  normal  expression  levels  can  say  
a  word  about  which  direction  will   take  dysregulation  events   to   perturb  
cellular  homeostasis.  
The  dual  nature  of  DYRK1A  in  cancer  is  not  an  isolate  case  at  all.  Other  
important   cancer   drivers   have   been   shown   to   play   both   tumor  
suppressor   and   oncogenic   roles.   As   already   remarked,   this   duality  
might  strongly  depend  on   the  cellular  context,  as   in   the  case  of  Notch  
(Lobry  et  al.,   2014),   or   the  previously  described  STAT1   (Meissl   et   al.,  
2017),  or  even  on  gene  dosage  dynamics,  like  it  has  been  observed  in  








5.  Final  remarks  
Advances  in  cancer  genomics  and  increasing  research  work  on  cancer-­
associated   alterations   are   accelerating   the   discovery   of   many   low-­
frequency-­mutated   new   driver   genes,   even   though   mechanisms   and  
tissue-­specificity   in   eliciting   tumor   progression   still   need   to   be  
elucidated.  
I   believe   that   this   work   has   generated   helpful   data   on   alterations   in  
members   of   the  DYRK   family   of   kinases   in   cancer   and   additionally,   it  
has  contributed  to  shed  light  on  the  role  played  by  the  kinase  DYRK1A  
in   cancer.   Nonetheless,   one   of   the   difficulties   of   this   work   lies   on  
DYRK1A   itself,   a   critical   cellular   kinase   involved   in   so   many   crucial  
cellular   processes,   with   an   increasing   list   of   substrates;;   this   situation  
makes   very   difficult   to   assign   a   complex   phenotype   as   cancer   to   a  
particular  or  unique   function.  This  also   likely  affects   to   the  assignment  
of  a  unique  label  as  “oncogene”  or  “tumor  suppressor”.  
Coming   back   to   our   dilemma:   DYRK1A   in   cancer,   is   it   good   or   evil?  
Maybe   it   is   a   naïve   question   and,   as   I   have   discussed,   the   current  
situation   pictures   a   very   complex   scenario.   To   make   a   “humanistic”  
parallelism,  if  we  hardly  trace  a  marked  line  to  separate  good  and  dark  
sides   of   a   person,   we   should   not   do   it   in   cell   biology   neither,   being  
aware   that   every   protein   has   to   be   put   into   context.   We   have   just  
started   to   shed   light   on   the   role   played   by  DYRK1A   in   cancer   and   to  
explore  the  biological  consequences  of  its  alterations  in  different  tumor  
types.   I  would   like   to   finish  concluding   that  DYRK1A   is,  as  a  matter  of  
fact,  a  tumor  driver,  although  much  more  remains  to  be  investigated.  
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1.   Genes  encoding  for  DYRK  kinases  are  differentially  expressed  
in  cancer.  
  
2.   DYRK1B   and   DYRK2   are   overexpressed   and   amplified   in  
several  TCGA  cohorts.  
  
3.   DYRK1A   is   downregulated   in   many   tumor   types   and   shows  
signals   of   positive   selection   in   three   TCGA   cohorts:   liver  
hepatocellular   carcinoma,   esophageal   carcinoma   and   uterine  
corpus  endometrial  carcinoma.  
  
4.   DYRK1A  cancer-­associated  mutations  are  LoF,  as   they  cause  
a  loss  of  kinase  activity  and/or  stability.  
  
5.   DYRK1A   catalytic   activity   and   protein   stability   show   positive  
correlation.  
  
6.   DYRK1A   overexpression   impairs   the   growth   of   DYRK1A-­
mutated  endometrial  cancer  cell  lines.  
  
7.   Reversion   to   wild   type   of   the   DYRK1A-­mutated   locus   in   the  
endometrial   cancer   cell   line   HEC59   negatively   affects   cell  
growth,  despite  unaltered  cell  cycle  profiles.  
  
8.   HEC59   DYRK1A-­/-­   cells   show   increased   colony   formation  
capability,  but  unaltered  proliferation  rates.  
  
9.   Restoring  DYRK1A  function   in  HEC59   leads   to  decreased  cell  






10.  Tumor   xenografts   derived   from  both   the   reverted  DYRK1Awt/wt  
and  DYRK1A-­/-­  HEC59  cells  show  delayed  growth  and  smaller  
tumor  volume,  compared  with  parental  HEC59-­derived  tumors.  
  
11.  Whole   proteome/phospho-­proteome   analysis   shows   DYRK1A  
dosage-­dependent  activation  of  the  interferon  type  I  pathway  in  
HEC59   cells,   as   indicated   by   STAT1   phosphorylation   and  
differential  expression  of  downstream  effectors  of  this  pathway.  
  
12.  DYRK1A/STAT1/IFN   signaling   might   represent   a   novel  
regulatory   axis   for   DYRK1A-­mediated   tumor   suppressive  
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53BP1:  p53  binding  protein  1  
ABC:  Ammonium  bicarbonate  
ACC:  Adrenocortical  carcinoma  
AD:  Alzheimer  disease  
ALL:  Acute  lymphoblastic  leukemia  
AGC:  Auto  gain  control  
AMKL:  Acute  megakaryoblastic  leukemia  
AML:  Acute  myeloid  leukemia  
APP:  Amyloid  precursor  protein  
ASD:  Autism  spectrum  disorders  
BLCA:  Bladder  Urothelial  Carcinoma  
BRCA:  Breast  invasive  carcinoma  
cBioPortal:  cBio  Cancer  Genomics  Portal  
CCLE:  Cancer  Cell  Line  Encyclopedia  
CDC37:  Cell  division  cycle  37  
CDK:  Cyclin-­dependent  kinase  
CDKL:  CDK-­like  kinase  
CESC:  Cervical  squamous  cell  carcinoma  and  endocervical  
adenocarcinoma  
CHOL:  Cholangiocarcinoma  
CLK:  Cdc2-­like  kinase  
CMV:  Cytomegalovirus  
CNA:  Copy  number  alteration  
CNS:  Central  nervous  system  
COAD:  Colon  adenocarcinoma  
COSMIC:  Catalogue  of  Somatic  Mutations  in  Cancer  
CRG:  Centre  for  Genomic  Regulation  
CRISPR:  clustered  regularly  interspaced  short  palindromic  repeats  
CUX1:  Cut  homeobox  protein  1  
DAPI:  4’,6-­diamino-­2-­phenylindole  
DBS:  Double-­strand  break  
DCAF7:  DDB1  and  CUL4  associated  factor  7  
DE:  Differential  expression  
DH:  DYRK  homology  
DHS:  DYRK1A  haploinsufficiency  syndrome  
DID:  DYRK1A-­increasing-­dosage  
DLBC:  Lymphoid  Neoplasm  Diffuse  Large  B-­cell  Lymphoma  
DMEM:  Dulbecco’s  Modified  Eagle’s  Medium  
DREAM:  Dimerization  partner  (DP),  RB  like,  E2F  and  multi-­vulval  
class  B  (MuvB)  
DS:  Down  syndrome  




DYRK:  Dual-­specificity  tyrosine-­regulated  kinase  
DTT:  Dithiothreitol  
EDTA:  Ethylendiamine  tetracetic  acid  
EF-­1:  Elongation  factor  1-­alpha  
EGCG:  Epigallocatechin  gallate  
EGFR:  Epidermal  growth  factor  receptor  
EMT:  Epithelial-­to-­mesenchymal  transition  
ESCA:  Esophageal  carcinoma  
ExAC:  Exome  Aggregation  Consortium  
FADD:  Fas  associated  via  Death  Domain  
FC:  Fold  change  
FDR:  False  discovery  rate  
FBS:  Fetal  bovine  serum  
GBM:  Glioblastoma  multiforme  
gDNA:  genomic  DNA  
GFP:  Green  Fluorescent  Protein  
GIST:  gastrointestinal  stromal  tumor  
GLI1:  Glioma-­Associated  Oncogene  Homologous  1  
GO:  Gene  Ontology  
GTEx:  Genotype-­tissue  expression  
HEPES:  4-­[2-­hydroxyethyl]-­1-­piperazineethanesulfonic  acid  
HGF:  Hepatocyte  growth  factor  
HGP:  Human  Genome  Project  
HH:  Hedge-­hog  
HIPK:  Homodomain-­interacting  kinase  
HNSC:  Head  and  Neck  squamous  cell  carcinoma  
HPV:  Human  papilloma  virus  
HRP:  Horse  Radish  Peroxydase  
HSP90:  Heat  shock  protein  90  
ICGC:  International  Cancer  Genome  Consortium  
ID2:  Inhibitor  of  DNA  binding  2  
ID:  Intellectual  disability  
IDIBAPS:  Institut  d’Investigacions  Biomèdiques  August  Pi  i  Sunyer  
IFN-­I:  Interferon  type  1  




IQR:  Interquartile  range  
IRB:  Institute  for  Research  in  Biomedicine  
IRES:  internal  ribosomal  entry  site  
IRF1:  Interferon  regulatory  factor  1  
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ISG:  IFN-­stimulated  genes  
IVK:  In  vitro  kinase  assay  
JCRB:  Japanese  Collection  of  Research  Biorecourses  
KICH:  Kidney  Chromophobe  
KIRC:  Kidney  renal  clear  cell  carcinoma  
KIRP:  Kidney  renal  papillary  cell  carcinoma  
KO:  knock-­out  
LAML:  Acute  Myeloid  Leukemia  
LATS2:  Large  tumor  suppressor  kinase  2  
LC:  Liquid  chromatography  
LGG:  Brain  Lower  Grade  Glioma  
LIHC:  Liver  hepatocellular  carcinoma  
LOH:  Loss  of  heterozygosity  
LTP:  Long  term  potentiation  
LUAD:  Lung  adenocarcinoma  
LUSC:  Lung  squamous  cell  carcinoma  
MAP:  microtubule  associated  protein  
MAPK:  Mitogen-­activated  protein  kinase  
MESO:  Mesothelioma  
Mirk:  minibrain-­related  kinase  
miRNA:  microRNA  
MRD7:  Mental  retardation  autosomal  dominant  7  
MS:  Mass  spectrometry  
NAPA:  N-­terminal  autophosphorylation  accessory  region  
NCBI:  National  Centre  for  Biotechnology  Information  
NCI:  National  Cancer  Institute  
NFAT:  Nuclear  factor  of  activated  T-­cells  
NLS:  nuclear  localization  signal  
NP-­40:  Nonidet  P-­40  
OMIM:  Online  Mendelian  Inheritance  in  Man  
OV:  Ovarian  serous  cystadenocarcinoma  
PAAD:  Pancreatic  adenocarcinoma  
PAGE:  Polyacrylamide  gel  electrophoresis  
PARP:  Poly(ADP-­ribose)  polymerase  
PBS:  Phosphate  Saline  Buffer  
PCA:  Principal  component  analysis  
PCPG  Pheochromocytoma  and  Paraganglioma  
PCR:  Polymerase  Chain  Reaction  
PDAC:  Pancreatic  ductal  adenocarcinoma  
PDB:  Protein  Data  Bank  
PDGFR:  Platelet-­derived  growth  factor  receptor  




PRBB:  Parc  de  Recerca  Biomedica  de  Barcelona  
PRP4K:  Pre-­messenger  RNA  processing  protein  4  kinase  
PSM:  Peptide  spectrum  match  
RCAN1:  Regulator  of  calcineurin  1  
READ:  Rectum  adenocarcinoma  
REST:  RE1  silencing  transcription  factor  
RNF169:  ring  finger  169  
RTK:  Receptor  tyrosine  kinase  
SARC:  Sarcoma  
SD:  Standard  deviation  
SDS:  Sodium  Dodecyl  Sulfate  
sgRNA:  single  guide  RNA  
SKCM:  Skin  Cutaneous  Melanoma  
SNV:  Single-­Nucleotide  Variation  
SPRED:  Sprouty-­related  protein  with  an  EVH1  domain  
SRPK:  Serine-­arginine-­rich  protein  kinase  
ssODN:  single-­stranded  DNA  oligonucleotides  
STAD:  Stomach  adenocarcinoma  
STAT:  signal  transducer  and  activator  of  transcription  
TBX5:  T-­box  transcription  factor  5  
TCGA:  The  Cancer  Genome  Atlas  
TGCT:  Testicular  germ  cell  tumor  
THCA:  Thyroid  carcinoma  
THYM:  Thymoma  
TMD:  Transient  myeloproliferative  disorder  
TUSON:  Tumor  Suppressor  and  Oncogene  
UCEC:  Uterine  Corpus  Endometrial  Carcinoma  
UCS:  Uterine  Carcinosarcoma  
UPF:  Universidad  Pompeu  Fabra  
UTR:  Untranslated  region  
UVM:  Uveal  Melanoma  
VHL:  Von-­Hippel  Lindau  
VEGFR:  Vascular  endothelial  growht  factor  receptor  
WB:  Western  Blot  
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